[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 2659
1. Romeike BF, Joellenbeck B, Stein H, Loddenkemper C, Hummel M, Firsching R, Mawrin C: Precursor T-lymphoblastic lymphoma within a recurrent pituitary adenoma. Acta Neurochir (Wien); 2008 Aug;150(8):833-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Precursor T-lymphoblastic lymphoma within a recurrent pituitary adenoma.
  • Only single examples of lymphoma associated with pituitary adenoma have been reported.
  • In our patient, a precursor T-lymphoblastic lymphoma developed within a recurrent pituitary adenoma 17 years after the first resection.
  • Histomorphologically, lymphoma and adenoma components were tightly admixed.
  • In both patients the lymphomas were composed of T-cells, there was no evidence of further sites involved, and both adenomas expressed follicle-stimulating hormone.
  • [MeSH-major] Neoplasm Recurrence, Local / pathology. Neoplasms, Multiple Primary / pathology. Pituitary Neoplasms / pathology. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Biomarkers, Tumor / analysis. Endoscopy. Female. Follicle Stimulating Hormone / analysis. Humans. Hypophysectomy. Magnetic Resonance Imaging. Middle Aged. Pituitary Gland / pathology. Reoperation

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. MENOTROPINS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18574548.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 9002-68-0 / Follicle Stimulating Hormone
  •  go-up   go-down


2. Manno M, Tomei F, Marchesan E, Adamo V: An important new adaption of a specific drug? Fertil Steril; 2007 Aug;88(2):533; author reply 533
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An important new adaption of a specific drug?
  • [MeSH-major] Adenoma / complications. Ergolines / therapeutic use. Ovarian Hyperstimulation Syndrome / drug therapy. Ovarian Hyperstimulation Syndrome / etiology. Pituitary Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Fertil Steril. 2006 Sep;86(3):719.e15-8 [16952513.001]
  • (PMID = 17644093.001).
  • [ISSN] 1556-5653
  • [Journal-full-title] Fertility and sterility
  • [ISO-abbreviation] Fertil. Steril.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Ergolines; 0 / Gonadotropins; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; LL60K9J05T / cabergoline
  •  go-up   go-down


3. Scheithauer BW, Kovacs K, Nose V, Lombardero M, Osamura YR, Lloyd RV, Horvath E, Pagenstecher A, Bohl JE, Tews DS: Multiple endocrine neoplasia type 1-associated thyrotropin-producing pituitary carcinoma: report of a probable de novo example. Hum Pathol; 2009 Feb;40(2):270-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple endocrine neoplasia type 1-associated thyrotropin-producing pituitary carcinoma: report of a probable de novo example.
  • Pituitary carcinomas are exceedingly rare.
  • We report a clinically and morphologically well-documented example of pituitary thyrotropin cell carcinoma in a man with multiple endocrine neoplasia type 1 syndrome.
  • Based on the study of several biopsies during disease progression, we believe that the carcinoma originated de novo without an intermediary adenoma phase.
  • [MeSH-major] Carcinoma / secondary. Multiple Endocrine Neoplasia Type 1 / pathology. Pituitary Neoplasms / pathology. Thyrotropin / biosynthesis


Advertisement
4. Netea-Maier RT, van Lindert EJ, den Heijer M, van der Eerden A, Pieters GF, Sweep CG, Grotenhuis JA, Hermus AR: Transsphenoidal pituitary surgery via the endoscopic technique: results in 35 consecutive patients with Cushing's disease. Eur J Endocrinol; 2006 May;154(5):675-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transsphenoidal pituitary surgery via the endoscopic technique: results in 35 consecutive patients with Cushing's disease.
  • OBJECTIVE AND DESIGN: The endoscopic technique has been recently introduced in the field of transsphenoidal pituitary surgery.
  • Our aim was to retrospectively analyze the results of pituitary surgery in 35 consecutive patients with Cushing's disease operated in our hospital after the introduction of the endoscopic technique (1998-2004).
  • RESULTS: Pituitary MRI showed a macroadenoma in 6 patients, a microadenoma in 17 patients and no adenoma in 12 patients.
  • Three of them had a second endoscopic pituitary surgery resulting in remission in two patients.
  • In one patient a second endoscopic pituitary surgery will soon follow.
  • CONCLUSIONS: Endoscopic transsphenoidal pituitary surgery resulted in our series of patients with Cushings disease in an excellent postoperative remission rate.
  • A randomized clinical trial, comparing endoscopic and conventional pituitary surgery in patients with Cushings disease, is needed to determine the pros and cons of both techniques.

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16645014.001).
  • [ISSN] 0804-4643
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


5. Ozbek M, Erdogan M, Akbal E, Gönülalan G: Disappearance of a GH secreting macroadenoma, during long-term somatostatin analogue administration. Exp Clin Endocrinol Diabetes; 2009 Jul;117(7):309-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disappearance of a GH secreting macroadenoma, during long-term somatostatin analogue administration.
  • Acromegaly is caused by excessive growth hormone secretion, usually from a pituitary adenoma.
  • A few cases have been reported in the literature, complete shrinkage of a pituitary GH secreting macroadenoma after long-term somatostatin analogue administration.
  • We report a patient in whom long term (60 months) octreotide-L.A.R administration resulted in complete disappearance of a growth hormone secreting pituitary macroadenoma.
  • [MeSH-major] Adenoma / drug therapy. Growth Hormone-Secreting Pituitary Adenoma / drug therapy. Octreotide / therapeutic use. Somatostatin / analogs & derivatives

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18841538.001).
  • [ISSN] 1439-3646
  • [Journal-full-title] Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
  • [ISO-abbreviation] Exp. Clin. Endocrinol. Diabetes
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Delayed-Action Preparations; 51110-01-1 / Somatostatin; RWM8CCW8GP / Octreotide
  •  go-up   go-down


6. Zhang R, Zhou LF, Mao Y: [Microsurgical treatment of nonmeningeal tumors of the cavernous sinus]. Zhonghua Yi Xue Za Zhi; 2005 Jun 1;85(20):1373-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To analyze the differential diagnosis of and effectiveness of surgical treatment on nonmeningeal tumors of cavernous sinus.
  • METHODS: The clinical data, including clinical manifestations, diagnosis and differential diagnosis, operative procedure, and treatment results of 67 cases of nonmeningeal tumors of cavernous sinus, 32 males and 35 females, aged 41 +/- 16, who underwent microsurgical treatment were analyzed respectively.
  • RESULTS: The main clinical presentation included cranial nerve paralysis (47 cases, 70.1%), neuroendocrine symptoms (11 cases, 16.4%), eye pain (9 cases, 13.6%), proptosis (7 cases, 10.6%), limb weakness (5 cases, 7.5%), headache, dizziness, lethargy, and temporal lobe epilepsy (4 cases each), and epistaxis (1 case).
  • Twenty cases were operated on via intradural approach, 33 cases via epidural approach, and 14 cases via epidural/intradural combination approach most of which suffered from invasive pituitary adenoma and dumbbell type trigeminal neurinoma.
  • Pathological examination revealed that hemangioma (24 cases), trigeminal schwannoma (18 cases), and invasive pituitary adenomas (11 cases) comprised the majority of tumors; the remaining tumor types were chordoma, chondroma, chondromyosarcoma, chondrofibroma, dermoid tumor, malignant nerve sheath tumor, metastatic tumor, and lymphoma.
  • [MeSH-major] Central Nervous System Neoplasms / surgery. Cranial Nerve Neoplasms / surgery. Hemangioma, Cavernous, Central Nervous System / surgery. Microsurgery. Trigeminal Nerve Diseases / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Cavernous Sinus / surgery. Child. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Neurilemmoma / diagnosis. Neurilemmoma / surgery. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16029646.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


7. Lee EJ, Ahn JY, Noh T, Kim SH, Kim TS, Kim SH: Tumor tissue identification in the pseudocapsule of pituitary adenoma: should the pseudocapsule be removed for total resection of pituitary adenoma? Neurosurgery; 2009 Mar;64(3 Suppl):ons62-9; discussion ons69-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor tissue identification in the pseudocapsule of pituitary adenoma: should the pseudocapsule be removed for total resection of pituitary adenoma?
  • OBJECTIVE: The microsurgical pseudocapsule can be found in the transition zone between an adenoma and the surrounding normal pituitary tissue.
  • Furthermore, we evaluated the remission rate, the changes in pituitary function, and the recurrence rate after intensive resection of the pseudocapsule.
  • METHODS: In 616 patients with pituitary adenomas (Hardy Types I-III) over a period of 14 years, we introduced intensive resection of the microsurgical pseudocapsule to achieve complete tumor removal.
  • A combined pituitary function test and radiological study were performed on the patients before surgery, 1 year after surgery, and at subsequent 1.5-year intervals 2 to 13 years postoperatively.
  • The presence of a pseudocapsule was slightly more frequent in prolactin-secreting tumors (70.9%) than in growth hormone-secreting (55.0%) and adrenocorticotropic hormone-secreting (40.0%) tumors.
  • In the 243 patients of the total resection group who underwent combined pituitary function tests more than 2 times after surgery, the surgical remission rate was 99.1% in clinically nonfunctional tumors, 88% in growth hormone-secreting, 70.6% in prolactin-secreting, and 100% in adrenocorticotropic hormone-secreting tumors.
  • The surgical remission rate was 86.2% in the presence of a pseudocapsule and 94.3% in the absence of a pseudocapsule.
  • There was no statistical difference in improvement or deterioration of pituitary function according to the existence or absence of the pseudocapsule.
  • These results indicate that intensive resection of the pseudocapsule could result in a higher remission rate without deteriorating pituitary function.
  • [MeSH-major] Neurosurgical Procedures / methods. Pituitary Gland / pathology. Pituitary Gland / surgery. Pituitary Neoplasms / pathology. Pituitary Neoplasms / surgery
  • [MeSH-minor] ACTH-Secreting Pituitary Adenoma / surgery. Follow-Up Studies. Growth Hormone-Secreting Pituitary Adenoma / surgery. Humans. Magnetic Resonance Imaging. Microsurgery. Neoplasm Recurrence, Local / epidemiology. Pituitary Function Tests. Postoperative Period. Prolactinoma / surgery. Prospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19240574.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Frank G, Pasquini E: Endoscopic endonasal cavernous sinus surgery, with special reference to pituitary adenomas. Front Horm Res; 2006;34:64-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic endonasal cavernous sinus surgery, with special reference to pituitary adenomas.
  • Since 1998, 65 patients with pituitary adenomas and intraoperative evidence of cavernous sinus invasion were treated with a purely endoscopic approach.
  • Radical tumor removal was obtained in 21/35 cases with nonfunctioning adenomas.
  • Hormonal remission was obtained in 13/30 functioning adenomas.
  • We advocate the central role of surgery in the treatment of cavernous sinus tumors, since it allows definition of true cavernous sinus involvement, histopathological diagnosis and, when cure is not feasible, tumor volume reduction, which might be an important factor in the response to adjuvant therapy.
  • [MeSH-major] Cavernous Sinus / surgery. Pituitary Neoplasms / surgery
  • [MeSH-minor] Acromegaly / etiology. Adolescent. Adult. Aged. Female. Human Growth Hormone / secretion. Humans. Male. Middle Aged. Monitoring, Intraoperative. Postoperative Complications / classification. Postoperative Complications / epidemiology. Prolactin / secretion. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16474216.001).
  • [ISSN] 0301-3073
  • [Journal-full-title] Frontiers of hormone research
  • [ISO-abbreviation] Front Horm Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 12629-01-5 / Human Growth Hormone; 9002-62-4 / Prolactin
  •  go-up   go-down


9. Flitsch J, Bernreuther C, Hagel C, Lüdecke DK: Hypophysectomy for prostate cancer: a revival of old knowledge? J Neurosurg; 2008 Oct;109(4):760-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The authors present the case of a 63-year-old man with metastatic prostate cancer who presented with high serum prostate-specific antigen levels (1216 microg/L) and cavernous sinus syndrome.
  • Contrast-enhanced MR imaging showed a pituitary lesion as well as metastatic infiltration of the skull base including the cavernous sinus.
  • The patient's serum level of prolactin was mildly elevated, testosterone was below the detection limit, and insulin-like growth factor-I (IGF-I) was in the upper range for a patient of his age (233 microg/L).
  • Because of the elevated prolactin and high-normal IGF-I levels he was offered a hypophysectomy in addition to pituitary tumor removal.
  • Histological examination of the resected lesion confirmed a nonsecreting pituitary adenoma with infiltration of prostate cancer cells.
  • [MeSH-major] Hypophysectomy. Pituitary Neoplasms / secondary. Pituitary Neoplasms / surgery. Prostatic Neoplasms / pathology

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18826367.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 67763-96-6 / Insulin-Like Growth Factor I
  •  go-up   go-down


10. Casanueva F: Pituitary tumorigenesis. Horm Res; 2007;68 Suppl 5:126
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pituitary tumorigenesis.
  • [MeSH-major] Adenoma / genetics. Pituitary Neoplasms / genetics. Proteins / genetics

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18174728.001).
  • [ISSN] 1423-0046
  • [Journal-full-title] Hormone research
  • [ISO-abbreviation] Horm. Res.
  • [Language] eng
  • [Publication-type] Introductory Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 0 / Proteins; 0 / aryl hydrocarbon receptor-interacting protein
  •  go-up   go-down


11. Jiang YN, Li YH, Ke MW, Tseng TY, Tang YB, Huang MC, Cheng WT, Ju YT: Caveolin-1 sensitizes rat pituitary adenoma GH3 cells to bromocriptine induced apoptosis. Cancer Cell Int; 2007;7:1
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Caveolin-1 sensitizes rat pituitary adenoma GH3 cells to bromocriptine induced apoptosis.
  • BACKGROUND: Prolactinoma is the most frequent pituitary tumor in humans.
  • The dopamine D2 receptor agonist bromocriptine has been widely used clinically to treat human breast tumor and prolactinoma through inhibition of hyperprolactinemia and induction of tumor cell apoptosis, respectively, but the molecular mechanism of bromocriptine induction of pituitary tumor apoptosis remains unclear.
  • Rat pituitary adenoma GH3 cells, which express endogenous caveolin-1, exhibit increased apoptosis and shrinkage after exposure to bromocriptine.
  • CONCLUSION: Our results reveal that caveolin-1 increases sensitivity for apoptosis induction in pituitary adenoma GH3 cells and may contribute to tumor shrinkage after clinical bromocriptine treatment.


12. Kupec JT, Goebel SU: The missing ring sign. Am J Med; 2009 Dec;122(12):e1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Acromegaly / etiology. Adenoma / diagnosis. Fingers. Jewelry. Pituitary Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19958874.001).
  • [ISSN] 1555-7162
  • [Journal-full-title] The American journal of medicine
  • [ISO-abbreviation] Am. J. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 12629-01-5 / Human Growth Hormone; 67763-96-6 / Insulin-Like Growth Factor I
  •  go-up   go-down


13. Ballian N, Chrisoulidou A, Nomikos P, Samara C, Kontogeorgos G, Kaltsas GA: Hypophysitis superimposed on a non-functioning pituitary adenoma: diagnostic clinical, endocrine, and radiologic features. J Endocrinol Invest; 2007 Sep;30(8):677-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypophysitis superimposed on a non-functioning pituitary adenoma: diagnostic clinical, endocrine, and radiologic features.
  • Pituitary adenomas are common neoplasms requiring medical and/or surgical treatment when associated with hormonal hypersecretion.
  • Treatment of non-functioning pituitary adenomas is necessary when symptoms of mass effect or hormonal deficits occur.
  • Hence, it is important to consider disorders that could present in a similar manner to pituitary adenomas, for which surgery is not the indicated therapeutic approach.
  • We describe herein a 38-yr-old woman who presented with a pituitary lesion that was considered to be a non-functioning pituitary adenoma.
  • Fifteen months after initial diagnosis, considerable enlargement of the lesion was noted, extending mainly superiorly and indenting the optic chiasm.
  • Repeated endocrine investigation revealed partial anterior pituitary insufficiency.
  • The patient underwent trans-sphenoidal resection of the pituitary lesion; histology revealed a null cell pituitary adenoma and lymphocytic hypophysitis (LYH) of the non-neoplastic adenohypophysial gland.
  • Post-operatively, complete anterior and partial posterior pituitary insufficiency developed.
  • This case illustrates the effects of new-onset LYH in a patient with a pre-existing non-functioning pituitary adenoma.
  • Being aware of this rare possibility is important, as enlargement of the pituitary lesion may not be caused by expansion of the preexisting tumor, but by the onset of LYH of the nonneoplastic pituitary tissue.
  • [MeSH-major] Adenoma / pathology. Hypopituitarism / pathology. Inflammation. Magnetic Resonance Imaging. Pituitary Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Humans. Pituitary Hormones / metabolism

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr J. 1998 Jun;45(3):357-61 [9790270.001]
  • [Cites] Neurosurgery. 1995 May;36(5):1016-9 [7791966.001]
  • [Cites] Ann Med Interne (Paris). 1999 Jun;150(4):327-41 [10519020.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Mar;86(3):1048-53 [11238484.001]
  • [Cites] Neurosurgery. 1997 Apr;40(4):713-22; discussion 722-3 [9092844.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Nov;84(11):3859-66 [10566620.001]
  • [Cites] Acta Neuropathol. 1995;90(6):637-44 [8615086.001]
  • [Cites] Radiology. 1995 Apr;195(1):30-4 [7892490.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Aug;80(8):2302-11 [7629223.001]
  • [Cites] Endocr Rev. 2005 Aug;26(5):599-614 [15634713.001]
  • [Cites] Medicine (Baltimore). 1989 Jul;68(4):240-56 [2661963.001]
  • [Cites] Neuroradiology. 1998 Feb;40(2):114-20 [9541922.001]
  • [Cites] Neurol India. 2003 Dec;51(4):461-5 [14742922.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Feb;83(2):609-18 [9467582.001]
  • [Cites] Eur J Endocrinol. 2003 Nov;149(5):363-76 [14585081.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Feb;88(2):650-4 [12574195.001]
  • [Cites] Endocr J. 1993 Aug;40(4):431-8 [7920896.001]
  • [Cites] J Reprod Med. 1995 Apr;40(4):251-9 [7623353.001]
  • [Cites] Clin Endocrinol (Oxf). 1995 Mar;42(3):315-22 [7758238.001]
  • [Cites] Endocr Relat Cancer. 2001 Dec;8(4):287-305 [11733226.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Feb;87(2):752-7 [11836316.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Oct;81(10):3455-9 [8855784.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jul;91(7):2484-9 [16621907.001]
  • [Cites] J Neuroradiol. 2002 Mar;29(1):57-60 [11984480.001]
  • [Cites] Endocr J. 2003 Dec;50(6):697-702 [14709840.001]
  • [Cites] J Neurosurg. 2004 Aug;101(2):262-71 [15309917.001]
  • [Cites] Eur J Endocrinol. 2001 Jun;144(6):569-75 [11375790.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Feb;92(2):604-7 [17090639.001]
  • (PMID = 17923800.001).
  • [ISSN] 1720-8386
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Pituitary Hormones
  •  go-up   go-down


14. Gillam MP, Molitch ME, Lombardi G, Colao A: Advances in the treatment of prolactinomas. Endocr Rev; 2006 Aug;27(5):485-534
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Prolactinomas account for approximately 40% of all pituitary adenomas and are an important cause of hypogonadism and infertility.
  • [MeSH-major] Pituitary Neoplasms / therapy. Prolactinoma / therapy

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16705142.001).
  • [ISSN] 0163-769X
  • [Journal-full-title] Endocrine reviews
  • [ISO-abbreviation] Endocr. Rev.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / K08 DK066044
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contraceptives, Oral, Hormonal; 0 / Dopamine Agonists
  • [Number-of-references] 626
  •  go-up   go-down


15. Nomura R, Yoshida D, Teramoto A: Stromal cell-derived factor-1 expression in pituitary adenoma tissues and upregulation in hypoxia. J Neurooncol; 2009 Sep;94(2):173-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stromal cell-derived factor-1 expression in pituitary adenoma tissues and upregulation in hypoxia.
  • In this study, we investigated whether SDF-1 is triggered by hypoxia and might be a major driving force for tumor angiogenesis in pituitary adenomas.
  • SDF-1 and microvascular density (MVD) were detected by double-immunofluorescence microscopy in CD34-positive vessels from 59 cases with pituitary adenomas.
  • In vitro secretion of SDF-1 by the AtT20 mouse pituitary adenoma cell line under hypoxic conditions was quantitatively analyzed by ELISA, and SDF-1 mRNA levels were determined by real-time RT-PCR.
  • The current study strongly suggests that SDF-1 is a crucial angiogenic factor in pituitary adenomas, where it acts as a homing agent to mediate the mobilization of CD34-positive endothelial progenitor cells to the tumor parenchyma under hypoxic conditions.
  • [MeSH-major] Adenoma / metabolism. Chemokine CXCL12 / metabolism. Hypoxia / metabolism. Pituitary Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Endocrinol. 2006 Oct;191(1):249-61 [17065408.001]
  • [Cites] Blood. 2002 Feb 15;99(4):1117-29 [11830456.001]
  • [Cites] Microsc Res Tech. 2003 Feb 1;60(2):236-43 [12539178.001]
  • [Cites] Endocr Pathol. 2005 Summer;16(2):115-21 [16199896.001]
  • [Cites] Nat Med. 2004 Aug;10(8):858-64 [15235597.001]
  • [Cites] J Mol Cell Cardiol. 2005 Nov;39(5):733-42 [16199052.001]
  • [Cites] Lab Invest. 2004 Dec;84(12):1666-76 [15467730.001]
  • [Cites] Blood. 2000 May 15;95(10):3106-12 [10807776.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Mar 15;91(6):2305-9 [8134392.001]
  • [Cites] J Mol Endocrinol. 2007 Mar;38(3):383-9 [17339401.001]
  • [Cites] Lab Invest. 2003 Dec;83(12 ):1811-20 [14691299.001]
  • [Cites] Mol Pharmacol. 2006 Feb;69(2):539-46 [16258074.001]
  • [Cites] Cancer Cell. 2008 Mar;13(3):206-20 [18328425.001]
  • [Cites] Stem Cells. 2007 Feb;25(2):392-401 [17038674.001]
  • [Cites] Circ Res. 2007 Mar 2;100(4):590-7 [17272812.001]
  • [Cites] Neurosurgery. 1987 Mar;20(3):369-78 [3574612.001]
  • [Cites] N Engl J Med. 2004 Apr 29;350(18):1828-37 [15115829.001]
  • [Cites] Am J Physiol Cell Physiol. 2007 Mar;292(3):C987-95 [16943240.001]
  • [Cites] Endocr Pathol. 2005 Summer;16(2):123-31 [16199897.001]
  • [Cites] Nat Med. 2001 Dec;7(12):1339-46 [11726975.001]
  • [Cites] J Cardiovasc Pharmacol. 2007 Sep;50(3):274-80 [17878755.001]
  • [Cites] Ann N Y Acad Sci. 2002 Nov;973:60-9 [12485835.001]
  • [Cites] Hum Pathol. 2005 Oct;36(10):1090-5 [16226108.001]
  • [Cites] Clin Cancer Res. 2008 Aug 15;14(16):5022-32 [18698020.001]
  • [Cites] Trends Cardiovasc Med. 2005 Feb;15(2):57-63 [15885571.001]
  • [Cites] J Endocrinol Invest. 2003 Jan;26(1):23-8 [12602530.001]
  • [Cites] Thromb Res. 2000 Sep 15;99(6):587-94 [10974345.001]
  • [Cites] Circulation. 2003 Mar 11;107(9):1322-8 [12628955.001]
  • [Cites] Arthritis Rheum. 2002 Oct;46(10 ):2587-97 [12384916.001]
  • [Cites] Circ Res. 2004 Aug 20;95(4):343-53 [15321944.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jan;88(1):408-16 [12519884.001]
  • [Cites] Neurosurgery. 2003 Oct;53(4):880-5; discussion 885-6 [14519220.001]
  • [Cites] Cancer Res. 2005 Jan 15;65(2):465-72 [15695388.001]
  • [Cites] Annu Rev Cell Dev Biol. 1995;11:73-91 [8689573.001]
  • [Cites] J Endocrinol. 2008 Nov;199(2):191-9 [18753332.001]
  • (PMID = 19280118.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chemokine CXCL12; 0 / RNA, Messenger
  •  go-up   go-down


16. Tinnel BA, Henderson MA, Witt TC, Fakiris AJ, Worth RM, Des Rosiers PM, Edmondson JW, Timmerman RD, Lo SS: Endocrine response after gamma knife-based stereotactic radiosurgery for secretory pituitary adenoma. Stereotact Funct Neurosurg; 2008;86(5):292-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endocrine response after gamma knife-based stereotactic radiosurgery for secretory pituitary adenoma.
  • PURPOSE: To examine treatment outcomes of Gamma Knife-based stereotactic radiosurgery (GK-based SRS) for secretory pituitary adenomas.
  • MATERIALS AND METHODS: 25 patients were treated with GK-based SRS for secretory pituitary adenomas with >or=12 months of follow-up.
  • CONCLUSION: GK-based SRS provides a reasonable rate of endocrine normalization of secretory pituitary adenoma.
  • [MeSH-major] Pituitary Neoplasms / surgery. Prolactin / blood. Prolactin / secretion. Prolactinoma / surgery. Radiosurgery
  • [MeSH-minor] ACTH-Secreting Pituitary Adenoma / secretion. ACTH-Secreting Pituitary Adenoma / surgery. Adenoma / secretion. Adenoma / surgery. Adrenocorticotropic Hormone / secretion. Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Growth Hormone-Secreting Pituitary Adenoma / secretion. Growth Hormone-Secreting Pituitary Adenoma / surgery. Human Growth Hormone / secretion. Humans. Hydrocortisone / blood. Insulin-Like Growth Factor I / metabolism. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. Corticotropin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel.
  • (PMID = 18758206.001).
  • [ISSN] 1423-0372
  • [Journal-full-title] Stereotactic and functional neurosurgery
  • [ISO-abbreviation] Stereotact Funct Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 12629-01-5 / Human Growth Hormone; 67763-96-6 / Insulin-Like Growth Factor I; 9002-60-2 / Adrenocorticotropic Hormone; 9002-62-4 / Prolactin; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


17. Swords FM, Monson JP, Besser GM, Chew SL, Drake WM, Grossman AB, Plowman PN: Gamma knife radiosurgery: a safe and effective salvage treatment for pituitary tumours not controlled despite conventional radiotherapy. Eur J Endocrinol; 2009 Dec;161(6):819-28
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gamma knife radiosurgery: a safe and effective salvage treatment for pituitary tumours not controlled despite conventional radiotherapy.
  • OBJECTIVE: We report the use of 'gamma knife' (GK) radiosurgery in 25 patients with pituitary adenomas not cured despite conventional therapy, including external beam radiotherapy.
  • PATIENTS AND METHODS: All patients had previously received conventional radiotherapy for a mean of 11.8 years prior to receiving GK; 23 out of 25 had also undergone pituitary surgery on at least one occasion.
  • Seventeen had hyperfunctioning adenomas that still required medical therapy without an adequate biochemical control--ten somatotroph adenomas, six corticotroph adenomas and one prolactinoma, while eight patients had non-functioning pituitary adenomas (NFPAs).
  • The results in corticotroph adenomas were variable.
  • Prior to GK, 72% of the patients were panhypopituitary, and 42% of the remainder have developed new anterior pituitary hormone deficiencies to date.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19773368.001).
  • [ISSN] 1479-683X
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 12629-01-5 / Human Growth Hormone; 67763-96-6 / Insulin-Like Growth Factor I
  •  go-up   go-down


18. Bonneville JF, Bonneville F, Cattin F: Magnetic resonance imaging of pituitary adenomas. Eur Radiol; 2005 Mar;15(3):543-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance imaging of pituitary adenomas.
  • Today, MR is the only method needed for the morphological investigation of endocrine-active pituitary adenomas.
  • We present the MR aspect of pituitary adenomas according to size, sex, age, endocrine activity and a few particular conditions such as hemorrhagic pituitary adenomas, pituitary adenomas during pregnancy, cavernous sinus invasion and postsurgical changes.
  • When an intrasellar mass extending out of the sella turcica is detected, the goal of the MR examination is to indicate precisely the origin of the tumor, its extension in relation to the various surrounding structures, its structure and its enhancement in order to help in the differential diagnosis.
  • Demonstration of very small pituitary adenomas remains a challenge.
  • [MeSH-major] Adenoma / pathology. Magnetic Resonance Imaging. Pituitary Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJNR Am J Neuroradiol. 1994 Sep;15(8):1591-5 [7985584.001]
  • [Cites] Radiology. 1992 Nov;185(2):521-7 [1410366.001]
  • [Cites] AJNR Am J Neuroradiol. 1988 Jan-Feb;9(1):23-6 [3124583.001]
  • [Cites] AJNR Am J Neuroradiol. 1997 Apr;18(4):765-72 [9127047.001]
  • [Cites] Radiology. 1993 Jun;187(3):857-61 [8497646.001]
  • [Cites] Acta Neurochir Suppl (Wien). 1991;53:65-71 [1803887.001]
  • [Cites] Neuroradiology. 1983;25(3):133-8 [6888713.001]
  • [Cites] J Neurosurg. 1996 Dec;85(6):1153-5 [8929510.001]
  • [Cites] AJR Am J Roentgenol. 1987 Apr;148(4):797-802 [3030083.001]
  • [Cites] Radiology. 1991 Sep;180(3):779-84 [1871293.001]
  • [Cites] AJR Am J Roentgenol. 1994 Sep;163(3):671-9 [8079866.001]
  • [Cites] AJNR Am J Neuroradiol. 1987 Sep-Oct;8(5):817-23 [3118674.001]
  • [Cites] Radiology. 1989 Jan;170(1 Pt 1):239-43 [2909102.001]
  • [Cites] Radiology. 1986 Dec;161(3):761-5 [3786729.001]
  • [Cites] AJNR Am J Neuroradiol. 1989 Mar-Apr;10(2):323-8 [2494851.001]
  • [Cites] AJNR Am J Neuroradiol. 1992 Sep-Oct;13(5):1279-91 [1414816.001]
  • [Cites] J Comput Assist Tomogr. 1988 Sep-Oct;12(5):728-35 [3170830.001]
  • [Cites] Radiology. 1993 Apr;187(1):1-14 [8451394.001]
  • [Cites] AJR Am J Roentgenol. 1986 Feb;146(2):257-62 [3484572.001]
  • (PMID = 15627195.001).
  • [ISSN] 0938-7994
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 21
  •  go-up   go-down


19. Sandhu SS, Gnanaraj L, James A, Figueiredo FC: Unusual cause of visual symptoms after bilateral laser in situ keratomileusis. J Cataract Refract Surg; 2005 Feb;31(2):446-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There were no signs in the anterior segment to explain the visual symptoms.
  • Ancillary tests and investigations confirmed a pituitary tumor, which was removed.
  • [MeSH-major] Adenoma / complications. Keratomileusis, Laser In Situ. Pituitary Neoplasms / complications. Vision Disorders / etiology. Visual Fields

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • MedlinePlus Health Information. consumer health - Vision Impairment and Blindness.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Cataract Refract Surg. 2006 Feb;32(2):187; author reply 187 [16564972.001]
  • [CommentIn] J Cataract Refract Surg. 2005 Feb;31(2):247-9 [15767118.001]
  • (PMID = 15767173.001).
  • [ISSN] 0886-3350
  • [Journal-full-title] Journal of cataract and refractive surgery
  • [ISO-abbreviation] J Cataract Refract Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Fogliata A, Clivio A, Nicolini G, Vanetti E, Cozzi L: Intensity modulation with photons for benign intracranial tumours: a planning comparison of volumetric single arc, helical arc and fixed gantry techniques. Radiother Oncol; 2008 Dec;89(3):254-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensity modulation with photons for benign intracranial tumours: a planning comparison of volumetric single arc, helical arc and fixed gantry techniques.
  • BACKGROUND AND PURPOSE: The potential benefits and limitations of the new RapidArc treatment concept compared to Helical Tomotherapy and fixed gantry intensity modulation techniques have been assessed at treatment planning level on 12 patients presenting with 'benign' brain tumours.
  • MATERIALS AND METHODS: Plans for five acoustic neurinomas, five meningiomas and two pituitary adenomas were computed for an Helical Tomotherapy (HT) unit, for RapidArc delivery (RA) on a linac equipped with two types of MLC (RA_HD120 with the new High Definition MLC with 2.5mm leaf width at isocentre and RA_M120 with the standard Millennium with 5mm resolution) and for fixed beam IMRT with the High Definition MLC.
  • [MeSH-major] Adenoma / radiotherapy. Brain Neoplasms / radiotherapy. Meningioma / radiotherapy. Neuroma, Acoustic / radiotherapy. Pituitary Neoplasms / radiotherapy. Radiotherapy Planning, Computer-Assisted / methods. Radiotherapy, Intensity-Modulated / methods

  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18760851.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


21. Castro DG, Cecílio SA, Canteras MM: Radiosurgery for pituitary adenomas: evaluation of its efficacy and safety. Radiat Oncol; 2010;5:109
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiosurgery for pituitary adenomas: evaluation of its efficacy and safety.
  • OBJECT: To assess the effects of radiosurgery (RS) on the radiological and hormonal control and its toxicity in the treatment of pituitary adenomas.
  • METHODS: Retrospective analysis of 42 patients out of the first 48 consecutive patients with pituitary adenomas treated with RS between 1999 and 2008 with a 6 months minimum follow-up.
  • There were 14 patients with non-secretory adenomas and, among functioning adenomas, 9 were prolactinomas, 9 were adrenocorticotropic hormone-secreting and 10 were growth hormone-secreting tumors.
  • The median dose was 12,5 Gy (9 - 15 Gy) and 20 Gy (12 - 28 Gy) for non-secretory and secretory adenomas, respectively.
  • CONCLUSIONS: RS is an effective and safe therapeutic option in the management of selected patients with pituitary adenomas.
  • [MeSH-major] Adenoma / surgery. Pituitary Neoplasms / surgery. Radiosurgery / adverse effects

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 2000 Mar;46(3):531-43 [10719848.001]
  • [Cites] J Neurosurg. 2011 Feb;114(2):303-9 [20540596.001]
  • [Cites] J Neurooncol. 2001 Sep;54(2):197-203 [11761436.001]
  • [Cites] J Neurosurg. 2002 Feb;96(2):195-208 [11838791.001]
  • [Cites] J Neurosurg. 2002 Sep;97(3):525-30 [12296634.001]
  • [Cites] Neurosurgery. 2003 Jul;53(1):51-9; discussion 59-61 [12823873.001]
  • [Cites] Yonsei Med J. 2003 Aug 30;44(4):602-7 [12950114.001]
  • [Cites] J Neurosurg. 1989 Oct;71(4):520-7 [2552045.001]
  • [Cites] Clin Endocrinol (Oxf). 1993 Jun;38(6):571-8 [8334743.001]
  • [Cites] Radiother Oncol. 1996 Oct;41(1):45-53 [8961367.001]
  • [Cites] J Neurosurg. 1998 Jun;88(6):1002-8 [9609294.001]
  • [Cites] Clin Endocrinol (Oxf). 2004 Nov;61(5):531-43 [15521954.001]
  • [Cites] Curr Opin Neurol. 2004 Dec;17(6):693-703 [15542978.001]
  • [Cites] J Neurosurg. 2005 Apr;102(4):678-91 [15871511.001]
  • [Cites] Neurosurg Clin N Am. 2006 Apr;17(2):129-41, vi [16793505.001]
  • [Cites] Arq Bras Endocrinol Metabol. 2006 Dec;50(6):996-1004 [17221104.001]
  • [Cites] J Neurosurg. 2000 Dec;93 Suppl 3:19-22 [11143245.001]
  • (PMID = 21083925.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2994872
  •  go-up   go-down


22. Aghi MK: Management of recurrent and refractory Cushing disease. Nat Clin Pract Endocrinol Metab; 2008 Oct;4(10):560-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cushing disease is most frequently caused by pituitary adenomas that secrete adrenocorticotrophic hormone.
  • [MeSH-major] Pituitary ACTH Hypersecretion / therapy
  • [MeSH-minor] ACTH-Secreting Pituitary Adenoma / complications. ACTH-Secreting Pituitary Adenoma / surgery. Adrenalectomy. Humans. Hypophysectomy / methods. Ketoconazole / therapeutic use. Models, Biological. Neoplasm Recurrence, Local / surgery. Pituitary Neoplasms / complications. Pituitary Neoplasms / surgery. Radiosurgery / methods. Recurrence. Sphenoid Bone / surgery. Treatment Failure

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. KETOCONAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18711406.001).
  • [ISSN] 1745-8374
  • [Journal-full-title] Nature clinical practice. Endocrinology & metabolism
  • [ISO-abbreviation] Nat Clin Pract Endocrinol Metab
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] R9400W927I / Ketoconazole
  • [Number-of-references] 54
  •  go-up   go-down


23. Kaku S, Tanaka T, Sawauchi S, Dobashi H, Ohtsuka T, Numoto RT, Murakami S, Komine K, Abe T: [A case of non-functional pituitary adenoma associated with Rathke's cleft cyst]. No Shinkei Geka; 2005 Aug;33(8):797-803
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of non-functional pituitary adenoma associated with Rathke's cleft cyst].
  • A very rare case of non-functional pituitary adenoma associated with Rathke's cleft cyst is reported.
  • The suprasellar tumor tightly adhered to the frontal lobe and the optic nerve, the tumor was grayish cyst and cyst fluid from the suprasellar mass had the appearance of motor oil and the intrasellar tumor contained old hematoma.
  • Histological findings revealed that the suprasellar mass was Rathke's cleft cyst and the intrasellar mass was diagnosed as pituitary adenoma (non-functional).
  • So far twenty-three cases of pituitary adenoma associated with Rathke's cleft cysts have been reported in the literature, but there was only one case reported of a non-functional pituitary adenoma associated with a Rathke's cleft cyst.
  • Etiology and pathogenesis of the coexistence of non-functional pituitary adenoma and Rathke's cleft cyst in the present case were not elucidated.
  • [MeSH-major] Adenoma / complications. Central Nervous System Cysts / complications. Pituitary Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16095210.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 24
  •  go-up   go-down


24. Tahir A, Chahal HS, Korbonits M: Molecular genetics of the aip gene in familial pituitary tumorigenesis. Prog Brain Res; 2010;182:229-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular genetics of the aip gene in familial pituitary tumorigenesis.
  • Pituitary adenomas usually occur as sporadic tumors, but familial cases are now increasingly identified.
  • As opposed to multiple endocrine neoplasia type 1 and Carney complex, in familial isolated pituitary adenoma (FIPA) syndrome no other disease is associated with the familial occurrence of pituitary adenomas.
  • Patients with AIP mutations have an overwhelming predominance of somatotroph and lactotroph adenomas, which often present in childhood or young adulthood.
  • AIP is shown to bind various proteins, including the aryl hydrocarbon receptor, Hsp90, phosphodiesterases, survivin, RET and the glucocorticoid receptor, but currently it is not clear which interaction has the leading role in pituitary tumorigenesis.
  • This chapter summarizes the available clinical and molecular data regarding the role of AIP in the pituitary gland.
  • [MeSH-major] Family Health. Intracellular Signaling Peptides and Proteins / genetics. Molecular Imaging. Pituitary Neoplasms / etiology. Pituitary Neoplasms / genetics
  • [MeSH-minor] Cell Proliferation. Chromosomes, Human, Pair 11. Humans. Male. Mutation / genetics. Pituitary Gland / metabolism

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20541668.001).
  • [ISSN] 1875-7855
  • [Journal-full-title] Progress in brain research
  • [ISO-abbreviation] Prog. Brain Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 0 / aryl hydrocarbon receptor-interacting protein
  •  go-up   go-down


25. Honegger JB, Psaras T, Petrick M, Beuschlein F, Reincke M: Spontaneous cerebrospinal fluid rhinorrhea in untreated macroprolactinoma--an indication for primary surgical therapy. Zentralbl Neurochir; 2006 Aug;67(3):149-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE REPORTS: Two out of 267 surgical cases with pituitary adenomas presented with spontaneous rhinorrhea.
  • Early detection and surgical repair of a CSF leak is crucial for a favorable clinical outcome.
  • [MeSH-major] Cerebrospinal Fluid Rhinorrhea / etiology. Cerebrospinal Fluid Rhinorrhea / surgery. Neurosurgical Procedures. Pituitary Neoplasms / complications. Pituitary Neoplasms / surgery. Prolactinoma / complications. Prolactinoma / surgery

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16958013.001).
  • [ISSN] 0044-4251
  • [Journal-full-title] Zentralblatt für Neurochirurgie
  • [ISO-abbreviation] Zentralbl. Neurochir.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Hormones
  •  go-up   go-down


26. Fleseriu M, Yedinak C, Campbell C, Delashaw JB: Significant headache improvement after transsphenoidal surgery in patients with small sellar lesions. J Neurosurg; 2009 Feb;110(2):354-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECT: Pituitary adenomas represent a large proportion of brain tumors that are increasing in incidence because of improved imaging techniques.
  • The prevalence and optimal treatment of headaches associated with pituitary tumors is still unclear, particularly in cases of microadenoma.
  • The authors identified 41 patients with small pituitary tumors who underwent TSS, and retrospectively evaluated the resolution and/or treatment of headache.
  • RESULTS: Ninety percent of patients who presented with nonfunctioning microadenomas and Rathke cleft cysts experienced resolution or improvement in their headaches after TSS, and 56% of patients who presented with hyperfunctioning pituitary microadenomas had improvement in their headaches.
  • CONCLUSIONS: In this retrospective study, the authors demonstrate the efficacy of TSS in the treatment of intractable headaches in patients who present with pituitary microadenomas (nonsecreting and hypersecretory) and Rathke cleft cysts.
  • [MeSH-major] Headache / etiology. Pituitary Neoplasms / surgery. Sphenoid Sinus / surgery
  • [MeSH-minor] Adult. Female. Growth Hormone-Secreting Pituitary Adenoma / complications. Growth Hormone-Secreting Pituitary Adenoma / surgery. Humans. Male. Middle Aged. Minimally Invasive Surgical Procedures. Pituitary Function Tests. Prolactinoma / complications. Prolactinoma / surgery. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Headache.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19012490.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 28
  •  go-up   go-down


27. Maciá-Bobes C, Ronzón-Fernández A, Castaño-Fernández G, Botas-Cervero P: [Incidentally discovered pituitary macroadenoma. Neurosurgical treatment indications illustrated by two cases]. Neurocirugia (Astur); 2006 Dec;17(6):538-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Incidentally discovered pituitary macroadenoma. Neurosurgical treatment indications illustrated by two cases].
  • [Transliterated title] Macroadenoma de hipófisis descubierto incidentalmente. Indicaciones del tratamiento quirúrgico a propósito de dos casos.
  • Pituitary macroadenomas (more than 10 mm in diameter) are infrequent as casual findings and optimal management strategy for these tumours has not been established.
  • Neurosurgical approach must be always considered in patients with visual field defects or with hormone-secreting adenomas (but prolactinoma), and in those with evidence of lesion's growth or if clinical pituitary apoplexy occurs.
  • We also discuss the benefits of including such unusual indications for neurosurgical treatment into the incidentally discovered pituitary macroadenomas evaluation strategy.
  • [MeSH-major] Adenoma / diagnosis. Hypophysectomy. Pituitary Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17242842.001).
  • [ISSN] 1130-1473
  • [Journal-full-title] Neurocirugía (Asturias, Spain)
  • [ISO-abbreviation] Neurocirugia (Astur)
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 3XMK78S47O / Testosterone
  •  go-up   go-down


28. Tiryakioglu O, Ugurlu S, Yalin S, Yirmibescik S, Caglar E, Yetkin DO, Kadioglu P: Screening for Cushing's syndrome in obese patients. Clinics (Sao Paulo); 2010;65(1):9-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Etiologic reasons for Cushing's syndrome were pituitary microadenoma (9 patients), adrenocortical adenoma (3 patients), and adrenocortical carcinoma (1 patient).
  • [MeSH-major] Cushing Syndrome / diagnosis. Obesity / complications

  • Genetic Alliance. consumer health - Cushing's Syndrome.
  • MedlinePlus Health Information. consumer health - Cushing's Syndrome.
  • MedlinePlus Health Information. consumer health - Obesity.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 1999 Dec 8;282(22):2136-42 [10591335.001]
  • [Cites] J Clin Endocrinol Metab. 2009 Oct;94(10):3857-64 [19602562.001]
  • [Cites] Endocrinol Metab Clin North Am. 2002 Mar;31(1):173-89 [12055988.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Dec;88(12):5808-13 [14671173.001]
  • [Cites] J Med Educ. 1969 Mar;44(3):214-20 [5774591.001]
  • [Cites] Am J Med Sci. 1981 Mar-Apr;281(2):79-96 [7015860.001]
  • [Cites] Diabetologia. 1985 Jul;28(7):412-9 [3899825.001]
  • [Cites] Am J Prev Med. 1987 Nov-Dec;3(6):339-45 [3452374.001]
  • [Cites] N Engl J Med. 1989 Aug 31;321(9):563-9 [2761600.001]
  • [Cites] Am J Cardiol. 1990 Mar 1;65(9):633-7 [2309634.001]
  • [Cites] N Engl J Med. 1990 Mar 29;322(13):882-9 [2314422.001]
  • [Cites] Am J Epidemiol. 1990 Sep;132(3):501-13 [2389754.001]
  • [Cites] Am J Epidemiol. 1994 Jan 15;139(2):119-29 [8296779.001]
  • [Cites] JAMA. 1994 Jul 20;272(3):205-11 [8022039.001]
  • [Cites] Endocrinol Metab Clin North Am. 1994 Sep;23(3):487-509 [7805650.001]
  • [Cites] N Engl J Med. 1995 Sep 14;333(11):677-85 [7637744.001]
  • [Cites] Ann Clin Biochem. 1997 May;34 ( Pt 3):222-9 [9158818.001]
  • [Cites] JAMA. 1997 Nov 5;278(17):1407-11 [9355998.001]
  • [Cites] Clin Endocrinol (Oxf). 2007 Aug;67(2):225-9 [17547690.001]
  • [Cites] Arq Bras Endocrinol Metabol. 2007 Oct;51(7):1118-27 [18157388.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Nov;86(11):5301-6 [11701696.001]
  • (PMID = 20126340.001).
  • [ISSN] 1980-5322
  • [Journal-full-title] Clinics (São Paulo, Brazil)
  • [ISO-abbreviation] Clinics (Sao Paulo)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Glucocorticoids; 7S5I7G3JQL / Dexamethasone; WI4X0X7BPJ / Hydrocortisone
  • [Other-IDs] NLM/ PMC2815288
  • [Keywords] NOTNLM ; Adrenocorticorticotropic hormone / Cortisol / Cushing’s syndrome / Obesity / Screening
  •  go-up   go-down


29. Porzionato A, Macchi V, Barzon L, Masi G, Iacobone M, Parenti A, Palù G, De Caro R: Immunohistochemical assessment of parafibromin in mouse and human tissues. J Anat; 2006 Dec;209(6):817-27
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Parafibromin is a protein encoded by the HRPT2 oncosuppressor gene, whose mutation causes the hyperparathyroidism-jaw tumour syndrome, characterized by the occurrence of parathyroid adenoma or carcinoma, fibro-osseous jaw tumours, and renal neoplastic and non-neoplastic abnormalities.
  • Moreover, higher parafibromin expression was found in cell types, such as hepatocytes, cells of the base of gastric glands, renal cortex tubules and the pars intermedia of the hypophysis, which are characterized by different proliferative capacity, thus indicating that the cellular function of parafibromin may not be reduced only to its anti-proliferative effect.
  • [MeSH-minor] Adult. Aged. Animals. Cell Nucleus / chemistry. Cytoplasm / chemistry. Female. Fibroma / genetics. Fibroma / metabolism. Gastric Mucosa / chemistry. Hepatocytes / chemistry. Humans. Hyperparathyroidism / genetics. Hyperparathyroidism / metabolism. Immunohistochemistry. Jaw Neoplasms / genetics. Jaw Neoplasms / metabolism. Kidney Tubules / chemistry. Male. Mice. Middle Aged. Mutation. Pituitary Gland / chemistry. Species Specificity. Syndrome

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 2000 Apr;85(4):1449-54 [10770180.001]
  • [Cites] Oncogene. 2005 Feb 10;24(7):1272-6 [15580289.001]
  • [Cites] QJM. 2001 Apr;94(4):213-22 [11294964.001]
  • [Cites] Mol Cell Biol. 2001 Jul;21(14):4737-47 [11416149.001]
  • [Cites] EMBO J. 2002 Apr 2;21(7):1764-74 [11927560.001]
  • [Cites] Mol Cell. 2002 Apr;9(4):799-809 [11983171.001]
  • [Cites] Mol Genet Genomics. 2002 Oct;268(2):272-85 [12395202.001]
  • [Cites] Eukaryot Cell. 2002 Oct;1(5):830-42 [12455700.001]
  • [Cites] Nat Genet. 2002 Dec;32(4):676-80 [12434154.001]
  • [Cites] Mol Cell. 2003 Mar;11(3):709-19 [12667453.001]
  • [Cites] Mol Cell. 2003 Mar;11(3):721-9 [12667454.001]
  • [Cites] Cell. 2003 May 16;113(4):429-32 [12757703.001]
  • [Cites] J Biol Chem. 2003 Sep 5;278(36):33625-8 [12876293.001]
  • [Cites] J Biol Chem. 2003 Sep 12;278(37):34739-42 [12876294.001]
  • [Cites] EMBO Rep. 2004 Jan;5(1):47-53 [14710186.001]
  • [Cites] Mol Cell. 2004 May 21;14(4):447-56 [15149594.001]
  • [Cites] Clin Cancer Res. 2004 Oct 1;10(19):6629-37 [15475453.001]
  • [Cites] Mol Cell Biol. 2005 Jun;25(12):5052-60 [15923622.001]
  • [Cites] Oncogene. 2005 Sep 15;24(41):6241-8 [16116486.001]
  • [Cites] Cell. 2006 Apr 21;125(2):327-41 [16630820.001]
  • [Cites] Endocr Relat Cancer. 2006 Jun;13(2):509-23 [16728578.001]
  • [Cites] Oral Oncol. 2006 Aug;42(7):735-9 [16458039.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Jun;83(6):2114-20 [9626148.001]
  • [Cites] Am J Hum Genet. 1995 Apr;56(4):944-50 [7717405.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Dec;81(12):4204-11 [8954016.001]
  • [Cites] Mol Cell Biol. 1997 Mar;17(3):1160-9 [9032243.001]
  • [Cites] Mol Cell Biol. 1997 Aug;17(8):4490-500 [9234706.001]
  • [Cites] Am J Hum Genet. 1999 Feb;64(2):518-25 [9973288.001]
  • [Cites] EMBO J. 1999 Mar 15;18(6):1660-72 [10075936.001]
  • [Cites] Curr Mol Med. 2004 Dec;4(8):895-7 [15579037.001]
  • [Cites] J Intern Med. 2005 Jan;257(1):18-26 [15606373.001]
  • [Cites] Mol Cell Biol. 2005 Jan;25(2):612-20 [15632063.001]
  • [Cites] Eukaryot Cell. 2005 Jan;4(1):209-20 [15643076.001]
  • [Cites] Exp Cell Res. 2000 Apr 10;256(1):213-24 [10739668.001]
  • (PMID = 17118068.001).
  • [ISSN] 0021-8782
  • [Journal-full-title] Journal of anatomy
  • [ISO-abbreviation] J. Anat.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CDC73 protein, human; 0 / Tumor Suppressor Proteins
  • [Other-IDs] NLM/ PMC2048996
  •  go-up   go-down


30. De Martino I, Visone R, Wierinckx A, Palmieri D, Ferraro A, Cappabianca P, Chiappetta G, Forzati F, Lombardi G, Colao A, Trouillas J, Fedele M, Fusco A: HMGA proteins up-regulate CCNB2 gene in mouse and human pituitary adenomas. Cancer Res; 2009 Mar 1;69(5):1844-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HMGA proteins up-regulate CCNB2 gene in mouse and human pituitary adenomas.
  • This protein family is involved, through different mechanisms, in both benign and malignant neoplasias.
  • We have recently reported that transgenic mice carrying the Hmga1 or Hmga2 genes under transcriptional control of the cytomegalovirus promoter develop pituitary adenomas secreting prolactin and growth hormone.
  • We have shown that the mechanism of the HMGA2-induced pituitary adenoma is based on the increased E2F1 activity.
  • The expression profile of mouse normal pituitary glands and adenomas induced in HMGA transgenic mice revealed an increased expression of the ccnb2 gene, coding for the cyclin B2 protein, in the neoplastic tissues compared with the normal pituitary gland.
  • Finally, we report an increased CCNB2 expression in human pituitary adenomas of different histotypes that is directly correlated with HMGA1 and HMGA2 expression.
  • Because cyclin B2 is involved in the regulation of the cell cycle, these results taken together indicate that HMGA-induced cyclin B2 overexpression gives an important contribution to experimental and human pituitary tumorigenesis.
  • [MeSH-major] Adenoma / genetics. Cyclin B / genetics. Gene Expression Regulation, Neoplastic. HMGA1a Protein / physiology. HMGA2 Protein / physiology. Pituitary Neoplasms / genetics


31. Losa M, Fortunato M, Molteni L, Peretti E, Mortini P: Thyrotropin-secreting pituitary adenomas: biological and molecular features, diagnosis and therapy. Minerva Endocrinol; 2008 Dec;33(4):329-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyrotropin-secreting pituitary adenomas: biological and molecular features, diagnosis and therapy.
  • Central hyperthyroidism due to a thyrotropin (TSH)-secreting pituitary adenoma is a rare cause of hyperthyroidism, representing 0.5-1.0% of all pituitary adenomas.
  • The etiopathogenesis of TSH-secreting-adenomas is unknown and no definite role for various oncogenes has been proven.
  • Patients with TSH-secreting adenoma usually present with signs and symptoms of hyperthyroidism milder than those in patients with hyperthyroidism of thyroid origin, in addition to symptoms secondary to mass effects of the pituitary tumour.
  • Mixed pituitary tumours co-secrete growth hormone and prolactin.
  • Measurement of markers of peripheral thyroid hormone action and dynamic tests may aid in the differential diagnosis with the syndrome of resistance to thyroid hormone.
  • Neuroimaging is fundamental to visualize the pituitary tumor.
  • Therapy of TSH-secreting adenomas can be accomplished by surgery, radiation therapies, and medical treatment with somatostatin analogs or dopamine agonists.
  • [MeSH-major] Adenoma / diagnosis. Adenoma / therapy. Hyperthyroidism / diagnosis. Hyperthyroidism / therapy. Pituitary Neoplasms / diagnosis. Pituitary Neoplasms / therapy. Thyrotropin / secretion
  • [MeSH-minor] Biomarkers / blood. Diagnosis, Differential. Dopamine Agonists / therapeutic use. Human Growth Hormone / blood. Humans. Prolactin / blood. Somatostatin / analogs & derivatives. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hyperthyroidism.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18923369.001).
  • [ISSN] 0391-1977
  • [Journal-full-title] Minerva endocrinologica
  • [ISO-abbreviation] Minerva Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Dopamine Agonists; 12629-01-5 / Human Growth Hormone; 51110-01-1 / Somatostatin; 9002-62-4 / Prolactin; 9002-71-5 / Thyrotropin
  • [Number-of-references] 59
  •  go-up   go-down


32. de Oliveira Machado AL, Adams EF, Schott W, Nomikos P, Fahlbusch R, Buchfelder M: Analysis of secretory, immunostaining and clinical characteristics of human "functionless" pituitary adenomas: transdifferentiation or gonadotropinomas? Exp Clin Endocrinol Diabetes; 2005 Jun;113(6):344-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of secretory, immunostaining and clinical characteristics of human "functionless" pituitary adenomas: transdifferentiation or gonadotropinomas?
  • In this study, the central technique of in vitro culture has been used to further investigate whether LH/FSH-expressing, but clinically "functionless" pituitary adenomas are gonadotropinomas or whether their hormone secretion is due to transdifferentiation events.
  • 664 "functionless" pituitary adenomas were examined for hormone secretion by in vitro culture and for hormone content by immunostaining.
  • 40 % of the tumours (n = 263) secreted at least one of the gonadotropins alone, 8 % (n = 53) exhibited various patterns of anterior pituitary hormones, whilst the remaining 52 % of tumours were not associated with any hormone.
  • We conclude that the term "gonadotropinoma" to describe functionless pituitary tumours associated with LH and/or FSH secretion is a misnomer, because the presence of LH and/or FSH confirmed by in vitro methods in the present series is a result of only a few scattered cells.
  • We suggest that primary pituitary tumour cells differentiate into a secretory type (transdifferentiation), possibly in response to altered serum hormone levels such as decreased steroids.
  • [MeSH-major] Adenoma / secretion. Follicle Stimulating Hormone / secretion. Luteinizing Hormone / secretion. Pituitary Neoplasms / secretion

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. MENOTROPINS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15977103.001).
  • [ISSN] 0947-7349
  • [Journal-full-title] Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
  • [ISO-abbreviation] Exp. Clin. Endocrinol. Diabetes
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 9002-67-9 / Luteinizing Hormone; 9002-68-0 / Follicle Stimulating Hormone
  •  go-up   go-down


33. Peitl MV, Pavlović E, Peitl A, Peitl V: Amenorrhoea - consequence of combined treatment with sulpiride and risperidone in a patient suffering from schizophrenia. Psychiatr Danub; 2010 Mar;22(1):123-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This case report is of a patient that was treated with large doses of sulpiride, but did not develop an adverse event like amenorrhoea.
  • Therefore, the patient was sent to perform an MRI of the brain, under work diagnosis of pituitary adenoma, which was later ruled out as a cause of the illness.

  • Genetic Alliance. consumer health - Schizophrenia.
  • MedlinePlus Health Information. consumer health - Schizophrenia.
  • Hazardous Substances Data Bank. RISPERIDONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20305607.001).
  • [ISSN] 0353-5053
  • [Journal-full-title] Psychiatria Danubina
  • [ISO-abbreviation] Psychiatr Danub
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / Antipsychotic Agents; 7MNE9M8287 / Sulpiride; 9002-62-4 / Prolactin; L6UH7ZF8HC / Risperidone
  •  go-up   go-down


34. Syro LV, Scheithauer BW, Ortiz LD, Fadul CE, Horvath E, Rotondo F, Kovacs K: Effect of temozolomide in a patient with recurring oncocytic gonadotrophic pituitary adenoma. Hormones (Athens); 2009 Oct-Dec;8(4):303-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of temozolomide in a patient with recurring oncocytic gonadotrophic pituitary adenoma.
  • The patient was a 70-year-old man with a recurrent pituitary tumor.
  • Based on histologic, immunohistochemical and ultrastructural studies, the diagnosis of oncocytic gonadotrophic pituitary adenoma was made.
  • The present case indicates that benign, typically slow-growing pituitary adenomas of oncocytic gonadotrophic type may respond to Temozolomide even when the tumor consists of an admixture of MGMT immunopositive and immunonegative cells.
  • [MeSH-major] Adenoma / drug therapy. Antineoplastic Agents, Alkylating / therapeutic use. Dacarbazine / analogs & derivatives. Neoplasm Recurrence, Local / drug therapy. Pituitary Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20045804.001).
  • [ISSN] 1109-3099
  • [Journal-full-title] Hormones (Athens, Greece)
  • [ISO-abbreviation] Hormones (Athens)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


35. Diekman T, Mees B: Images in clinical medicine. Cerebrospinal fluid leak. N Engl J Med; 2009 Oct 1;361(14):e26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenoma / radiography. Cerebrospinal Fluid Rhinorrhea / radiography. Pituitary Neoplasms / radiography. Sella Turcica / radiography

  • Genetic Alliance. consumer health - Cerebrospinal Fluid Leak.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] N Engl J Med. 2011 Apr 7;364(14):1382
  • (PMID = 19797279.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Osa LE, Horjen J, Aanderud S, Lund-Johansen M: [Surgical treatment of hormone-producing pituitary adenomas]. Tidsskr Nor Laegeforen; 2006 May 11;126(10):1330-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment of hormone-producing pituitary adenomas].
  • BACKGROUND: Transsphenoidal surgical treatment is established as a treatment of hormonally active pituitary tumours, except prolactinomas.
  • METHODS: We did a retrospective survey evaluating the operative results of one surgeon operating hormonally active pituitary tumours from 1993 through 2002 at Haukeland University Hospital.
  • [MeSH-major] Adenoma / surgery. Pituitary Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Clinical Competence. Female. Humans. Male. Middle Aged. Neurosurgical Procedures / adverse effects. Neurosurgical Procedures / methods. Postoperative Complications / diagnosis. Postoperative Complications / etiology. Retrospective Studies. Sphenoid Bone / surgery. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16691270.001).
  • [ISSN] 0807-7096
  • [Journal-full-title] Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række
  • [ISO-abbreviation] Tidsskr. Nor. Laegeforen.
  • [Language] nor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


37. Jabbour SA, Davidovici BB, Wolf R: Rare syndromes. Clin Dermatol; 2006 Jul-Aug;24(4):299-316
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Dermatologists may also encounter patients presenting with skin lesions that reflect an underlying endocrine disorder not commonly seen in daily practice.
  • Multiple endocrine neoplasia type 1 is an autosomal dominant predisposition to tumors of the parathyroid glands (four-gland hyperplasia), anterior pituitary, and pancreatic islet cells; hence, the mnemonic device of the "3 Ps"; multiple cutaneous lesions (angiofibromas and collagenomas) are frequent in patients with multiple endocrine neoplasia type 1.
  • Carney complex may be viewed as a form of multiple endocrine neoplasia because affected patients often have tumors of two or more endocrine glands, including primary pigmented nodular adrenocortical disease (some with Cushing's syndrome), pituitary adenoma, testicular neoplasms, thyroid adenoma or carcinoma, and ovarian cysts.
  • Additional unusual manifestations include psammomatous melanotic schwannoma, breast ductal adenoma, and a rare bone tumor, osteochondromyxoma.
  • Mast cell diseases include all disorders of mast cell proliferation.
  • These diseases can be limited to the skin, referred to as "cutaneous mastocytosis," or involve extracutaneous tissues, called "systemic mastocytosis."
  • [MeSH-major] Endocrine System Diseases / genetics. Endocrine System Diseases / pathology. Mastocytosis, Cutaneous / pathology. Multiple Endocrine Neoplasia / genetics. Multiple Endocrine Neoplasia / pathology

  • MedlinePlus Health Information. consumer health - Endocrine Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16828412.001).
  • [ISSN] 0738-081X
  • [Journal-full-title] Clinics in dermatology
  • [ISO-abbreviation] Clin. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 155
  •  go-up   go-down


38. Kiviranta R, Järveläinen H, Laine H: [Weakened glucose balance and numb hands]. Duodecim; 2005;121(20):2223, 2225-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenoma / diagnosis. Diabetes Mellitus, Type 2 / diagnosis. Diabetes Mellitus, Type 2 / drug therapy. Pituitary Neoplasms / diagnosis
  • [MeSH-minor] Blood Glucose / analysis. Diagnosis, Differential. Follow-Up Studies. Hand. Humans. Hypesthesia / diagnosis. Magnetic Resonance Imaging. Male. Middle Aged. Muscle Weakness / diagnosis. Severity of Illness Index. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Diabetes Type 2.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16457192.001).
  • [ISSN] 0012-7183
  • [Journal-full-title] Duodecim; lääketieteellinen aikakauskirja
  • [ISO-abbreviation] Duodecim
  • [Language] fin
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Finland
  • [Chemical-registry-number] 0 / Blood Glucose
  •  go-up   go-down


39. Chanson P, Borson-Chazot F, Chabre O, Estour B: Drug treatment of hyperprolactinemia. Ann Endocrinol (Paris); 2007 Jun;68(2-3):113-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In patients with macroprolactinoma treated with DA, MRI monitoring should be carried out after 3 months of treatment to verify tumor size reduction, then after 1 year, yearly for the next 5 years and once every 5 years if adenoma size is stable.
  • When a prolonged treatment is interrupted, especially with cabergoline, progressive increase in serum prolactin and return of hyperprolactinemia symptoms are seen in only around 20-30% of cases, particularly when residual adenoma exists after prolonged treatment.
  • When normal prolactin levels have been achieved with DA, another solution consists in reducing the dose or dosing frequency of DA in steps to the lowest effective dose consistent with maintenance of normal prolactin levels and stable adenoma size.
  • It is therefore necessary to check for absence of pituitary adenoma and where necessary, begin treatment with sex steroids so as to ensure satisfactory impregnation with sex steroids and avoid osteoporosis.
  • [MeSH-minor] Female. Humans. Pituitary Neoplasms / complications. Pituitary Neoplasms / diagnosis. Pituitary Neoplasms / surgery. Postmenopause / physiology. Prolactinoma / complications. Prolactinoma / drug therapy. Prolactinoma / surgery. Treatment Outcome

  • Genetic Alliance. consumer health - Galactorrhoea-Hyperprolactinaemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17532288.001).
  • [ISSN] 0003-4266
  • [Journal-full-title] Annales d'endocrinologie
  • [ISO-abbreviation] Ann. Endocrinol. (Paris)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Dopamine Agonists
  • [Number-of-references] 46
  •  go-up   go-down


40. Zhang F, Chen J, Lu Y, Ding X: Manifestation, management and outcome of subclinical pituitary adenoma apoplexy. J Clin Neurosci; 2009 Oct;16(10):1273-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Manifestation, management and outcome of subclinical pituitary adenoma apoplexy.
  • The objective of this study was to investigate the clinical features, diagnosis, treatment and outcomes of subclinical pituitary adenoma apoplexy (SPAA) in 185 consecutive patients between January 1990 and May 2007.
  • Pituitary imaging was obtained by CT scans or MRI.
  • Visual disturbance, headache and pituitary function impairment improved significantly in all patients.
  • Prolactinoma was the most frequent type of pituitary adenoma in our series (51.89%).
  • SPAA usually occurred in patients with large or giant adenomas (85.95%).
  • The incidence of SPAA is relatively high compared with that of acute pituitary apoplexy.
  • [MeSH-major] Adenoma / surgery. Pituitary Apoplexy / surgery. Pituitary Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19577475.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


41. Kabil MS, Shahinian HK: Application of the supraorbital endoscopic approach to tumors of the anterior cranial base. J Craniofac Surg; 2005 Nov;16(6):1070-4; discussion 1075
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Application of the supraorbital endoscopic approach to tumors of the anterior cranial base.
  • Access to tumors of the anterior cranial fossa traditionally has required wide exposure of the surgical field, along with prolonged retraction of the frontal lobes or potentially disfiguring transfacial approaches.
  • With the introduction of progressively less-invasive approaches, intracranial tumors with craniofacial involvement have become amenable to en bloc resection with a minimum of deleterious consequences.
  • This technique is suitable for lesions situated in the region of the anterior cranial fossa, the suprasellar, and parasellar regions.
  • Pathologies treated were meningiomas, craniopharyngiomas, pituitary adenomas with extrasellarextensions, and other variable supratentorial pathologies.
  • The use of endoscopy allowed thorough visualization of all critical structures at the paramedian skull base without the need for a bicoronal scalp flap, bifrontal osteotomies, or brain retraction.
  • These cases demonstrate how the application of endoscopy to surgery of the anterior skull base and craniofacial skeleton can eliminate the need for traditional open techniques without compromising surgical success.
  • [MeSH-major] Cranial Fossa, Anterior / surgery. Endoscopy / methods. Orbit / surgery. Skull Base Neoplasms / surgery
  • [MeSH-minor] Adenoma / surgery. Adult. Aged. Arachnoid Cysts / surgery. Craniopharyngioma / surgery. Electrocoagulation. Female. Follow-Up Studies. Frontal Sinus / surgery. Humans. Male. Meningeal Neoplasms / surgery. Meningioma / surgery. Middle Aged. Minimally Invasive Surgical Procedures. Mucocele / surgery. Paranasal Sinus Diseases / surgery. Pituitary Neoplasms / surgery. Postoperative Complications. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16327556.001).
  • [ISSN] 1049-2275
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Bronstein MD, Melmed S: [Pituitary tumorigenesis]. Arq Bras Endocrinol Metabol; 2005 Oct;49(5):615-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pituitary tumorigenesis].
  • Pituitary adenomas, almost invariably adenomas, account for 10% to 15% of all intracranial neoplasms and are incidentally detected in up to 27% of non selected autopsies.
  • Functionally, they are classified as secreting adenomas (PRL, GH, ACTH, TSH, LH, and FSH, and those co-secreting two or more hormones), and clinically non secreting or "non functioning" tumors.
  • Diagnosis is based on the hypersecretion phenotype (acromegaly, Cushing, etc), and on mass effect of macroadenomas leading to neurological disturbances, mainly visual complaints and headache.
  • Pituitary tumorigenesis mechanisms include those of primary hypothalamic versus pituitary origin, the latter is supported by evidence of pituitary adenoma monoclonality, as well as the absence of hyperplastic tissue surrounding the surgically removed tumor, and the relative independence of tumor hypothalamic control.
  • Several molecular mechanisms involved in pituitary tumorigenesis have been unraveled including oncogenes, tumor suppressor genes and growth factors involved in neoplastic development, and will be described in this review.
  • [MeSH-major] Adenoma. Pituitary Neoplasms

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16444345.001).
  • [ISSN] 0004-2730
  • [Journal-full-title] Arquivos brasileiros de endocrinologia e metabologia
  • [ISO-abbreviation] Arq Bras Endocrinol Metabol
  • [Language] por
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Brazil
  • [Number-of-references] 68
  •  go-up   go-down


43. Muthukumar N, Rossette D, Soundaram M, Senthilbabu S, Badrinarayanan T: Blindness following pituitary apoplexy: timing of surgery and neuro-ophthalmic outcome. J Clin Neurosci; 2008 Aug;15(8):873-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Blindness following pituitary apoplexy: timing of surgery and neuro-ophthalmic outcome.
  • The aim of this study is to report the neuro-ophthalmic outcome in patients who underwent transsphenoidal decompression for unilateral or bilateral blindness that was due to pituitary apoplexy.
  • Four patients who were rendered blind (with an absence of light perception) unilaterally or bilaterally as a result of pituitary apoplexy were studied.
  • All four patients underwent transethmoidal decompression of the pituitary adenoma.
  • Although blindness following pituitary apoplexy is rare, visual acuity improves in most patients following transsphenoidal surgery.
  • [MeSH-major] Blindness / etiology. Blindness / surgery. Decompression, Surgical / methods. Pituitary Apoplexy / complications. Pituitary Apoplexy / surgery. Vision, Ocular / physiology

  • Genetic Alliance. consumer health - Blindness.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18502643.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


44. Saveanu A, Jaquet P: Somatostatin-dopamine ligands in the treatment of pituitary adenomas. Rev Endocr Metab Disord; 2009 Jun;10(2):83-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Somatostatin-dopamine ligands in the treatment of pituitary adenomas.
  • Somatostatin receptors (sst1-5) and dopamine receptor 2 (D2DR) are well expressed and co-localized in several human pituitary adenomas, suggesting possible functional interactions in the control of hormonal hypersecretion and tumor cell growth.
  • The present review describes the expression and functionality of these receptors in the different classes of human pituitary adenomas.
  • Such drugs are much less effective in the control of the others pituitary adenomas also expressing ssts and D2DR receptors.
  • Such ligands bearing distinct ssts and DRD2 pharmacophores may synergistically produce an increased control of secretion and/or of proliferation in the different types of pituitary adenomas.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Pituitary Neoplasms / drug therapy. Receptors, Dopamine D2 / agonists. Receptors, Somatostatin / agonists

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 1997 Nov 1;100(9):2386-92 [9410919.001]
  • [Cites] J Biol Chem. 2003 Nov 21;278(47):46741-9 [12933819.001]
  • [Cites] Eur J Endocrinol. 2005 Apr;152(4):645-54 [15817922.001]
  • [Cites] J Biol Chem. 2001 Jun 22;276(25):22621-9 [11278324.001]
  • [Cites] Pituitary. 2001 Aug;4(3):173-8 [12138990.001]
  • [Cites] Eur J Endocrinol. 1998 Nov;139(5):516-21 [9849816.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Apr;89(4):1674-83 [15070930.001]
  • [Cites] J Med Chem. 1998 Jun 18;41(13):2175-9 [9632348.001]
  • [Cites] J Nucl Med. 2003 Aug;44(8):1315-21 [12902423.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jan;86(1):140-5 [11231991.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2005 Aug;289(2):E278-87 [15769796.001]
  • [Cites] Endocr Rev. 1992 May;13(2):220-40 [1352243.001]
  • [Cites] Nat Rev Drug Discov. 2002 Oct;1(10):808-20 [12360258.001]
  • [Cites] Mol Endocrinol. 2007 Oct;21(10):2565-78 [17609435.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Sep;84(9):3268-76 [10487698.001]
  • [Cites] Cell Signal. 2007 Nov;19(11):2304-16 [17706924.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Nov;88(11):5414-21 [14602782.001]
  • [Cites] Eur J Endocrinol. 1994 Jan;130(1):80-91 [8124483.001]
  • [Cites] Biochem Biophys Res Commun. 1996 Oct 3;227(1):200-4 [8858125.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Aug;75(2):540-6 [1353505.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Feb;78(2):398-403 [8106629.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jun;88(6):2797-802 [12788890.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Nov;91(11):4482-8 [16940446.001]
  • [Cites] Br J Clin Pharmacol. 2004 Apr;57(4):373-87 [15025734.001]
  • [Cites] J Clin Endocrinol Metab. 2004 May;89(5):2452-62 [15126577.001]
  • [Cites] Neuroendocrinology. 2006;83(3-4):258-63 [17047391.001]
  • [Cites] J Pharmacol Exp Ther. 2000 Aug;294(2):407-12 [10900212.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jul;87(7):3013-8 [12107192.001]
  • [Cites] Int J Cancer. 1997 Mar 4;70(5):530-7 [9052751.001]
  • [Cites] Horm Res. 1997;47(4-6):227-34 [9167956.001]
  • [Cites] Eur J Endocrinol. 2005 Jul;153(1):135-41 [15994755.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Apr;93(4):1412-7 [18211974.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2005 Dec;289(6):E1044-50 [16046458.001]
  • [Cites] Eur J Endocrinol. 2007 Jan;156(1):65-74 [17218727.001]
  • [Cites] Endocrine. 2001 Apr;14(3):329-36 [11444429.001]
  • [Cites] J Clin Endocrinol Metab. 1972 Dec;35(6):941-3 [4634493.001]
  • [Cites] Eur J Endocrinol. 2001 Jul;145(1):35-41 [11415850.001]
  • [Cites] J Biol Chem. 2004 May 14;279(20):21374-82 [15001578.001]
  • [Cites] Eur J Endocrinol. 2008 May;158(5):595-603 [18426817.001]
  • [Cites] Eur J Nucl Med. 2001 Jul;28(7):836-46 [11504080.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Oct;89(10):5181-8 [15472224.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Feb;85(2):781-92 [10690891.001]
  • [Cites] J Biol Chem. 2002 May 31;277(22):19762-72 [11896051.001]
  • [Cites] Endocr Rev. 2003 Aug;24(4):389-427 [12920149.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Dec;87(12):5545-52 [12466351.001]
  • [Cites] J Biol Chem. 2001 Apr 27;276(17):14027-36 [11134004.001]
  • [Cites] EMBO Rep. 2004 Jan;5(1):30-4 [14710183.001]
  • [Cites] Clin Endocrinol (Oxf). 2000 Apr;52(4):437-45 [10762286.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Feb;83(2):374-8 [9467544.001]
  • [Cites] J Biol Chem. 2000 Mar 17;275(11):7862-9 [10713101.001]
  • [Cites] Mol Endocrinol. 2003 Jan;17(1):93-106 [12511609.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Nov;75(5):1318-25 [1358910.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Apr;93(4):1203-10 [18198230.001]
  • [Cites] Life Sci. 2006 Jan 11;78(7):689-93 [16115652.001]
  • [Cites] Eur J Endocrinol. 2003 Apr;148(4):433-42 [12656664.001]
  • [Cites] J Pharmacol Exp Ther. 2005 Aug;314(2):485-94 [15805429.001]
  • [Cites] Science. 2000 Apr 7;288(5463):154-7 [10753124.001]
  • [Cites] Front Neuroendocrinol. 1999 Jul;20(3):157-98 [10433861.001]
  • [Cites] Trends Pharmacol Sci. 2005 Mar;26(3):131-7 [15749158.001]
  • [Cites] Clin Endocrinol (Oxf). 2005 Jul;63(1):39-44 [15963059.001]
  • [Cites] Cancer Cell Int. 2006 Mar 06;6:5 [16519802.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Sep;88(9):4239-45 [12970293.001]
  • [Cites] J Clin Endocrinol Metab. 1989 Sep;69(3):500-9 [2760167.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Nov;75(5):1310-7 [1430093.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):3294-9 [11880655.001]
  • [Cites] J Biol Chem. 2004 Sep 10;279(37):38636-43 [15247250.001]
  • [Cites] Pituitary. 1999;1(2):115-20 [11081189.001]
  • [Cites] Eur J Endocrinol. 1999 Oct;141(4):396-408 [10526255.001]
  • [Cites] Endocr Rev. 2003 Feb;24(1):28-47 [12588807.001]
  • [Cites] FEBS Lett. 2003 Aug 28;550(1-3):11-7 [12935878.001]
  • [Cites] Regul Pept. 2007 Oct 4;143(1-3):109-17 [17531331.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Feb;89(2):638-45 [14764775.001]
  • (PMID = 18651224.001).
  • [ISSN] 1573-2606
  • [Journal-full-title] Reviews in endocrine & metabolic disorders
  • [ISO-abbreviation] Rev Endocr Metab Disord
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Receptors, Dopamine D2; 0 / Receptors, Somatostatin
  • [Number-of-references] 72
  •  go-up   go-down


45. Sánchez-Ortiga R, Sánchez Tejada L, Peiró Cabrera G, Moreno-Pérez O, Arias Mendoza N, Aranda López FI, Picó Alfonso A: [Rol of pituitary tumour-transforming gene (PTTG) in the pituitary adenomas]. Endocrinol Nutr; 2010 Jan;57(1):28-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Rol of pituitary tumour-transforming gene (PTTG) in the pituitary adenomas].
  • [Transliterated title] Papel de pituitary tumour-transforming gene (PTTG) en los adenomas hipofisarios.
  • The pathogenesis of pituitary tumours is far to be understood.
  • Pituitary transforming tumour gene (PTTG), a gen that induces aneuploidy, genetic instability, cellular proliferation and to stimulate angiogenesis, has been involved in neoplasic transformation and shown overexpressed in many neoplasm as lung, breast, endometrium, thyroid and colon malignant tumours.
  • On the other hand, PTTG has been inconsistently studied in pituitary tumours.
  • The goal of this review is to resume the role of PTTG in tumourogenesis and critically to revise the studies published in humans in order to advance in the knowledge of the pathogenesis of pituitary adenomas and to find clinical useful predictors of the behavior of these tumours.
  • [MeSH-major] Neoplasm Proteins / genetics. Pituitary Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Sociedad Española de Endocrinología y Nutrición. Published by Elsevier Espana. All rights reserved.
  • (PMID = 20172484.001).
  • [ISSN] 1575-0922
  • [Journal-full-title] Endocrinología y nutrición : órgano de la Sociedad Española de Endocrinología y Nutrición
  • [ISO-abbreviation] Endocrinol Nutr
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Securin; 0 / pituitary tumor-transforming protein 1, human
  • [Number-of-references] 53
  •  go-up   go-down


46. Raverot G, Arnous W, Calender A, Trouillas J, Sassolas G, Bournaud C, Pugeat M, Borson-Chazot F: Familial pituitary adenomas with a heterogeneous functional pattern: clinical and genetic features. J Endocrinol Invest; 2007 Oct;30(9):787-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Familial pituitary adenomas with a heterogeneous functional pattern: clinical and genetic features.
  • Familial pituitary adenoma is a rare syndrome which may present either as isolated lesions, or in association with other endocrine tumors, for example in the frame of multiple endocrine neoplasia (MEN-1) or Carney complex (CNC).
  • The most frequently described forms of familial isolated pituitary adenoma (FIPA) are familial somatotropinomas or prolactinomas.
  • A prospective survey also suggested the occurrence of a silent microadenoma in the proband's sister.
  • In conclusion, these data suggest that familial pituitary adenomas can occur with a heterogeneous functional pattern that is distinguished from MEN-1 or CNC.
  • [MeSH-major] Adenoma / genetics. Adenoma / physiopathology. Pituitary Neoplasms / genetics. Pituitary Neoplasms / physiopathology

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mayo Clin Proc. 1986 Mar;61(3):165-72 [3945116.001]
  • [Cites] Nat Genet. 2000 Sep;26(1):89-92 [10973256.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Sep;91(9):3316-23 [16787992.001]
  • [Cites] Pituitary. 2004;7(2):73-82 [15761655.001]
  • [Cites] J Clin Invest. 2000 Sep;106(5):R31-8 [10974026.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Feb;87(2):457-65 [11836268.001]
  • [Cites] Ann Intern Med. 1994 May 15;120(10):817-20 [8154641.001]
  • [Cites] Am J Hum Genet. 1998 Aug;63(2):455-67 [9683585.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Dec;91(12):4769-75 [16968795.001]
  • [Cites] Hum Mol Genet. 2000 Dec 12;9(20):3037-46 [11115848.001]
  • [Cites] Science. 2006 May 26;312(5777):1228-30 [16728643.001]
  • [Cites] Horm Metab Res. 2005 Jun;37(6):347-54 [16001326.001]
  • [Cites] Endocrinology. 2004 Dec;145(12):5452-8 [15331577.001]
  • [Cites] Growth Horm IGF Res. 2004 Jun;14 Suppl A:S90-6 [15135786.001]
  • (PMID = 17993773.001).
  • [ISSN] 1720-8386
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / MEN1 protein, human; 0 / Proto-Oncogene Proteins; 0 / Receptors, Aryl Hydrocarbon
  •  go-up   go-down


47. Feletti A, Marton E, Rossi S, Canal F, Longatti P, Billeci D: Pituitary metastasis of Merkel cell carcinoma. J Neurooncol; 2010 Apr;97(2):295-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pituitary metastasis of Merkel cell carcinoma.
  • We here present a unique case of a pituitary metastasis of MCC in a 65-year-old patient with a history of pituitary adenoma.
  • [MeSH-major] Carcinoma, Merkel Cell / secondary. Pituitary Neoplasms / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1992 Jul;16(7):658-66 [1530107.001]
  • [Cites] Arch Surg. 1991 Dec;126(12):1514-9 [1842182.001]
  • [Cites] J Neuroradiol. 2005 Mar;32(2):138-41 [15984406.001]
  • [Cites] Arch Otolaryngol. 1984 Nov;110(11):707-12 [6487123.001]
  • [Cites] Virchows Arch. 2008 May;452(5):559-63 [18386054.001]
  • [Cites] Ann Surg. 1988 Feb;207(2):201-7 [3277546.001]
  • [Cites] Neurosurg Rev. 1999;22(1):54-7 [10348209.001]
  • [Cites] Am J Surg Pathol. 1997 Feb;21(2):226-34 [9042291.001]
  • [Cites] Clin Neurol Neurosurg. 1989;91(4):317-20 [2555091.001]
  • [Cites] Isr Med Assoc J. 2003 Jun;5(6):450-1 [12841023.001]
  • [Cites] Med Pediatr Oncol. 1985;13(6):357-62 [3900664.001]
  • [Cites] Am J Otolaryngol. 1997 Jan-Feb;18(1):55-65 [9006679.001]
  • [Cites] Am J Clin Oncol. 2007 Dec;30(6):624-36 [18091058.001]
  • [Cites] J Neurosurg. 1988 May;68(5):811-6 [3282041.001]
  • [Cites] Cancer. 1988 Oct 15;62(8):1479-86 [3048629.001]
  • [Cites] J Plast Reconstr Aesthet Surg. 2008;61(2):165-71 [17382612.001]
  • [Cites] J Am Acad Dermatol. 2000 Nov;43(5 Pt 1):755-67 [11050578.001]
  • [Cites] J Neurooncol. 1994;22(3):231-4 [7760100.001]
  • [Cites] J Neurosurg. 2009 Apr;110(4):744-8 [19072308.001]
  • [Cites] Am J Otolaryngol. 2005 May-Jun;26(3):210-3 [15858780.001]
  • [Cites] Arch Dermatol. 1972 Jan;105(1):107-10 [5009611.001]
  • [Cites] Tumori. 2008 Sep-Oct;94(5):758-61 [19112956.001]
  • [Cites] Am J Clin Pathol. 1983 Jan;79(1):6-13 [6336886.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2300-9 [15800320.001]
  • [Cites] Ann Otol Rhinol Laryngol. 2004 Sep;113(9):683-7 [15453522.001]
  • [Cites] Mayo Clin Proc. 2001 Mar;76(3):327-30 [11243282.001]
  • [Cites] Head Neck. 2007 Mar;29(3):249-57 [17163472.001]
  • [Cites] J Am Acad Dermatol. 1993 Aug;29(2 Pt 1):143-56 [8335732.001]
  • [Cites] Ann Surg Oncol. 2001 Apr;8(3):204-8 [11314935.001]
  • [Cites] Horm Res. 2005;64(1):16-9 [16088203.001]
  • (PMID = 19806319.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Kiehna EN, Keil M, Lodish M, Stratakis C, Oldfield EH: Pseudotumor cerebri after surgical remission of Cushing's disease. J Clin Endocrinol Metab; 2010 Apr;95(4):1528-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All underwent resection of an ACTH-secreting adenoma, and postoperative serum cortisol reached a nadir of less than 2 microg/dl.

  • Genetic Alliance. consumer health - Pseudotumor cerebri.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. ACETAZOLAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1973 Aug 25;2(7826):418-21 [4124896.001]
  • [Cites] J Neurosurg. 1973 Oct;39(4):480-4 [4730337.001]
  • [Cites] J Neurosurg. 1975 Jun;42(6):690-5 [1141965.001]
  • [Cites] Neurosurgery. 1981 Jun;8(6):699-702 [6269017.001]
  • [Cites] Neurosurgery. 1982 Feb;10(2):297 [6280099.001]
  • [Cites] Endocr Pract. 2004 Nov-Dec;10(6):492-6 [16033722.001]
  • [Cites] Neurol Clin. 1991 Feb;9(1):73-95 [2011112.001]
  • [Cites] Postgrad Med J. 1994 Feb;70(820):115-7 [8170882.001]
  • [Cites] J Child Neurol. 1994 Apr;9(2):144-9 [8006364.001]
  • [Cites] Can J Neurol Sci. 1997 Aug;24(3):219-21 [9276106.001]
  • [Cites] Am J Ophthalmol. 1999 Feb;127(2):178-82 [10030560.001]
  • [Cites] Neurosurgery. 1983 Aug;13(2):195-8 [6310437.001]
  • (PMID = 20164289.001).
  • [ISSN] 1945-7197
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / Z01 HD000642; United States / NICHD NIH HHS / HD / Z01-HD-000642-04; United States / Intramural NIH HHS / /
  • [Publication-type] Case Reports; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Carbonic Anhydrase Inhibitors; 0 / Steroids; O3FX965V0I / Acetazolamide; WI4X0X7BPJ / Hydrocortisone
  • [Other-IDs] NLM/ PMC2853987
  •  go-up   go-down


49. Durán-Prado M, Gahete MD, Martínez-Fuentes AJ, Luque RM, Quintero A, Webb SM, Benito-López P, Leal A, Schulz S, Gracia-Navarro F, Malagón MM, Castaño JP: Identification and characterization of two novel truncated but functional isoforms of the somatostatin receptor subtype 5 differentially present in pituitary tumors. J Clin Endocrinol Metab; 2009 Jul;94(7):2634-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification and characterization of two novel truncated but functional isoforms of the somatostatin receptor subtype 5 differentially present in pituitary tumors.
  • DESIGN AND RESULTS: A rapid amplification of cDNA ends PCR approach on samples from a human pituitary tumor and a cell line enabled identification of two novel alternatively spliced sst5 receptor variants.
  • Both novel receptors show a differential expression pattern in normal tissues and are also present in pituitary tumors of diverse etiology including nonfunctioning adenomas, corticotropinomas, somatotropinomas, and a prolactinoma.
  • CONCLUSIONS: Our results demonstrate the existence of two previously unidentified sst5 spliced variants with distinct distribution in normal tissues and pituitary tumors, unique ligand-selective signaling properties, and subcellular distribution, which could contribute to somatostatin and cortistatin signaling in normal and tumoral cells.
  • [MeSH-major] Adenoma / genetics. Pituitary Neoplasms / genetics. Receptors, Somatostatin / genetics

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Guide to Pharmacology. gene/protein/disease-specific - SST5 receptor - data and references .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19401364.001).
  • [ISSN] 1945-7197
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Isoforms; 0 / Receptors, Somatostatin; 0 / somatostatin receptor 5
  •  go-up   go-down


50. Daousi C, Foy PM, MacFarlane IA: Ablative thyroid treatment for thyrotoxicosis due to thyrotropin-producing pituitary tumours. J Neurol Neurosurg Psychiatry; 2007 Jan;78(1):93-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ablative thyroid treatment for thyrotoxicosis due to thyrotropin-producing pituitary tumours.
  • BACKGROUND: Thyrotropin (TSH)-secreting pituitary adenomas (TSHomas) are rare tumours that can be invasive.
  • AIM: To study the effects of thyroid ablative treatment on tumour size and thyroid status in two patients with TSHomas in whom the size of the adenoma was clearly documented before treatment was started.
  • (1) a female patient with a TSHoma who declined to undergo pituitary surgery and underwent a total thyroidectomy instead and (2) a male patient who opted for radioiodine treatment for his recurrent TSHoma.
  • [MeSH-major] Pituitary Neoplasms / complications. Thyroid Gland / surgery. Thyrotoxicosis / etiology. Thyrotoxicosis / surgery. Thyrotropin / secretion

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 2000 Apr;85(4):1487-91 [10770186.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Feb;84(2):476-86 [10022404.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jun;86(6):2849-53 [11397898.001]
  • [Cites] Acta Endocrinol (Copenh). 1982 Feb;99(2):224-31 [6277128.001]
  • [Cites] J Clin Endocrinol Metab. 1984 Nov;59(5):817-24 [6480809.001]
  • [Cites] J Endocrinol Invest. 1984 Aug;7(4):313-7 [6438219.001]
  • [Cites] N Engl J Med. 1987 Jul 2;317(1):12-7 [2884564.001]
  • [Cites] J Clin Endocrinol Metab. 1989 Jan;68(1):208-14 [2491862.001]
  • [Cites] Mol Cell Endocrinol. 1993 Feb;91(1-2):75-81 [8472856.001]
  • [Cites] Ann Intern Med. 1993 Aug 1;119(3):236-40 [8323093.001]
  • [Cites] Clin Endocrinol (Oxf). 1994 Feb;40(2):275-8 [7511073.001]
  • [Cites] Clin Endocrinol (Oxf). 1994 Mar;40(3):421-8 [8187308.001]
  • [Cites] Eur J Endocrinol. 1994 Jun;130(6):559-64 [8205254.001]
  • [Cites] Endocr Rev. 1996 Dec;17(6):610-38 [8969971.001]
  • [Cites] Thyroid. 2000 Nov;10(11):1001-7 [11128714.001]
  • (PMID = 17172570.001).
  • [ISSN] 1468-330X
  • [Journal-full-title] Journal of neurology, neurosurgery, and psychiatry
  • [ISO-abbreviation] J. Neurol. Neurosurg. Psychiatry
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 9002-71-5 / Thyrotropin
  • [Other-IDs] NLM/ PMC2117800
  •  go-up   go-down


51. Wei YX, Han DM: [Management of nasal skull-base neoplasms with endoscopic minimally invasive technique: a report of 36 cases]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2008 Dec;43(12):915-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Thirty-six patients with nasal skull base neoplasms were treated from January 2000 to Jun 2004 under nasal endoscopy, including 16 nasopharyngeal fibroangioma, 8 sinus osteofibroma, 8 pituitary adenoma, 4 olfactory neuroblastoma.
  • All olfactory neuroblastoma and 2 pituitary adenoma received radiotherapy after operation.
  • RESULTS: Total or most of nasopharyngeal fibroangioma, sinus osteofibroma, olfactory neuroblastoma and pituitary adenoma were excised.
  • CONCLUSIONS: When the indications are selected appropriately, nasal skull-base neoplasms, including benign and malignant, can be well treated with nasal endoscopic minimally invasive surgery.
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Fibroma, Ossifying / surgery. Humans. Male. Middle Aged. Minimally Invasive Surgical Procedures. Nasopharyngeal Neoplasms / surgery. Neuroblastoma / surgery. Nose / surgery. Olfactory Nerve / pathology. Pituitary Neoplasms / surgery. Young Adult

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19141243.001).
  • [ISSN] 1673-0860
  • [Journal-full-title] Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  • [ISO-abbreviation] Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


52. Edo AE, Eregie A: Pregnancy associated with recurrent acromegaly: a case report. West Afr J Med; 2010 Mar-Apr;29(2):120-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Acromegaly is an uncommon endocrine disorder.
  • METHODS: Clinical and biochemical evaluation of a 39-year-old female Nigerian with features of acromegaly before and after macroadenectomy and postpartum was done.
  • Investigations carried out included oral glucose tolerance test with serial growth hormone assays and insulin-like growth factor 1 as well as computed tomography scan and magnetic resonance imaging of the pituitary.
  • [MeSH-major] Acromegaly / pathology. Growth Hormone-Secreting Pituitary Adenoma / pathology. Human Growth Hormone / blood. Pregnancy Complications / pathology

  • Genetic Alliance. consumer health - Acromegaly.
  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Health Problems in Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20544639.001).
  • [ISSN] 0189-160X
  • [Journal-full-title] West African journal of medicine
  • [ISO-abbreviation] West Afr J Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Nigeria
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Hormone Antagonists; 12629-01-5 / Human Growth Hormone; 3A64E3G5ZO / Bromocriptine; 67763-96-6 / Insulin-Like Growth Factor I; RWM8CCW8GP / Octreotide
  •  go-up   go-down


53. Lubina A, Olchovsky D, Berezin M, Ram Z, Hadani M, Shimon I: Management of pituitary apoplexy: clinical experience with 40 patients. Acta Neurochir (Wien); 2005 Feb;147(2):151-7; discussion 157
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of pituitary apoplexy: clinical experience with 40 patients.
  • BACKGROUND: Pituitary apoplexy is a rare major clinical event with neurological, neuro-ophthalmological, cardiovascular and hormonal consequences, resulting from an acute infarction of pituitary adenoma.
  • We report our experience with a series of 40 patients presenting with pituitary apoplexy.
  • PATIENTS: Forty patients (27 males, 13 females; mean age, 51.2 yr) were admitted to our medical center between years 1985-2002 with acute presentation of pituitary apoplexy.
  • Sixty-three percent of adenomas were nonfunctional, and prolactinomas comprised 31%.
  • RESULTS: Thirty-four patients underwent transsphenoidal pituitary decompression.
  • Serial sellar MRI showed disappearance of pituitary tumor in 63% of operated subjects.
  • Six patients (3 with PRL-secreting and 3 nonfunctional adenomas) were treated medically (corticosteroids, dopamine agonists), two patients (out of three) with visual deficits improved, and tumor shrinkage was noted in four.
  • CONCLUSIONS: We present a large series of patients with pituitary apoplexy.
  • [MeSH-major] Adenoma / complications. Decompression, Surgical / methods. Neurosurgical Procedures / methods. Pituitary Apoplexy / complications. Pituitary Apoplexy / surgery. Pituitary Neoplasms / complications
  • [MeSH-minor] Adolescent. Adrenal Cortex Hormones / therapeutic use. Adult. Aged. Aged, 80 and over. Clinical Protocols. Dopamine Agonists / therapeutic use. Female. Humans. Hypopituitarism / etiology. Hypopituitarism / physiopathology. Hypopituitarism / surgery. Magnetic Resonance Imaging. Male. Middle Aged. Optic Chiasm / physiopathology. Optic Chiasm / surgery. Optic Nerve / physiopathology. Optic Nerve / surgery. Pituitary Gland / pathology. Pituitary Gland / physiopathology. Pituitary Gland / surgery. Retrospective Studies. Sphenoid Bone / pathology. Sphenoid Bone / surgery. Treatment Outcome. Vision, Low / etiology. Vision, Low / physiopathology. Vision, Low / surgery

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15570437.001).
  • [ISSN] 0001-6268
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Dopamine Agonists
  •  go-up   go-down


54. Solheim O, Selbekk T, Løvstakken L, Tangen GA, Solberg OV, Johansen TF, Cappelen J, Unsgård G: Intrasellar ultrasound in transsphenoidal surgery: a novel technique. Neurosurgery; 2010 Jan;66(1):173-85; discussion 185-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The risk of a residual mass increases with tumor size and parasellar or suprasellar growth.
  • METHODS: In 9 patients with pituitary macroadenomas, intrasphenoidal and intrasellar ultrasound was assessed during transsphenoidal operations.
  • A small side-looking, high-frequency ultrasound probe can be used to ensure orientation in the midline for the surgical approach to identify important neurovascular structures to be avoided during surgery and for resection control and identification of normal pituitary tissue.
  • [MeSH-major] Adenoma / surgery. Neurosurgical Procedures / methods. Pituitary Neoplasms / surgery. Sella Turcica / surgery. Sphenoid Sinus / surgery

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20023548.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


55. Morita S, Otsuki M, Izumi M, Asanuma N, Izumoto S, Saitoh Y, Yoshimine T, Kasayama S: Reduced epinephrine reserve in response to insulin-induced hypoglycemia in patients with pituitary adenoma. Eur J Endocrinol; 2007 Sep;157(3):265-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced epinephrine reserve in response to insulin-induced hypoglycemia in patients with pituitary adenoma.
  • Insulin-induced hypoglycemia is used for evaluating GH-IGF-I and ACTH-adrenal axes in patients with pituitary disorders.
  • The aim of this study was to determine whether the response of catecholamine secretion to hypoglycemia is disrupted in patients with pituitary adenoma.
  • METHODS: The study population comprised 23 patients with pituitary adenoma (non-functioning adenoma or prolactinoma).
  • CONCLUSIONS: Impaired epinephrine secretion in response to insulin-induced hypoglycemia was frequently observed in patients with pituitary adenoma.
  • This disorder was especially severe in patients with secondary adrenal insufficiency.

  • Genetic Alliance. consumer health - Hypoglycemia.
  • MedlinePlus Health Information. consumer health - Hypoglycemia.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. Norepinephrine .
  • Hazardous Substances Data Bank. EPINEPHRINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17766707.001).
  • [ISSN] 0804-4643
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Hypoglycemic Agents; 0 / Insulin; X4W3ENH1CV / Norepinephrine; YKH834O4BH / Epinephrine
  •  go-up   go-down


56. Mooi WJ: Oncogene-induced cellular senescence: causal factor in the growth arrest of pituitary microadenomas? Horm Res; 2009 Apr;71 Suppl 2:78-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncogene-induced cellular senescence: causal factor in the growth arrest of pituitary microadenomas?
  • Pituitary microadenomas are exceedingly common in the general population, and only a very few progress to a size of more than a few millimetres.
  • The early and total, or near- total, growth arrest preventing the outgrowth of these adenomas calls to mind the phenomenon of oncogene- induced cellular senescence (OIS), a growth arrest response brought about by oncogenic signalling.
  • In the past, OIS has been demonstrated in a variety of benign neoplastic lesions, in animal models as well as in man.
  • A few recent studies on pituitary tumorigenesis in Rb+/- mice, as well as some preliminary observations in human pituitary adenomas, lend support to the idea that OIS is also an important mediator of growth arrest in these occult pituitary tumours.
  • If so, the fact that over 99.9% of pituitary adenomas never produce clinical problems of mass effect attests to the efficacy of this response.
  • [MeSH-major] Cell Aging. Cell Proliferation. Oncogenes. Pituitary Neoplasms / metabolism. Signal Transduction

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19407502.001).
  • [ISSN] 1423-0046
  • [Journal-full-title] Hormone research
  • [ISO-abbreviation] Horm. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 23
  •  go-up   go-down


57. Fernández-Miró M, Isern V, Marín JH, Manresa R, Chillarón JJ: [Panhypopituitarism and cranial nerve IV palsy: pituitary macroadenoma?]. Endocrinol Nutr; 2010 Dec;57(10):502-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Panhypopituitarism and cranial nerve IV palsy: pituitary macroadenoma?].
  • [Transliterated title] Panhipopituitarismo y parálisis del iv par craneal: ¿macroadenoma hipofisario?
  • [MeSH-major] Adenoma / complications. Carotid Artery Diseases / complications. Hypopituitarism / etiology. Intracranial Aneurysm / complications. Nerve Compression Syndromes / etiology. Pituitary Neoplasms / complications. Trochlear Nerve Diseases / etiology
  • [MeSH-minor] Aged, 80 and over. Carotid Artery, Internal. Cavernous Sinus. Empty Sella Syndrome / etiology. Female. Humans. Hydrocortisone / blood. Pituitary Hormones, Anterior / blood. Thyroid Hormones / blood. Thyrotropin / blood


58. Kessler M, David R, Pawelczak M, Hanono A, Shah B: Thyrotropin-secreting pituitary adenoma in an adolescent boy: challenges in management. Pediatrics; 2010 Aug;126(2):e474-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyrotropin-secreting pituitary adenoma in an adolescent boy: challenges in management.
  • We present here the case of a 16-year-old boy with a thyrotropin-secreting pituitary macroadenoma who underwent partial resection via a transsphenoidal approach and was left with significant residual tumor and continued hyperthyroidism.
  • [MeSH-major] Adenoma / secretion. Hyperthyroidism / etiology. Pituitary Neoplasms. Somatostatin / therapeutic use. Thyrotropin / secretion

  • MedlinePlus Health Information. consumer health - Hyperthyroidism.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20624809.001).
  • [ISSN] 1098-4275
  • [Journal-full-title] Pediatrics
  • [ISO-abbreviation] Pediatrics
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 51110-01-1 / Somatostatin; 9002-71-5 / Thyrotropin
  •  go-up   go-down


59. Tokumaru AM, Sakata I, Terada H, Kosuda S, Nawashiro H, Yoshii M: Optic nerve hyperintensity on T2-weighted images among patients with pituitary macroadenoma: correlation with visual impairment. AJNR Am J Neuroradiol; 2006 Feb;27(2):250-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optic nerve hyperintensity on T2-weighted images among patients with pituitary macroadenoma: correlation with visual impairment.
  • PURPOSE: Visual acuity (VA) disturbance other than field defect is important in evaluating patients with pituitary macroadenoma.
  • The purpose of this study was to evaluate MR imaging appearances of optic nerves in patients with pituitary macroadenoma and to ascertain whether visual impairment was correlated with abnormality in optic nerve signal intensity.
  • PATIENTS AND METHODS: Twenty-seven patients with pituitary macroadenoma were examined.
  • Optic nerves were evaluated on T2-weighted images and correlations of signal intensity abnormality with VA disturbance, visual field disturbance, degree of optic chiasm compression, pathologic findings of surgical specimen, and disease duration were statistically analyzed.
  • Bilateral signal intensity abnormality of the optic nerve was seen in 5 patients.
  • Signal intensity abnormality of the optic nerve was seen at the site of compression and in the ventral side of the tumor.
  • These patients did not demonstrate signal intensity abnormality posterior to the tumor.
  • CONCLUSION: Hyperintensity of the optic nerves ventral to the pituitary macroadenoma was associated with VA impairment.
  • MR imaging of the optic nerves can provide valuable information for management of pituitary macroadenoma.
  • [MeSH-major] Adenoma / diagnosis. Magnetic Resonance Imaging. Optic Nerve / pathology. Pituitary Neoplasms / diagnosis. Vision Disorders / diagnosis
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Nerve Compression Syndromes / diagnosis. Optic Chiasm / pathology. Optic Nerve Diseases / diagnosis. Papilledema / diagnosis. Sensitivity and Specificity. Statistics as Topic. Visual Acuity / physiology. Visual Fields / physiology


60. Yu R, Bonert V, Saporta I, Raffel LJ, Melmed S: Aryl hydrocarbon receptor interacting protein variants in sporadic pituitary adenomas. J Clin Endocrinol Metab; 2006 Dec;91(12):5126-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aryl hydrocarbon receptor interacting protein variants in sporadic pituitary adenomas.
  • CONTEXT: Proximal pathogenesis of pituitary tumors remains largely unclear.
  • Recently, three heterozygous germline mutations were reported in the aryl hydrocarbon receptor interacting protein (AIP) gene in Finnish and Italian families with pituitary tumor predisposition and in Finnish patients harboring sporadic pituitary tumors.
  • OBJECTIVE: The objectives of this study were to examine the frequency of the three AIP germline mutations in U.S. patients harboring sporadic pituitary tumors and to correlate clinical features of pituitary tumors with these mutations, if they exist in these patients.
  • DESIGN: Genomic DNA was extracted from lymphoblastoid cell lines established from patients with sporadic pituitary tumors.
  • PATIENTS: The subjects were 66 consecutive patients (including 52 with acromegaly or prolactinoma) participating in a pituitary tumor database who consented to genetic study.
  • CONCLUSIONS: The three specific AIP germline mutations do not play an important role in pathogenesis of sporadic pituitary tumors in U.S. patients.
  • [MeSH-major] Adenoma / genetics. Genetic Variation. Pituitary Neoplasms / genetics. Proteins / genetics

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17018653.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA75979
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 0 / Proteins; 0 / aryl hydrocarbon receptor-interacting protein
  •  go-up   go-down


61. Ahlhelm F, Nabhan A, Naumann N, Grunwald I, Shariat K, Reith W: [Skull base tumors]. Radiologe; 2005 Sep;45(9):807-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Modern imaging techniques have great importance in the diagnosis and therapy of skull-base pathologies.
  • Tumors commonly found in the anterior skull base include carcinoma, rhabdomyosarcoma, esthesioneuroblastoma and meningioma.
  • In the central cranial fossa, nasopharyngeal carcinoma, metastases, meningioma, pituitary adenoma and neurinoma have to be considered.
  • [MeSH-major] Image Processing, Computer-Assisted. Imaging, Three-Dimensional. Magnetic Resonance Imaging / methods. Skull Base Neoplasms / diagnosis. Tomography, Spiral Computed / methods
  • [MeSH-minor] Cerebellopontine Angle / pathology. Diagnosis, Differential. Humans. Neuroma, Acoustic / diagnosis. Neuroma, Acoustic / pathology. Sensitivity and Specificity. Skull Base / pathology

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Laryngoscope. 1981 Aug;91(8):1326-31 [7266211.001]
  • [Cites] Semin Roentgenol. 1990 Apr;25(2):174-97 [2190325.001]
  • [Cites] Magn Reson Imaging Clin N Am. 2002 Nov;10 (4):547-71, v [12685495.001]
  • [Cites] AJNR Am J Neuroradiol. 1996 Nov-Dec;17(10):1937-45 [8933883.001]
  • [Cites] AJNR Am J Neuroradiol. 1990 Sep-Oct;11(5):935-8 [2120998.001]
  • [Cites] J Neurosurg. 1988 Dec;69(6):850-60 [3057125.001]
  • [Cites] Paraplegia. 1993 Dec;31(12):803-7 [8115174.001]
  • [Cites] Radiology. 1989 Mar;170(3 Pt 1):857-62 [2916043.001]
  • [Cites] Radiol Clin North Am. 1989 Mar;27(2):315-30 [2645605.001]
  • [Cites] Radiology. 2000 Aug;216(2):342-9 [10924551.001]
  • [Cites] Neuroimaging Clin N Am. 1994 Aug;4(3):561-78 [7952956.001]
  • [Cites] J Comput Assist Tomogr. 1987 Sep-Oct;11(5):824-30 [3655045.001]
  • [Cites] AJR Am J Roentgenol. 1980 Oct;135(4):781-7 [6778113.001]
  • [Cites] Isr J Med Sci. 1992 Mar-Apr;28(3-4):173-82 [1592584.001]
  • [Cites] AJNR Am J Neuroradiol. 1987 Mar-Apr;8(2):353-9 [3105291.001]
  • [Cites] Neuroimaging Clin N Am. 1994 Aug;4(3):599-617 [7952958.001]
  • [Cites] AJR Am J Roentgenol. 1992 Sep;159(3):581-9 [1503031.001]
  • [Cites] J Comput Assist Tomogr. 1987 Jul-Aug;11(4):577-82 [3597877.001]
  • [Cites] J Comput Assist Tomogr. 1988 Jan-Feb;12 (1):70-4 [3257222.001]
  • [Cites] Neurology. 1981 May;31(5):530-7 [6972014.001]
  • [Cites] Otolaryngol Clin North Am. 1995 Jun;28(3):453-71 [7675464.001]
  • [Cites] Eur Radiol. 2005 Mar;15(3):534-42 [15633062.001]
  • [Cites] Neuroimaging Clin N Am. 1994 Aug;4(3):515-27 [7952953.001]
  • [Cites] Radiographics. 2003 Jul-Aug;23(4):995-1009 [12853676.001]
  • [Cites] Radiology. 1990 Jan;174(1):65-71 [2152985.001]
  • [Cites] AJNR Am J Neuroradiol. 1992 Nov-Dec;13(6):1627-36 [1442442.001]
  • [Cites] Radiology. 1989 Apr;171(1):161-4 [2928520.001]
  • [Cites] J Comput Assist Tomogr. 1979 Jun;3(3):335-8 [438373.001]
  • [Cites] Radiology. 1984 Dec;153(3):705-11 [6494466.001]
  • [Cites] Radiology. 1988 Jun;167(3):803-8 [3363145.001]
  • [Cites] Radiology. 1988 Nov;169(2):439-44 [3174990.001]
  • [Cites] Neuroradiology. 1997 Aug;39(8):571-6 [9272494.001]
  • [Cites] AJNR Am J Neuroradiol. 1992 Mar-Apr;13(2):655-90 [1566723.001]
  • [Cites] AJR Am J Roentgenol. 1987 Jan;148(1):201-4 [3024473.001]
  • (PMID = 16096741.001).
  • [ISSN] 0033-832X
  • [Journal-full-title] Der Radiologe
  • [ISO-abbreviation] Radiologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


62. Blomquist E, Bjelkengren G, Glimelius B: The potential of proton beam radiation therapy in intracranial and ocular tumours. Acta Oncol; 2005;44(8):862-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In intracranial benign and malignant tumours, it is estimated that between 130 and 180 patients each year are candidates for proton beam therapy.
  • Of these, between 50 and 75 patients have malignant glioma, 30-40 meningeoma, 20-25 arteriovenous malformations, 20-25 skull base tumours and 10-15 pituitary adenoma.
  • [MeSH-minor] Adenoma / radiotherapy. Chordoma / radiotherapy. Glioma / radiotherapy. Humans. Meningeal Neoplasms / radiotherapy. Pituitary Neoplasms / radiotherapy. Radiotherapy Planning, Computer-Assisted. Skull Neoplasms / radiotherapy. Sweden

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16332593.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Protons
  • [Number-of-references] 93
  •  go-up   go-down


63. Gul S, Bahadir B, Dusak A, Kalayci M, Edebali N, Acikgoz B: Spherical amyloid deposition in a prolactin-producing pituitary adenoma. Neuropathology; 2009 Feb;29(1):81-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spherical amyloid deposition in a prolactin-producing pituitary adenoma.
  • MRI demonstrated a mass arising from the pituitary gland.
  • The patient underwent trans-sphenoidal resection of the pituitary adenoma.
  • Histological examination revealed an adenoma with spheroid amyloid deposits adjacent to prolactin-staining adenoma cells.
  • [MeSH-major] Adenoma / pathology. Amyloid / metabolism. Pituitary Neoplasms / pathology
  • [MeSH-minor] Adult. Birefringence. Congo Red. Humans. Immunohistochemistry. Keratins / metabolism. Magnetic Resonance Imaging. Male. Pituitary Hormones, Anterior / metabolism. Prolactin / metabolism

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. C.I. DIRECT RED 28 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Neuropathology. 2009 Apr;29(2):208
  • (PMID = 18498287.001).
  • [ISSN] 1440-1789
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Amyloid; 0 / Pituitary Hormones, Anterior; 3U05FHG59S / Congo Red; 68238-35-7 / Keratins; 9002-62-4 / Prolactin
  •  go-up   go-down


64. Rivera J, Alves S, Bianchi CC, Al-Mutawa N, Guiot MC, Zeitouni A: An unusual collision tumor comprising a prolactinoma and a plasmocytoma originating from the sellar region. Pituitary; 2010 Jun;13(2):189-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MR imaging showed a large sellar mass with significant destruction of the pituitary fossa.
  • A transsphenoidal excisional biopsy was performed which demonstrated two distinct populations of cells, corresponding to a plasma cell tumor and a lactotroph adenoma.
  • Only a few cases of solitary plasmocytomas of the pituitary region have been reported.
  • We suggest that in the presence of extensive cranial nerve involvement, atypical imaging findings for a pituitary adenoma and severe hyperprolactinemia, the possibility of a collision tumor should lead the physician to consider excisional tumor biopsy or surgery in addition to dopamine agonist therapy.
  • [MeSH-major] Neoplasms, Multiple Primary / diagnosis. Pituitary Neoplasms / diagnosis. Plasmacytoma / diagnosis. Prolactinoma / diagnosis. Sella Turcica / pathology

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pituitary. 2006;9(1):65-72 [16703411.001]
  • [Cites] Neurology. 1988 Apr;38(4):614-6 [2832785.001]
  • [Cites] Surg Neurol. 1992 May;37(5):388-93 [1631767.001]
  • [Cites] Mayo Clin Proc. 2007 Jul;82(7):836-42 [17605964.001]
  • [Cites] Breast Dis. 2003;18:75-86 [15687690.001]
  • [Cites] Blood Rev. 2007 Nov;21(6):285-99 [17850941.001]
  • [Cites] Pituitary. 2008;11(3):317-23 [17917812.001]
  • [Cites] Immunol Lett. 2002 Jul 3;82(3):191-6 [12036601.001]
  • [Cites] Biomed Pharmacother. 2004 Jun;58(5):310-9 [15194167.001]
  • [Cites] Arch Pathol Lab Med. 1977 Jan;101(1):55-6 [576202.001]
  • [Cites] J Endocrinol Invest. 2000 Jan;23(1):37-41 [10698050.001]
  • [Cites] Trends Endocrinol Metab. 2006 Apr;17(3):110-6 [16517173.001]
  • [Cites] Neuroimmunomodulation. 2001;9(4):231-6 [11847486.001]
  • [Cites] Neuroimmunomodulation. 2001;9(2):95-102 [11549891.001]
  • [Cites] Semin Arthritis Rheum. 2001 Aug;31(1):21-32 [11503136.001]
  • [Cites] Blood. 1995 Feb 15;85(4):863-72 [7849308.001]
  • [Cites] Ann Med. 2004;36(6):414-25 [15513293.001]
  • [Cites] Pituitary. 2004;7(3):179-181 [16328566.001]
  • [Cites] Acta Neurochir (Wien). 1999;141(2):219-20 [10189508.001]
  • [Cites] Neurosurgery. 1998 May;42(5):1197-9 [9588573.001]
  • [Cites] Autoimmun Rev. 2007 Sep;6(8):537-42 [17854745.001]
  • (PMID = 18846427.001).
  • [ISSN] 1573-7403
  • [Journal-full-title] Pituitary
  • [ISO-abbreviation] Pituitary
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Cauley K, Dalal A, Olson B, Onyiuke H: Lymphocytic hypophysitis. Conn Med; 2005 Mar;69(3):143-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lymphocytic hypophysitis (LH) is a rare but increasingly recognized inflammatory disorder of the pituitary, usually associated with pregnancy.
  • Cases are usually discovered at biopsy and surgical intervention for a presumptive pituitary neoplasm.
  • In the first case the patient underwent surgery for presumptive adenoma, and pathology at resection established the diagnosis of lymphocytic hypophysitis.
  • [MeSH-major] Autoimmune Diseases / diagnosis. Pituitary Diseases / diagnosis. Pituitary Gland / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Hypopituitarism / diagnosis. Hypopituitarism / physiopathology. Inflammation / diagnosis. Inflammation / etiology. Lymphocytes / pathology. Lymphocytosis / diagnosis. Lymphocytosis / physiopathology. Magnetic Resonance Imaging. Pituitary Hormones / deficiency. Pituitary Neoplasms / diagnosis


66. Mucha SA, Meleń-Mucha G, Godlewski A, Stepień H: Inhibition of estrogen-induced pituitary tumor growth and angiogenesis in Fischer 344 rats by the matrix metalloproteinase inhibitor batimastat. Virchows Arch; 2007 Mar;450(3):335-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of estrogen-induced pituitary tumor growth and angiogenesis in Fischer 344 rats by the matrix metalloproteinase inhibitor batimastat.
  • The development of estrogen-induced pituitary prolactinoma in Fischer 344 (F344) rats is associated with enhanced neovascularization.
  • Based on the significance of matrix metalloproteinases (MMPs) for tumor growth and angiogenesis, we have studied the effect of batimastat (BB-94), a synthetic MMPs inhibitor (MMPI) on the progression of prolactin-secreting pituitary adenoma in rats.
  • Pituitary tumors were induced in male F344 rats by s.c. implantation of Silastic tubes containing diethylstilbestrol (DES).
  • The effects of chronic treatment with BB-94 (30 mg/kg b.w.) on pituitary weight, cell proliferation, apoptosis and vascular density were evaluated.
  • We have stated that chronic treatment with batimastat caused a significant reduction in the pituitary weight.
  • A marked increase in the apoptotic index within the pituitary was observed in the study group.
  • The ability of BB-94 to suppress established pituitary tumor growth suggests a possible application of MMPIs in the treatment of pituitary adenomas.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Neovascularization, Pathologic / prevention & control. Phenylalanine / analogs & derivatives. Pituitary Gland, Anterior / blood supply. Pituitary Neoplasms / drug therapy. Prolactinoma / drug therapy. Protease Inhibitors / therapeutic use. Thiophenes / therapeutic use

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. DIETHYLSTILBESTROL .
  • Hazardous Substances Data Bank. (L)-Phenylalanine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 1999 Dec;45(6):1432-40; discussion 1440-1 [10598711.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Aug;85(8):2931-5 [10946906.001]
  • [Cites] Clin Endocrinol (Oxf). 1994 Sep;41(3):359-64 [7893282.001]
  • [Cites] Cancer Res. 1999 Oct 15;59(20):5356-64 [10537320.001]
  • [Cites] Prostate. 1998 Jun 1;35(4):248-54 [9609547.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Jul;81(14):4549-53 [6589610.001]
  • [Cites] Invest New Drugs. 1996;14(2):193-202 [8913840.001]
  • [Cites] Endocr Rev. 1992 May;13(2):220-40 [1352243.001]
  • [Cites] Breast Cancer Res Treat. 1995;36(2):169-80 [8534865.001]
  • [Cites] Endocr Rev. 1998 Dec;19(6):798-827 [9861546.001]
  • [Cites] Cancer Res. 1993 May 1;53(9):2087-91 [8347186.001]
  • [Cites] Am J Respir Cell Mol Biol. 1992 Aug;7(2):120-5 [1497900.001]
  • [Cites] Nature. 1987 Apr 2-8;326(6112):515-7 [2882423.001]
  • [Cites] N Engl J Med. 1971 Nov 18;285(21):1182-6 [4938153.001]
  • [Cites] Biol Reprod. 1999 Jan;60(1):176-82 [9858503.001]
  • [Cites] Endocr Pathol. 2000 Winter;11(4):341-352 [12114758.001]
  • [Cites] Drugs. 2000 May;59(5):1043-55 [10852638.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Jan;85(1):263-9 [10634397.001]
  • [Cites] Endocrine. 1999 Dec;11(3):217-33 [10786818.001]
  • [Cites] Anticancer Res. 1998 Sep-Oct;18(5A):3615-9 [9858948.001]
  • [Cites] Mol Cell Endocrinol. 1996 Nov 29;124(1-2):33-42 [9027322.001]
  • [Cites] FASEB J. 1991 May;5(8):2145-54 [1850705.001]
  • [Cites] Eur J Cancer. 1996 Dec;32A(14):2528-33 [9059343.001]
  • [Cites] Am J Anat. 1987 Aug;179(4):315-23 [3661455.001]
  • [Cites] Endocr Pathol. 1997 Winter;8(4):259-272 [12114787.001]
  • [Cites] Prostate. 2000 May 1;43(2):77-82 [10754522.001]
  • [Cites] Int J Cancer. 1996 Jul 3;67(1):45-53 [8690524.001]
  • [Cites] J Endocrinol. 1996 Jul;150(1):99-106 [8708569.001]
  • [Cites] J Natl Cancer Inst. 1995 Oct 18;87(20):1546-50 [7563189.001]
  • [Cites] J Surg Res. 1997 May;69(2):367-71 [9224409.001]
  • [Cites] Int J Cancer. 1995 Mar 29;61(1):27-34 [7705930.001]
  • [Cites] J Cell Biol. 1992 Nov;119(3):493-501 [1400587.001]
  • [Cites] Int J Cancer. 1994 Aug 1;58(3):460-4 [8050828.001]
  • [Cites] Ann Oncol. 1995 Dec;6(10):967-74 [8750146.001]
  • [Cites] J Neurosurg. 1986 Dec;65(6):733-44 [3095506.001]
  • [Cites] Baillieres Best Pract Res Clin Endocrinol Metab. 1999 Oct;13(3):353-65 [10909428.001]
  • [Cites] J Clin Endocrinol Metab. 1989 Sep;69(3):500-9 [2760167.001]
  • [Cites] Cell Res. 1998 Sep;8(3):171-7 [9791730.001]
  • [Cites] J Clin Endocrinol Metab. 1993 May;76(5):1089-94 [8496297.001]
  • [Cites] Br J Cancer. 1993 Feb;67(2):205-8 [8431353.001]
  • [Cites] Endocrinology. 1981 Nov;109(5):1700-7 [7297500.001]
  • [Cites] J Natl Cancer Inst. 1995 Feb 15;87(4):293-8 [7535861.001]
  • [Cites] Am J Pathol. 1997 Sep;151(3):671-7 [9284815.001]
  • [Cites] Cancer Res. 1994 Sep 1;54(17):4726-8 [8062271.001]
  • [Cites] Neuroendocrinology. 1983 Jul;37(1):23-31 [6888657.001]
  • [Cites] N Engl J Med. 1991 Jan 3;324(1):1-8 [1701519.001]
  • (PMID = 17235567.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Estrogens; 0 / Proliferating Cell Nuclear Antigen; 0 / Protease Inhibitors; 0 / Thiophenes; 47E5O17Y3R / Phenylalanine; 731DCA35BT / Diethylstilbestrol; BK349F52C9 / batimastat; EC 3.4.24.- / Metalloendopeptidases
  •  go-up   go-down


67. Salehi F, Kovacs K, Scheithauer BW, Cantelmi D, Horvath E, Lloyd RV, Cusimano M: Immunohistochemical expression of pituitary tumor transforming gene (PTTG) in pituitary adenomas: a correlative study of tumor subtypes. Int J Surg Pathol; 2010 Feb;18(1):5-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical expression of pituitary tumor transforming gene (PTTG) in pituitary adenomas: a correlative study of tumor subtypes.
  • OBJECTIVE: We investigated the correlation between immunohistochemical expression of the pituitary tumor transforming gene (PTTG) and pituitary adenoma subtype.
  • METHODS: Pituitary adenomas (n = 89) were stained for PTTG using the streptavidin-biotin-peroxidase complex method and a monoclonal PTTG antibody.
  • Reactivity was highest in growth hormone (GH) adenomas as compared with other tumors, including prolactin (PRL), follicle-stimulating hormone/luteinizing hormone/alpha subunit, as well as adrenocorticotrophic hormone-secreting adenomas.
  • PRL adenomas exhibited the lowest expression levels.
  • Among GH adenomas, untreated tumors demonstrated significantly higher PTTG levels than octreotide-treated examples.
  • Although dopamine agonist-treated PRL adenomas tended to show lower expression levels, statistical significance was not reached.
  • CONCLUSIONS: Our finding that PTTG was differentially expressed in pituitary adenoma subtypes suggests a cell-specific function for PTTG.
  • Moreover, treatment of GH adenomas with somatostatin analogues lowered PTTG expression.
  • [MeSH-major] Neoplasm Proteins / metabolism. Pituitary Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20106827.001).
  • [ISSN] 1940-2465
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Biomarkers, Tumor; 0 / Hormone Antagonists; 0 / Neoplasm Proteins; 0 / Securin; 0 / pituitary tumor-transforming protein 1, human; 3A64E3G5ZO / Bromocriptine; RWM8CCW8GP / Octreotide
  •  go-up   go-down


68. Goglia U, Ferone D, Sidoti M, Spaziante R, Dadati P, Ravetti JL, Villa G, Bodei L, Paganelli G, Minuto F, Giusti M: Treatment of a pituitary metastasis from a neuroendocrine tumour: case report and literature review. Pituitary; 2008;11(1):93-102
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of a pituitary metastasis from a neuroendocrine tumour: case report and literature review.
  • Herein we report a rare case of a pituitary metastasis from a neuroendocrine tumour mimicking an adenoma.
  • Moreover, starting from this unusual case, the relevant literature concerning the diagnosis and management of patients with metastasis at pituitary level is reviewed.
  • MRI showed a large pituitary mass compressing the optic chiasm and infiltrating the cavernous sinus.
  • Trans-sphenoidal biopsy revealed a pituitary metastasis from a neuroendocrine tumour, in line with the multiple liver lesions that were already considered metastases from an ileal primary neuroendocrine tumour.
  • In vitro receptor characterisation of both pituitary and liver tissues by immunohistochemistry showed a heterogeneous somatostatin receptor subtype pattern, with a predominant expression of sst(2) within the pituitary lesion.
  • However, the liver metastasis receptor profile was completely different from the pituitary.
  • To our knowledge, this is the first case of combined treatment using "cold" and radiolabelled octreotide in a pituitary metastasis from a neuroendocrine tumour.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Ileal Neoplasms / pathology. Neuroendocrine Tumors / therapy. Octreotide / analogs & derivatives. Octreotide / therapeutic use. Organometallic Compounds / therapeutic use. Pituitary Neoplasms / therapy. Radiopharmaceuticals / therapeutic use
  • [MeSH-minor] Adenoma / diagnosis. Adult. Aged. Biopsy. Delayed-Action Preparations. Diagnosis, Differential. Diplopia / etiology. Diplopia / therapy. Female. Headache / etiology. Headache / therapy. Humans. Immunohistochemistry. Liver Neoplasms / secondary. Magnetic Resonance Imaging. Male. Middle Aged. Quality of Life. Radionuclide Imaging. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Nucl Med. 2002 May;43(5):610-6 [11994522.001]
  • [Cites] Endocr Rev. 2004 Jun;25(3):458-511 [15180952.001]
  • [Cites] J Clin Pathol. 1997 May;50(5):440-2 [9215132.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 Jul;31(7):1038-46 [15150675.001]
  • [Cites] Semin Nucl Med. 2002 Apr;32(2):133-40 [11965608.001]
  • [Cites] Pituitary. 2004;7(1):51-7 [15638299.001]
  • [Cites] Presse Med. 1991 Feb 9;20(5):223 [1848934.001]
  • [Cites] Br J Neurosurg. 1989;3(1):71-9 [2789715.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Nov;88(11):5150-7 [14602742.001]
  • [Cites] Clin Endocrinol (Oxf). 1999 Sep;51(3):377-81 [10469019.001]
  • [Cites] Surg Neurol. 1997 Oct;48(4):389-94 [9315138.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Apr;85(4):1719-26 [10770220.001]
  • [Cites] Med Oncol. 2003;20(1):59-67 [12665686.001]
  • [Cites] Neurology. 1981 Aug;31(8):998-1002 [7196526.001]
  • [Cites] J Neurosurg Sci. 1992 Jan-Mar;36(1):51-4 [1323647.001]
  • [Cites] Am Surg. 2000 Dec;66(12):1179-80 [11149595.001]
  • [Cites] Eur J Endocrinol. 2004 Mar;150(3):299-303 [15012614.001]
  • [Cites] J Endocrinol Invest. 2001 Jul-Aug;24(7):522-8 [11508787.001]
  • [Cites] Neuroradiology. 1992;34(2):131-4 [1603311.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Aug;82(8):2731-7 [9253362.001]
  • [Cites] Rev Mal Respir. 2000 Dec;17(6):1107-9 [11217509.001]
  • [Cites] Curr Opin Oncol. 2000 Jul;12(4):368-77 [10888424.001]
  • [Cites] Endocrinology. 1982 Apr;110(4):1147-54 [6120829.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Feb;89(2):574-80 [14764764.001]
  • [Cites] Endocr Rev. 2003 Feb;24(1):28-47 [12588807.001]
  • [Cites] World J Surg. 1998 Jul;22(7):679-83 [9606281.001]
  • [Cites] Arch Pathol Lab Med. 1985 Mar;109(3):287-9 [2983639.001]
  • [Cites] Neurochirurgia (Stuttg). 1990 Jul;33(4):127-31 [2203980.001]
  • [Cites] Neth J Med. 1998 Jul;53(1):32-6 [9718940.001]
  • [Cites] Tumori. 1988 Feb 29;74(1):101-5 [2451332.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2754-62 [15837990.001]
  • (PMID = 17458701.001).
  • [ISSN] 1573-7403
  • [Journal-full-title] Pituitary
  • [ISO-abbreviation] Pituitary
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / (177lutetium-DOTA(O)Tyr3)octreotate; 0 / 90Y-octreotide, DOTA-Tyr(3)-; 0 / Antineoplastic Agents, Hormonal; 0 / Delayed-Action Preparations; 0 / Organometallic Compounds; 0 / Radiopharmaceuticals; RWM8CCW8GP / Octreotide
  • [Number-of-references] 32
  •  go-up   go-down


69. Kaltsas GA, Evanson J, Chrisoulidou A, Grossman AB: The diagnosis and management of parasellar tumours of the pituitary. Endocr Relat Cancer; 2008 Dec;15(4):885-903
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The diagnosis and management of parasellar tumours of the pituitary.
  • The sellar and parasellar region is an anatomically complex area where a number of neoplastic, inflammatory, infectious, developmental and vascular diseases can develop.
  • Although most sellar lesions are due to pituitary adenomas, a number of other pathologies involving the parasellar region can present in a similar manner.
  • The diagnosis of such lesions involves a multidisciplinary approach, and detailed endocrinological, ophthalmological, neuroimaging, neurological and finally histological studies are required.
  • Correct diagnosis prior to any intervention is essential as the treatment of choice will be different for each disorder, particularly in the case of primary malignant parasellar tumours.
  • [MeSH-major] Adenoma / diagnosis. Adenoma / therapy. Pituitary Neoplasms / diagnosis. Pituitary Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18809592.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 99
  •  go-up   go-down


70. Nielsen K, Madsen KH, Frederiksen JL, Leffers AM, Lund TE: Functional magnetic resonance imaging corresponds to Humphrey perimetry in a patient with pituitary adenoma. Acta Ophthalmol Scand; 2006 Apr;84(2):267-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Functional magnetic resonance imaging corresponds to Humphrey perimetry in a patient with pituitary adenoma.
  • [MeSH-major] Adenoma / diagnosis. Magnetic Resonance Imaging / methods. Pituitary Neoplasms / diagnosis. Vision Disorders / diagnosis. Visual Field Tests / methods. Visual Fields


71. Haap M, Gallwitz B, Meyermann R, Mittelbronn M: Cushing's disease associated with both pituitary microadenoma and corticotroph hyperplasia. Exp Clin Endocrinol Diabetes; 2009 Jun;117(6):289-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cushing's disease associated with both pituitary microadenoma and corticotroph hyperplasia.
  • Herein, we present the case of a 63-year old female patient with initial symptoms of myopathy, hypokaliemia, glucosuria and psychotic symptoms.
  • MRI imaging revealed a possible pituitary microadenoma.
  • To confirm the diagnosis a bilateral inferior petrosal sinus sampling was performed presenting higher ACTH levels on the right side.
  • Neuropathological autopsy revealed nodular proliferations of corticotropic cells in the pituitary gland that are assumed to be morphological entities between diffuse hyperplasias and adenomas, termed as tumorlets.
  • In single reports, multiple pituitary lesions in patients with Cushing's disease have been demonstrated, but to our knowledge none of these cases presented the combination of an ACTH-producing microadenoma and corticotroph cell hyperplasia in the same patient.
  • Therefore, even after resection of a pituitary microadenoma one should be aware of the possibility of continuously elevated ACTH level being due to multifocal nodular corticotroph hyperplasia which is invisible by neuroradiological examination.
  • [MeSH-major] ACTH-Secreting Pituitary Adenoma / pathology. Pituitary ACTH Hypersecretion / pathology. Pituitary Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. Corticotropin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Exp Clin Endocrinol Diabetes. 2010 Jan;118(1):68 [20127571.001]
  • (PMID = 19085700.001).
  • [ISSN] 1439-3646
  • [Journal-full-title] Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
  • [ISO-abbreviation] Exp. Clin. Endocrinol. Diabetes
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 9002-60-2 / Adrenocorticotropic Hormone; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


72. Bellodi C, Krasnykh O, Haynes N, Theodoropoulou M, Peng G, Montanaro L, Ruggero D: Loss of function of the tumor suppressor DKC1 perturbs p27 translation control and contributes to pituitary tumorigenesis. Cancer Res; 2010 Jul 15;70(14):6026-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of function of the tumor suppressor DKC1 perturbs p27 translation control and contributes to pituitary tumorigenesis.
  • Here, we report that impairment in p27 IRES-mediated translation due to decreased levels of DKC1 activity markedly increases spontaneous pituitary tumorigenesis in p27 heterozygous mice.
  • Using a new bioluminescent mouse model, we monitored p27 translation in vivo and show that p27 IRES-mediated translation is reduced in the pituitary of DKC1 hypomorphic mice (DKC1(m)).
  • An analysis of human tumors identified a novel mutation of DKC1 (DKC1(S485G)) in a human pituitary adenoma.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c)2010 AACR.
  • [Cites] Nat Rev Mol Cell Biol. 2005 Apr;6(4):318-27 [15803138.001]
  • [Cites] Nature. 1998 Nov 12;396(6707):177-80 [9823898.001]
  • [Cites] Chromosoma. 2005 May;114(1):1-14 [15770508.001]
  • [Cites] Mol Endocrinol. 2005 Sep;19(9):2371-9 [15919720.001]
  • [Cites] Science. 2006 May 12;312(5775):902-6 [16690864.001]
  • [Cites] J Pathol. 2006 Sep;210(1):10-8 [16841302.001]
  • [Cites] Endocr Relat Cancer. 2006 Sep;13(3):707-16 [16954426.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Oct 17;103(42):15558-63 [17030811.001]
  • [Cites] Clin Genet. 2008 Feb;73(2):103-12 [18005359.001]
  • [Cites] Blood. 2008 Feb 15;111(4):2388-91 [18077792.001]
  • [Cites] Recent Prog Horm Res. 1999;54:397-438; discussion 438-9 [10548885.001]
  • [Cites] J Cell Physiol. 2000 Apr;183(1):10-7 [10699961.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1211-6 [10728677.001]
  • [Cites] Genes Dev. 2002 Dec 1;16(23):3087-99 [12464637.001]
  • [Cites] Science. 2003 Jan 10;299(5604):259-62 [12522253.001]
  • [Cites] Hum Mol Genet. 2003 Jul 15;12(14):1767-79 [12837699.001]
  • [Cites] Hum Mol Genet. 2008 Apr 1;17(7):1031-42 [18202102.001]
  • [Cites] Nat Rev Cancer. 2008 Apr;8(4):253-67 [18354415.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Nov 11;105(45):17498-503 [18981426.001]
  • [Cites] Nature. 2008 Dec 18;456(7224):971-5 [19011615.001]
  • [Cites] Cell. 2009 Feb 20;136(4):731-45 [19239892.001]
  • [Cites] Nat Cell Biol. 2009 Jul;11(7):903-8 [19525934.001]
  • [Cites] J Genet Genomics. 2009 Aug;36(8):447-54 [19683667.001]
  • [Cites] PLoS One. 2009;4(9):e7147 [19779612.001]
  • [Cites] Br J Cancer. 2009 Oct 20;101(8):1410-6 [19755982.001]
  • [Cites] J Clin Invest. 2009 Nov;119(11):3189-202 [19884662.001]
  • [Cites] Nat Genet. 2010 Jan;42(1):83-8 [19966802.001]
  • [Cites] Mol Cell Biol. 2001 Aug;21(15):4960-7 [11438653.001]
  • [Cites] Pituitary. 2002;5(4):235-42 [14558671.001]
  • [Cites] Mol Cell Biol. 2004 Aug;24(15):6861-70 [15254251.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10756-61 [15240872.001]
  • [Cites] Cancer Res. 1987 Jan 1;47(1):169-72 [3791205.001]
  • [Cites] Nature. 1992 Sep 24;359(6393):288-94 [1406932.001]
  • [Cites] Cancer Res. 1995 Apr 15;55(8):1613-6 [7712461.001]
  • [Cites] Science. 1996 Mar 29;271(5257):1861-4 [8596954.001]
  • [Cites] Genes Dev. 1996 Aug 1;10(15):1870-9 [8756345.001]
  • [Cites] J Biol Chem. 1997 Mar 14;272(11):7093-8 [9054402.001]
  • [Cites] Mol Endocrinol. 1997 Apr;11(4):433-41 [9092795.001]
  • [Cites] Genes Dev. 1998 Sep 15;12(18):2899-911 [9744866.001]
  • [Cites] Mol Endocrinol. 2005 May;19(5):1383-91 [15677710.001]
  • (PMID = 20587522.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL085572; United States / NHLBI NIH HHS / HL / 3R01HL085572-05S1; United States / NHLBI NIH HHS / HL / R01 HL085572-05; United States / NHLBI NIH HHS / HL / R01 HL085572-05S1; United States / NHLBI NIH HHS / HL / R01 HL085572-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Dkc1 protein, mouse; 0 / Nuclear Proteins; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27
  • [Other-IDs] NLM/ NIHMS210968; NLM/ PMC2913864
  •  go-up   go-down


73. Wu ZB, Chen Y, Lü QP, Wang CD, Su ZP, Wu JS, Zheng WM, Zhuge QC: [Natural history study of postoperative residual non-functioning pituitary adenomas]. Zhonghua Yi Xue Za Zhi; 2010 Mar 9;90(9):597-600
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Natural history study of postoperative residual non-functioning pituitary adenomas].
  • OBJECTIVE: To observe the postoperative residual non-functioning pituitary adenomas (PR-NFPAs) without postoperative radiotherapy and to analyze the natural history of PR-NFPAs' growth in order to provide a basis for selecting appropriate strategies of clinical treatment.
  • Among which, 17 adenomas increased in volume and 3 remained unchanged during a follow-up period of 7 months to 17 years (mean 3.90 yr).
  • In conjunctions with the volume of PR-NFPAs and the distance between residual adenoma and optic chiasm, we should take the TVDT into consideration and determine the appropriate and safe follow-up period.
  • [MeSH-major] Adenoma / pathology. Neoplasm, Residual / pathology. Pituitary Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20450781.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


74. Enseñat J, Ortega A, Topcewski T, Vilalta J, Obiols G, Mesa J, Sahuquillo J: [Predictive value of the Knosp classification in grading the surgical resection of invasive pituitary macroadenomas. A prospective study of 23 cases]. Neurocirugia (Astur); 2006 Dec;17(6):519-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Predictive value of the Knosp classification in grading the surgical resection of invasive pituitary macroadenomas. A prospective study of 23 cases].
  • [Transliterated title] Valor predictivo de la clasificación de Knosp en el grado de resección quirúrgica de los macroadenomas invasivos. Estudio prospectivo de una serie de 23 casos.
  • OBJECTIVE: To evaluate our experience regarding the treatment of pituitary macroadenomas with cavernous sinus invasion in a series of 23 cases of transphenoidal resection.
  • Preoperatively all lesions were diagnosed by MRI and staged according to the Knosp classification.
  • The remaining seven patients with grade 4 adenomas had a Partial (less than 80%) excision.
  • We compare de resection grade versus invasion grade with exact Fisher test.
  • CONCLUSION: The Knosp classification alone cannot predict the behavior of these tumors.
  • In our experience, despite tumor extension to the cavernous sinus, pituitary macroadenomas can be safely resected with low morbidity and mortality.
  • [MeSH-major] Adenoma / classification. Cavernous Sinus / pathology. Hypophysectomy / statistics & numerical data. Neoplasm Invasiveness. Neoplasm Staging / methods. Pituitary Neoplasms / classification

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17242839.001).
  • [ISSN] 1130-1473
  • [Journal-full-title] Neurocirugía (Asturias, Spain)
  • [ISO-abbreviation] Neurocirugia (Astur)
  • [Language] spa
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Ergolines; 51110-01-1 / Somatostatin; LL60K9J05T / cabergoline
  •  go-up   go-down


75. Kristof RA, Kirchhofer D, Handzel D, Neuloh G, Schramm J, Mueller CA, Eter N: Functional impairments caused by chiasma syndromes prior to and following transsphenoidal pituitary adenoma surgery. Acta Neurochir (Wien); 2010 Aug;152(8):1283-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Functional impairments caused by chiasma syndromes prior to and following transsphenoidal pituitary adenoma surgery.
  • PURPOSE: To describe the functional impairment caused by chiasma syndromes (CS) prior to and following transsphenoidal pituitary adenoma surgery.
  • METHODS: Pertinent data of a successive series of patients operated transsphenoidally for the first time for pituitary adenoma were retrospectively analyzed.
  • [MeSH-major] Adenoma / surgery. Hypophysectomy / adverse effects. Optic Chiasm / injuries. Pituitary Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20454981.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


76. Berkmann S, Tolnay M, Hänggi D, Ghaffari A, Gratzl O: Sarcoma of the sella after radiotherapy for pituitary adenoma. Acta Neurochir (Wien); 2010 Oct;152(10):1725-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sarcoma of the sella after radiotherapy for pituitary adenoma.
  • Secondary malignancies are infrequent sequelae of pituitary radiotherapy.
  • The goal of the present case study is to analyze clinical features of a selected group of cases to define the special characteristics of these tumors.
  • We report the illustrative case of a 38-year-old man with acromegaly who had transsphenoidal surgery and radiotherapy 7 years before presenting with a sellar high-grade sarcoma.
  • Radiation-induced sarcoma is a rare sequela of pituitary radiotherapy.
  • Additionally, one must include these tumors into the differential diagnosis in pituitary patients presenting with tumor recurrence more than 5 years after radiotherapy in combination with a secondary lack of hormonal activity.
  • [MeSH-major] Adenoma / radiotherapy. Fibrosarcoma / etiology. Fibrosarcoma / pathology. Pituitary Neoplasms / radiotherapy. Radiotherapy / adverse effects. Skull Base Neoplasms / etiology. Skull Base Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20512596.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


77. Dunkley MJ, Reveley MA: Successful treatment of refractory schizophrenia with combined olanzapine and quetiapine in a patient with a prolactin secreting pituitary microadenoma. J Psychopharmacol; 2005 Jan;19(1):97-101
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of refractory schizophrenia with combined olanzapine and quetiapine in a patient with a prolactin secreting pituitary microadenoma.
  • Hyperprolactinaemia (elevation of serum prolactin levels) is a common side-effect of antipsychotics and one that it is especially important to minimize in patients with primary pituitary pathology.
  • We present a patient with treatment resistant schizophrenia and a prolactin-secreting microadenoma of the pituitary who was intolerant of clozapine therapy.
  • [MeSH-major] Adenoma / complications. Adenoma / metabolism. Antipsychotic Agents / therapeutic use. Benzodiazepines / therapeutic use. Dibenzothiazepines / therapeutic use. Pituitary Neoplasms / complications. Pituitary Neoplasms / metabolism. Prolactin / metabolism. Schizophrenia / drug therapy

  • Genetic Alliance. consumer health - Schizophrenia.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • MedlinePlus Health Information. consumer health - Schizophrenia.
  • Hazardous Substances Data Bank. Olanzapine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15671135.001).
  • [ISSN] 0269-8811
  • [Journal-full-title] Journal of psychopharmacology (Oxford, England)
  • [ISO-abbreviation] J. Psychopharmacol. (Oxford)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antipsychotic Agents; 0 / Dibenzothiazepines; 12794-10-4 / Benzodiazepines; 132539-06-1 / olanzapine; 2S3PL1B6UJ / Quetiapine Fumarate; 9002-62-4 / Prolactin
  •  go-up   go-down


78. Pecori Giraldi F: Recent challenges in the diagnosis of Cushing's syndrome. Horm Res; 2009 Jan;71 Suppl 1:123-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recent challenges in the diagnosis of Cushing's syndrome.
  • BACKGROUND: The diagnosis of Cushing's syndrome still represents a challenge for the endocrinologist.
  • The diagnosis should be established based on results of two or more concordant first-line tests (e.g., urinary free cortisol, midnight serum cortisol and low-dose dexamethasone testing); otherwise, second-line tests such as the dexamethasone-suppressed corticotrophin-releasing hormone (CRH) test, desmopressin stimulation or later reevaluation can confirm/exclude the diagnosis.
  • Aetiological diagnosis requires measurement of plasma corticotrophin (ACTH) to distinguish between ACTH-dependent (pituitary or extrapituitary ACTH-secreting tumors) and ACTH-independent Cushing's syndrome (adrenal cortisol-secreting lesions), and the possible detection of normal ACTH levels in patients with adrenal Cushing's syndrome must be kept in mind.
  • Lastly, the differential diagnosis between pituitary and ectopic ACTH secretion can be performed using CRH testing, high-dose dexamethasone suppression and inferior petrosal sinus sampling.
  • [MeSH-major] Cushing Syndrome / diagnosis. Diagnostic Techniques, Endocrine / trends
  • [MeSH-minor] ACTH Syndrome, Ectopic / diagnosis. ACTH-Secreting Pituitary Adenoma / diagnosis. ACTH-Secreting Pituitary Adenoma / secretion. Adrenocorticotropic Hormone / secretion. Algorithms. Diagnosis, Differential. Humans. Petrosal Sinus Sampling / methods. Pituitary Neoplasms / diagnosis. Pituitary Neoplasms / secretion

  • Genetic Alliance. consumer health - Cushing's Syndrome.
  • MedlinePlus Health Information. consumer health - Cushing's Syndrome.
  • Hazardous Substances Data Bank. Corticotropin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19153521.001).
  • [ISSN] 1423-0046
  • [Journal-full-title] Hormone research
  • [ISO-abbreviation] Horm. Res.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 9002-60-2 / Adrenocorticotropic Hormone
  • [Number-of-references] 13
  •  go-up   go-down


79. Koppeschaar HP: Adult clinical session. Introduction. Endocrine incidentaloma. Horm Res; 2007;68 Suppl 5:189-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Endocrine Gland Neoplasms / diagnosis. Endocrine Gland Neoplasms / epidemiology. Incidental Findings
  • [MeSH-minor] Adenoma / diagnosis. Adenoma / epidemiology. Adrenal Gland Neoplasms / diagnosis. Adrenal Gland Neoplasms / epidemiology. Autopsy. Humans. Pituitary Neoplasms / diagnosis. Pituitary Neoplasms / epidemiology. Prevalence. Thyroid Nodule / diagnosis. Thyroid Nodule / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18174743.001).
  • [ISSN] 1423-0046
  • [Journal-full-title] Hormone research
  • [ISO-abbreviation] Horm. Res.
  • [Language] eng
  • [Publication-type] Introductory Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


80. Yoneoka Y, Isogawa M, Terumitsu M, Matsuzawa H, Fujii Y: Insidious extension of pituitary prolactinoma: two can't-miss findings depicted on a 3.0-T MR system. J Neuroimaging; 2010 Jul;20(3):267-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Insidious extension of pituitary prolactinoma: two can't-miss findings depicted on a 3.0-T MR system.
  • METHODS: We reviewed six cases of pituitary prolactinoma; each had vague or occult bulk of adenoma on 1.5-T MR imaging, which were finally confirmed by surgery.
  • With the 3.0-T MR system, 3-dimension-anisotropy-contrast (3DAC) MR imaging and 3-dimension fast spoiled gradient recalled acquisition in the steady state (3D-FSPGR) imaging were used for depiction of the adenoma.
  • RESULTS: 3DAC imaging revealed cavernous sinus (CS) pathology in three cases, and multiplanar reconstruction of 3D-FSPGR imaging revealed normal pituitary gland and invasive adenoma into the CS in three cases and creeping extension up to the contralateral side of the CS invasion in four cases.
  • (1) intrasellar creeping extension up to the opposite side of the adenoma main body and (2) intracavernous-localized adenoma with indistinct intrasellar mass should be carefully considered when neurosurgeons perform adenomectomy for patients with prolactinoma, even in cases of microprolactinoma.
  • [MeSH-major] Image Processing, Computer-Assisted / methods. Magnetic Resonance Imaging / methods. Pituitary Neoplasms / pathology. Prolactinoma / pathology

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19453836.001).
  • [ISSN] 1552-6569
  • [Journal-full-title] Journal of neuroimaging : official journal of the American Society of Neuroimaging
  • [ISO-abbreviation] J Neuroimaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Sesmilo G, Webb SM, Neuroendocrinology Group of the Spanish Society of Endocrinology and Nutrition: Twelve years of the Spanish acromegaly registry: a historical view of acromegaly management in Spain. Endocrinol Nutr; 2010 Feb;57(2):39-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adenoma / complications. Adenoma / radiotherapy. Adenoma / surgery. Combined Modality Therapy. Comorbidity. Cranial Irradiation / utilization. Data Collection / methods. Disease Management. Drug Therapy, Combination. Drug Utilization. History, 20th Century. History, 21st Century. Human Growth Hormone / administration & dosage. Human Growth Hormone / analogs & derivatives. Human Growth Hormone / therapeutic use. Humans. Hypophysectomy / utilization. Peptides, Cyclic / administration & dosage. Peptides, Cyclic / therapeutic use. Pituitary Neoplasms / complications. Pituitary Neoplasms / radiotherapy. Pituitary Neoplasms / surgery. Receptors, Somatostatin / agonists. Retrospective Studies. Somatostatin / administration & dosage. Somatostatin / analogs & derivatives. Somatostatin / therapeutic use. Spain / epidemiology

  • Genetic Alliance. consumer health - Acromegaly.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20189894.001).
  • [ISSN] 1575-0922
  • [Journal-full-title] Endocrinología y nutrición : órgano de la Sociedad Española de Endocrinología y Nutrición
  • [ISO-abbreviation] Endocrinol Nutr
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Peptides, Cyclic; 0 / Receptors, Somatostatin; 0 / pegvisomant; 118992-92-0 / lanreotide; 12629-01-5 / Human Growth Hormone; 51110-01-1 / Somatostatin; 98H1T17066 / pasireotide
  • [Investigator] Alcázar Lazaro V; Alvarez Escolá C; Alvarez Vázquez P; Bernabeu Morón I; Blanco Carrera C; Cámara Balda A; Cámara Gómez R; Cáncer Minchot E; Castells Fust I; Del Pozo Picó C; Díez Gómez JJ; Díez Hernández A; Fajardo Montañana C; Forga Llenas L; García Centeno R; García Fernández H; Gargallo Fernández M; Gaztambide Sáenz S; Halperin Rabinovich I; Hernández Bayo JA; Jaunsolo Barranechea MA; Martí Ippoliti C; Martínez Olmos MA; Mas F; Moreno Carazo A; Moreno Esteban B; Moreno Fernandez J; Obiols Alfonso G; Pascual Saura H; Picó Alfonso A; Ruíz-Valdepeñas Herrero MP; Salinas i Vert I; Sanabria Pérez MC; Santiago Fernández P; Serraclara Pla A; Sesmilo León G; Soto llorens AL; Torres Vela E; Varela Dacosta C; Venegas Moreno E; Villabona Artero C; Webb Youdale S
  •  go-up   go-down


82. Kalavalapalli S, Reid H, Kane J, Buckler H, Trainer P, Heald AH: Silent growth hormone secreting pituitary adenomas: IGF-1 is not sufficient to exclude growth hormone excess. Ann Clin Biochem; 2007 Jan;44(Pt 1):89-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Silent growth hormone secreting pituitary adenomas: IGF-1 is not sufficient to exclude growth hormone excess.
  • We here present three cases of women (two of whom were on the oestrogen containing contraceptive pill at the time of presentation) who had normal circulating IGF-1 and no overt clinical features of acromegaly at the time of their pituitary surgery.
  • Postoperatively, all were confirmed to have growth hormone excess in keeping with the presence of active somatotroph pituitary adenomas.
  • We suggest that for optimal patient management, formal evaluation of growth hormone status with oral glucose tolerance testing should ideally be performed on all individuals for whom pituitary surgery is planned.
  • [MeSH-major] Growth Hormone-Secreting Pituitary Adenoma / metabolism. Insulin-Like Growth Factor I / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17270100.001).
  • [ISSN] 0004-5632
  • [Journal-full-title] Annals of clinical biochemistry
  • [ISO-abbreviation] Ann. Clin. Biochem.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Contraceptives, Oral, Hormonal; 67763-96-6 / Insulin-Like Growth Factor I; 9002-72-6 / Growth Hormone
  •  go-up   go-down


83. Webb SM, Mo D, Lamberts SW, Melmed S, Cavagnini F, Pecori Giraldi F, Strasburger CJ, Zimmermann AG, Woodmansee WW, International HypoCCS Advisory Board: Metabolic, cardiovascular, and cerebrovascular outcomes in growth hormone-deficient subjects with previous cushing's disease or non-functioning pituitary adenoma. J Clin Endocrinol Metab; 2010 Feb;95(2):630-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metabolic, cardiovascular, and cerebrovascular outcomes in growth hormone-deficient subjects with previous cushing's disease or non-functioning pituitary adenoma.
  • OBJECTIVE: The aim of the study was to compare the prevalence and incidence of metabolic syndrome (Adult Treatment Panel III criteria), diabetes mellitus, cardiovascular disease, and cerebrovascular disease in GH-treated subjects with previous CD with GH-treated subjects with previous nonfunctioning pituitary adenoma (NFPA).
  • DESIGN: We conducted post hoc analysis of the observational Hypopituitary Control and Complications Study conducted at 362 international centers (1995-2006).
  • Multiple pituitary deficits were prevalent in both groups.
  • [MeSH-major] Adenoma / complications. Cardiovascular Diseases / epidemiology. Cerebrovascular Disorders / epidemiology. Human Growth Hormone / deficiency. Metabolic Syndrome X / epidemiology. Pituitary ACTH Hypersecretion / complications. Pituitary Neoplasms / complications


84. Mondok A, Aranyi Z, Kovacs GG, Czirjak S, Pusztai P, Varga I, Racz K: Rapid progression of amyotrophic lateral sclerosis in an acromegalic patient after surgical resection of a growth hormone-producing pituitary adenoma. Neurologist; 2010 Sep;16(5):315-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid progression of amyotrophic lateral sclerosis in an acromegalic patient after surgical resection of a growth hormone-producing pituitary adenoma.
  • CASE REPORT: We describe a case of a 65-year-old woman with a 2-year history of symptoms and signs of acromegaly because of a pituitary microadenoma.
  • After octreotide long-acting release (LAR) treatment, the patient underwent uneventful pituitary surgery.
  • Neurologic investigations confirmed the diagnosis of ALS and riluzole therapy was given.
  • Two years after surgery the patient died of a sudden respiratory arrest.
  • Histopathologic examination of the brain and spinal cord confirmed the diagnosis of ALS.
  • [MeSH-major] Acromegaly. Amyotrophic Lateral Sclerosis. Disease Progression. Growth Hormone-Secreting Pituitary Adenoma. Pituitary Neoplasms


85. Chang EF, Zada G, Kim S, Lamborn KR, Quinones-Hinojosa A, Tyrrell JB, Wilson CB, Kunwar S: Long-term recurrence and mortality after surgery and adjuvant radiotherapy for nonfunctional pituitary adenomas. J Neurosurg; 2008 Apr;108(4):736-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term recurrence and mortality after surgery and adjuvant radiotherapy for nonfunctional pituitary adenomas.
  • OBJECT: Long-term outcomes following surgery for nonfunctional pituitary adenomas (NFPAs) are unclear.
  • [MeSH-major] Adenoma / radiotherapy. Adenoma / surgery. Neoplasm Recurrence, Local / etiology. Pituitary Neoplasms / radiotherapy. Pituitary Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18377253.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Tanwani LK, Mokshagundam SL: Visual vignette. Dynamic MRI. Endocr Pract; 2005 Sep-Oct;11(5):351
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] ACTH-Secreting Pituitary Adenoma / diagnosis. Magnetic Resonance Imaging / methods. Pituitary Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16191499.001).
  • [ISSN] 1530-891X
  • [Journal-full-title] Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • [ISO-abbreviation] Endocr Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] AU0V1LM3JT / Gadolinium
  •  go-up   go-down


87. Almeida MQ, Stratakis CA: Solid tumors associated with multiple endocrine neoplasias. Cancer Genet Cytogenet; 2010 Nov;203(1):30-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MEN type 1 (MEN1) describes the association of pituitary, parathyroid, and pancreatic islet cell tumors with a variety of many other lesions.
  • In the Carney triad, patients can manifest gastrointestinal stromal tumors, lung chondroma, paraganglioma, adrenal adenoma and pheochromocytoma, esophageal leiomyoma, and other conditions.
  • [MeSH-minor] Adrenal Gland Neoplasms / genetics. Germ-Line Mutation. Humans. Multiple Endocrine Neoplasia Type 1 / complications. Multiple Endocrine Neoplasia Type 2a / complications. Pheochromocytoma / genetics. Thyroid Neoplasms / etiology

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • [Cites] Science. 2000 Feb 4;287(5454):848-51 [10657297.001]
  • [Cites] J Urol. 1999 Sep;162(3 Pt 1):659-64 [10458336.001]
  • [Cites] Nat Genet. 2000 Sep;26(1):89-92 [10973256.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Oct;85(10):3860-5 [11061550.001]
  • [Cites] Nat Genet. 2000 Nov;26(3):268-70 [11062460.001]
  • [Cites] Hum Mol Genet. 2000 Dec 12;9(20):3037-46 [11115848.001]
  • [Cites] Am J Hum Genet. 2001 Jul;69(1):49-54 [11404820.001]
  • [Cites] Cytokine Growth Factor Rev. 2001 Dec;12(4):361-73 [11544105.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Sep;86(9):4041-6 [11549623.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Dec;86(12):5658-71 [11739416.001]
  • [Cites] N Engl J Med. 2002 May 9;346(19):1459-66 [12000816.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Aug;89(8):3737-8 [15292298.001]
  • [Cites] Medicine (Baltimore). 1968 Sep;47(5):371-409 [4386574.001]
  • [Cites] Clin Endocrinol Metab. 1980 Jul;9(2):299-315 [6994943.001]
  • [Cites] Br J Dermatol. 1980 Oct;103(4):421-9 [7437308.001]
  • [Cites] N Engl J Med. 1981 Dec 31;305(27):1617-27 [6796886.001]
  • [Cites] J Am Acad Dermatol. 1984 Jan;10(1):72-82 [6693605.001]
  • [Cites] Medicine (Baltimore). 1985 Jul;64(4):270-83 [4010501.001]
  • [Cites] Endocr Rev. 1987 Nov;8(4):391-405 [2891500.001]
  • [Cites] N Engl J Med. 1990 Mar 15;322(11):723-7 [1968616.001]
  • [Cites] Cell. 1990 Jul 13;62(1):187-92 [1694727.001]
  • [Cites] Science. 1993 May 28;260(5112):1317-20 [8493574.001]
  • [Cites] Nature. 1993 Jun 3;363(6428):458-60 [8099202.001]
  • [Cites] Semin Dermatol. 1995 Jun;14(2):90-8 [7640202.001]
  • [Cites] Clin Endocrinol (Oxf). 1995 Jul;43(1):123-7 [7641404.001]
  • [Cites] Oncogene. 1995 Nov 16;11(10):2039-45 [7478523.001]
  • [Cites] Oncogene. 1996 Feb 1;12(3):481-7 [8637703.001]
  • [Cites] J Clin Endocrinol Metab. 1953 Jan;13(1):20-47 [13022748.001]
  • [Cites] Am J Med. 1953 Mar;14(3):318-27 [13030489.001]
  • [Cites] Curr Mol Med. 2004 Dec;4(8):833-42 [15579030.001]
  • [Cites] Cell Mol Life Sci. 2004 Dec;61(23):2954-64 [15583857.001]
  • [Cites] Am J Surg Pathol. 2005 Feb;29(2):254-74 [15644784.001]
  • [Cites] Am J Gastroenterol. 2006 Feb;101(2):266-73 [16454829.001]
  • [Cites] Endocr Relat Cancer. 2006 Jun;13(2):415-25 [16728571.001]
  • [Cites] N Engl J Med. 2006 Jun 22;354(25):2729-31 [16790714.001]
  • [Cites] Nat Genet. 2006 Jul;38(7):794-800 [16767104.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Oct 17;103(42):15558-63 [17030811.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Nov;91(11):4505-9 [16912137.001]
  • [Cites] Curr Opin Oncol. 2007 Jan;19(1):24-9 [17133108.001]
  • [Cites] Curr Opin Genet Dev. 2007 Feb;17(1):71-7 [17208433.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4537-40 [17510376.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Jul;92(7):2784-92 [17426081.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Aug;92(8):2938-43 [17535989.001]
  • [Cites] J Med Genet. 2007 Sep;44(9):586-7 [17557926.001]
  • [Cites] N Engl J Med. 2007 Sep 6;357(10):1054-6 [17804857.001]
  • [Cites] Nat Clin Pract Endocrinol Metab. 2008 Feb;4(2):111-5 [18212813.001]
  • [Cites] N Engl J Med. 2008 Feb 14;358(7):750-2 [18272904.001]
  • [Cites] Expert Rev Anticancer Ther. 2008 Apr;8(4):625-32 [18402529.001]
  • [Cites] Nat Rev Cancer. 2008 Aug;8(8):592-603 [18650835.001]
  • [Cites] J Am Acad Dermatol. 2008 Nov;59(5):801-10 [18804312.001]
  • [Cites] Cancer Res. 2009 Apr 15;69(8):3650-6 [19351833.001]
  • [Cites] J Clin Endocrinol Metab. 2009 Jun;94(6):2085-91 [19293268.001]
  • [Cites] Pigment Cell Melanoma Res. 2009 Oct;22(5):580-7 [19650827.001]
  • [Cites] J Clin Endocrinol Metab. 2009 Oct;94(10):3656-62 [19723753.001]
  • [Cites] Clin Cancer Res. 2009 Oct 15;15(20):6378-85 [19825962.001]
  • [Cites] Surg Clin North Am. 2009 Oct;89(5):1193-204 [19836492.001]
  • [Cites] Best Pract Res Clin Endocrinol Metab. 2009 Dec;23(6):713-22 [19942148.001]
  • [Cites] Clin Cancer Res. 2009 Dec 1;15(23):7119-23 [19934298.001]
  • [Cites] Genet Med. 2009 Dec;11(12):825-35 [19904212.001]
  • [Cites] Genet Med. 2010 Jan;12(1):1-11 [20027112.001]
  • [Cites] Medicine (Baltimore). 1997 Jan;76(1):21-9 [9064485.001]
  • [Cites] Clin Endocrinol (Oxf). 1997 Nov;47(5):507-12 [9425388.001]
  • [Cites] J Pediatr Endocrinol Metab. 2000 Apr;13(4):373-9 [10776991.001]
  • (PMID = 20951316.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS241024; NLM/ PMC2957471
  •  go-up   go-down


88. Falchetti A, Marini F, Luzi E, Tonelli F, Brandi ML: Multiple endocrine neoplasms. Best Pract Res Clin Rheumatol; 2008 Mar;22(1):149-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MEN1 is characterized by the occurrence of parathyroid, gastro-entero-pancreatic and anterior pituitary tumours, but it can include various combinations of more than 20 endocrine and non-endocrine tumours.
  • Generally, tumours in MEN1 are benign, although gastrinomas and foregut carcinoids may exhibit a malignant course.
  • [MeSH-minor] Adenoma / genetics. Adrenocortical Carcinoma / genetics. Gastrointestinal Neoplasms / genetics. Humans. Pancreatic Neoplasms / genetics. Pheochromocytoma / genetics. Pituitary Neoplasms / genetics. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins c-ret / genetics

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • SciCrunch. KEGG: Data: Disease Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Best Pract Res Clin Rheumatol. 2008 Dec;22(6):III. Brandt, Maria Luisa [corrected to Brandi, Maria Luisa]
  • (PMID = 18328987.001).
  • [ISSN] 1521-6942
  • [Journal-full-title] Best practice & research. Clinical rheumatology
  • [ISO-abbreviation] Best Pract Res Clin Rheumatol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MEN1 protein, human; 0 / Proto-Oncogene Proteins; EC 2.7.10.1 / Proto-Oncogene Proteins c-ret
  • [Number-of-references] 68
  •  go-up   go-down


89. Metzner C, Hadziselimovic S, Grafe I, Nawroth P, Kasperk C: [Therapeutic management of acromegaly]. Med Klin (Munich); 2006 Jan 15;101(1):15-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Only 60% of the patients with acromegaly are biochemically cured (growth hormone [GH] nadir < 1.0 microg/l after an oral glucose load, normalized age- and gender-matched insulin-like growth factor-1 [IGF-1] levels) after transsphenoidal surgery of the pituitary gland.
  • In the absence of a remission there are effective pharmacological treatment regimens available which are able to lower GH and IGF-1 serum levels.
  • In the absence of a remission there are effective pharmacological treatment regimens available among which somatostatin analogs are recommended as the first-line treatment.
  • [MeSH-minor] Adenoma / surgery. Adult. Aged. Algorithms. Drug Therapy, Combination. Female. Growth Hormone / blood. Human Growth Hormone / administration & dosage. Human Growth Hormone / analogs & derivatives. Human Growth Hormone / therapeutic use. Humans. Insulin-Like Growth Factor I / analysis. Male. Middle Aged. Octreotide / administration & dosage. Octreotide / therapeutic use. Pituitary Neoplasms / surgery. Remission Induction

  • Genetic Alliance. consumer health - Acromegaly.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16418810.001).
  • [ISSN] 0723-5003
  • [Journal-full-title] Medizinische Klinik (Munich, Germany : 1983)
  • [ISO-abbreviation] Med. Klin. (Munich)
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Dopamine Agonists; 0 / Receptors, Somatotropin; 0 / pegvisomant; 12629-01-5 / Human Growth Hormone; 51110-01-1 / Somatostatin; 67763-96-6 / Insulin-Like Growth Factor I; 9002-72-6 / Growth Hormone; RWM8CCW8GP / Octreotide
  • [Number-of-references] 62
  •  go-up   go-down


90. Castinetti F, Brue T: Gamma Knife radiosurgery in pituitary adenomas: Why, who, and how to treat? Discov Med; 2010 Aug;10(51):107-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gamma Knife radiosurgery in pituitary adenomas: Why, who, and how to treat?
  • Pituitary adenomas are benign tumors that can be either secreting (acromegaly, Cushing's disease, prolactinomas) or non-secreting.
  • Several studies reported the efficacy and low risk of adverse effects induced by this technique: in secreting pituitary adenomas, hypersecretion is controlled in about 50% of cases and tumor volume is stabilized or decreased in 80-90% of cases, making Gamma Knife a valuable adjunctive or first-line treatment.
  • Gamma Knife is thus useful in the therapeutic algorithms of pituitary adenomas in well-defined indications, mainly low secreting small lesions well identified on magnetic resonance imaging (MRI).
  • [MeSH-major] Pituitary Neoplasms / surgery. Radiosurgery / methods

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20807470.001).
  • [ISSN] 1944-7930
  • [Journal-full-title] Discovery medicine
  • [ISO-abbreviation] Discov Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Choi H, Kim S, Moon JH, Lee YH, Rhee Y, Kang ES, Ahn CW, Cha BS, Lee EJ, Kim KR, Lee HC, Jeong SY, Kim HJ, Lim SK: Multiple endocrine neoplasia type 1 with multiple leiomyomas linked to a novel mutation in the MEN1 gene. Yonsei Med J; 2008 Aug 30;49(4):655-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MEN1 is characterized by the presence of functioning and nonfunctioning tumors or hyperplasia of the pituitary gland, parathyroid glands, and pancreatic islet cells.
  • However, there has been no report of a case of MEN1 with leiomyoma in Korea so far.
  • There was hyperprolactinemia with pituitary microadenoma in sella MRI.
  • This is the first case of MEN1 accompanied with multiple leiomyomas, parathyroid adenoma, pituitary adenoma, pancreatic tumor, and adrenal tumor.


92. Mallea-Gil MS, Cristina C, Perez-Millan MI, Villafañe AM, Ballarino C, Stalldecker G, Becu-Villalobos D: Invasive giant prolactinoma with loss of therapeutic response to cabergoline: expression of angiogenic markers. Endocr Pathol; 2009;20(1):35-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The present study reports the case of a 70-year-old Caucasian man who was referred to the Military Hospital of Buenos Aires for evaluation of a giant sellar-extrasellar mass with extension in the right temporal lobe and compression of the third ventricle.
  • Immunohistochemistry of the excised tumor revealed strong immunoreactivity for VEGF and FGF-2, two potent angiogenic factors, and CD31 (an endothelial marker) indicating high vascularization of the adenoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Drug Resistance, Neoplasm / genetics. Ergolines / therapeutic use. Neovascularization, Pathologic / metabolism. Pituitary Neoplasms / pathology. Prolactinoma / pathology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Horm Res. 1998;49(5):250-3 [9568811.001]
  • [Cites] Clin Endocrinol (Oxf). 2007 Jan;66(1):149-50 [17201816.001]
  • [Cites] Endocr Pathol. 2005 Summer;16(2):115-21 [16199896.001]
  • [Cites] Nat Med. 2001 May;7(5):569-74 [11329058.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Jul;82(7):2102-7 [9215279.001]
  • [Cites] J Neurosurg. 2002 Feb;96(2):352-60 [11838811.001]
  • [Cites] Neurosurgery. 1988 Jan;22(1 Pt 1):1-6 [2449627.001]
  • [Cites] Virchows Arch. 2007 Mar;450(3):335-41 [17235567.001]
  • [Cites] J Neuroendocrinol. 1996 Oct;8(10):737-46 [8910802.001]
  • [Cites] J Clin Endocrinol Metab. 1988 Oct;67(4):713-9 [3417848.001]
  • [Cites] Endocrinology. 2005 Jul;146(7):2952-62 [15817666.001]
  • [Cites] J Comput Assist Tomogr. 1992 Jul-Aug;16(4):519-28 [1629407.001]
  • [Cites] Front Horm Res. 2006;35:50-63 [16809922.001]
  • [Cites] Cancer. 1997 Feb 15;79(4):804-12 [9024719.001]
  • [Cites] Endocr Rev. 1997 Feb;18(1):4-25 [9034784.001]
  • [Cites] Endocr Pathol. 1999 Autumn;10(3):229-235 [12114703.001]
  • [Cites] Endocr Pathol. 2006 Summer;17(2):143-53 [17159247.001]
  • [Cites] Horm Res. 1992;38(1-2):84-9 [1306523.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2007 Nov;293(5):E1341-51 [17848635.001]
  • [Cites] Endocr Rev. 1997 Feb;18(1):26-45 [9034785.001]
  • [Cites] Nat Med. 2003 Jun;9(6):669-76 [12778165.001]
  • [Cites] Pituitary. 2005;8(1):43-52 [16411068.001]
  • [Cites] Eur J Endocrinol. 2007 Feb;156(2):143-53 [17287403.001]
  • [Cites] J Endocrinol. 1996 Jul;150(1):99-106 [8708569.001]
  • [Cites] J Steroid Biochem Mol Biol. 1998 Jan;64(1-2):59-67 [9569011.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Sep;87(9):4238-44 [12213878.001]
  • [Cites] Neuroendocrinology. 1994 Sep;60(3):314-22 [7969790.001]
  • [Cites] Braz J Med Biol Res. 2002 May;35(5):561-5 [12011941.001]
  • [Cites] Cytobios. 2000;101(398):151-9 [10755214.001]
  • [Cites] J Endocrinol. 2000 May;165(2):475-81 [10810311.001]
  • [Cites] Acta Endocrinol (Copenh). 1991 Nov;125(5):494-501 [1759539.001]
  • [Cites] Histol Histopathol. 1996 Oct;11(4):909-13 [8930634.001]
  • [Cites] Hiroshima J Med Sci. 2004 Jun;53(2):23-7 [15453394.001]
  • [Cites] Clin Endocrinol (Oxf). 2003 May;58(5):662-70 [12699451.001]
  • [Cites] Clin Cancer Res. 2004 Jul 1;10(13):4349-56 [15240521.001]
  • [Cites] Endocr Pathol. 1995 Summer;6(2):115-124 [12114647.001]
  • [Cites] Front Horm Res. 2004;32:133-45 [15281344.001]
  • (PMID = 19172414.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Ergolines; 9002-62-4 / Prolactin; LL60K9J05T / cabergoline
  •  go-up   go-down


93. Feelders RA, Hofland LJ, van Aken MO, Neggers SJ, Lamberts SW, de Herder WW, van der Lely AJ: Medical therapy of acromegaly: efficacy and safety of somatostatin analogues. Drugs; 2009 Nov 12;69(16):2207-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most frequent cause of acromegaly is a GH-producing pituitary adenoma.
  • Primary medical therapy has been increasingly applied in recent years, especially when a priori chances of surgical cure are low (because of adenoma size and localization) and in patients with advanced age and/or serious co-morbidity.
  • [MeSH-minor] Adenoma / complications. Antineoplastic Agents / adverse effects. Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Female. Growth Hormone-Secreting Pituitary Adenoma / complications. Human Growth Hormone / metabolism. Human Growth Hormone / secretion. Humans. Male. Octreotide / adverse effects. Octreotide / pharmacology. Octreotide / therapeutic use. Peptides, Cyclic / adverse effects. Peptides, Cyclic / pharmacology. Peptides, Cyclic / therapeutic use

  • Genetic Alliance. consumer health - Acromegaly.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Drugs. 1997 Apr;53(4):681-99 [9098666.001]
  • [Cites] J Clin Invest. 1997 Nov 1;100(9):2386-92 [9410919.001]
  • [Cites] Eur J Endocrinol. 2005 Dec;153(6):737-40 [16322377.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Oct;83(10):3419-26 [9768641.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Mar;90(3):1856-63 [15613435.001]
  • [Cites] Pituitary. 2001 Aug;4(3):163-71 [12138989.001]
  • [Cites] Neuroendocrinology. 2004 Mar;79(3):142-8 [15103227.001]
  • [Cites] Surg Neurol. 2006 Jul;66(1):26-31; discussion 31 [16793431.001]
  • [Cites] Lancet. 2001 Nov 24;358(9295):1754-9 [11734231.001]
  • [Cites] Clin Endocrinol (Oxf). 2003 Mar;58(3):288-95 [12608933.001]
  • [Cites] Clin Endocrinol (Oxf). 2002 Oct;57(4):425-41 [12354124.001]
  • [Cites] Eur J Endocrinol. 2006 Aug;155(2):371-9 [16868153.001]
  • [Cites] Clin Endocrinol (Oxf). 2006 Sep;65(3):320-6 [16918950.001]
  • [Cites] Eur J Endocrinol. 2004 Sep;151(3):317-24 [15362960.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Jul;90(7):4405-10 [15827109.001]
  • [Cites] Clin Endocrinol (Oxf). 2008 Mar;68(3):458-65 [17941904.001]
  • [Cites] Clin Endocrinol (Oxf). 2000 Nov;53(5):577-86 [11106918.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jan;86(1):140-5 [11231991.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Sep;79(3):724-9 [7521350.001]
  • [Cites] Eur J Endocrinol. 2005 Jul;153(1):67-71 [15994747.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jan;91(1):85-92 [16263832.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Sep;86(9):4072-7 [11549628.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jun;86(6):2779-86 [11397887.001]
  • [Cites] J Biol Chem. 1987 Apr 15;262(11):4987-93 [2881926.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Oct;90(10 ):5627-31 [16046586.001]
  • [Cites] J Clin Endocrinol Metab. 1989 Apr;68(4):844-50 [2537844.001]
  • [Cites] Endocrinology. 2002 Oct;143(10):4123-30 [12239124.001]
  • [Cites] Pituitary. 2006;9(1):27-34 [16703406.001]
  • [Cites] J Neurosurg. 2006 Jun;104(6):899-906 [16776333.001]
  • [Cites] J Clin Neurosci. 2003 Jul;10 (4):444-8 [12852883.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Aug;85(8):2958-61 [10946911.001]
  • [Cites] Clin Endocrinol (Oxf). 2007 Aug;67(2):282-9 [17524029.001]
  • [Cites] Drugs. 2003;63(22):2473-99 [14609359.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Oct;93(10 ):3853-9 [18647806.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jun;88(6):2797-802 [12788890.001]
  • [Cites] Eur J Endocrinol. 2004 Apr;150(4):473-80 [15080776.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Aug;90(8):4465-73 [15886238.001]
  • [Cites] Eur J Endocrinol. 2008 Nov;159(5):525-32 [18755874.001]
  • [Cites] Growth Horm IGF Res. 2003 Aug;13(4):171-84 [12914750.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Feb;86(2):478-81 [11157994.001]
  • [Cites] Mol Endocrinol. 2009 Mar;23(3):337-48 [19131507.001]
  • [Cites] Anesth Analg. 2005 Oct;101(4):1170-81 [16192540.001]
  • [Cites] Neuroendocrinology. 2006;83(3-4):230-9 [17047388.001]
  • [Cites] Clin Endocrinol (Oxf). 2006 Feb;64(2):209-14 [16430722.001]
  • [Cites] Clin Cancer Res. 1997 Feb;3(2):265-72 [9815682.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jul;87(7):3013-8 [12107192.001]
  • [Cites] Clin Endocrinol (Oxf). 2007 Aug;67(2):310-5 [17555503.001]
  • [Cites] Mol Cell Endocrinol. 2008 May 14;286(1-2):69-74 [17977644.001]
  • [Cites] Acta Neurochir (Wien). 2005 May;147(5):485-93; discussion 493 [15806331.001]
  • [Cites] J Clin Endocrinol Metab. 2007 May;92(5):1592-9 [17311860.001]
  • [Cites] Eur J Endocrinol. 2005 Jul;153(1):135-41 [15994755.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Oct;83(10):3411-8 [9768640.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Jul;79(1):145-51 [8027218.001]
  • [Cites] Eur J Endocrinol. 2007 Jan;156(1):65-74 [17218727.001]
  • [Cites] Front Horm Res. 2006;34:236-55 [16474223.001]
  • [Cites] Exp Clin Endocrinol Diabetes. 2005 Mar;113(3):139-44 [15789272.001]
  • [Cites] Clin Endocrinol (Oxf). 2005 Mar;62(3):282-8 [15730408.001]
  • [Cites] J Clin Pharmacol. 2005 Jul;45(7):836-44 [15951474.001]
  • [Cites] Eur J Endocrinol. 2006 Jul;155(1):73-8 [16793952.001]
  • [Cites] J Endocrinol Invest. 2003 Jul;26(7):599-603 [14594107.001]
  • [Cites] Eur J Endocrinol. 2005 Aug;153(2):203-5 [16061824.001]
  • [Cites] Rev Endocr Metab Disord. 2005 Jan;6(1):29-37 [15711912.001]
  • [Cites] J Neurosurg. 1998 Sep;89(3):353-8 [9724106.001]
  • [Cites] J Endocrinol Invest. 2003 Dec;26(12):1242-7 [15055479.001]
  • [Cites] J Endocrinol Invest. 2005;28(11 Suppl International):43-7 [16625844.001]
  • [Cites] Lancet. 2005 May 7-13;365(9471):1644-6 [15885297.001]
  • [Cites] Clin Endocrinol (Oxf). 1980 Jan;12(1):71-9 [7379316.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Aug;93(8):2957-68 [18477663.001]
  • [Cites] Clin Endocrinol (Oxf). 2003 Apr;58(4):471-81 [12641631.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Dec;85(12):4712-20 [11134133.001]
  • [Cites] J Endocrinol Invest. 2005;28(11 Suppl International):21-7 [16625841.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Nov;86(11):5194-200 [11701676.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Oct;88(10 ):4759-67 [14557452.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Feb;85(2):781-92 [10690891.001]
  • [Cites] Eur J Endocrinol. 2005 Jan;152(1):61-6 [15762188.001]
  • [Cites] Cancer Res. 1990 Oct 1;50(19):6238-42 [2169342.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Apr;91(4):1397-403 [16449332.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Dec;87(12):5545-52 [12466351.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Aug;79(2):461-5 [8045964.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Nov;80(11):3267-72 [7593436.001]
  • [Cites] Mayo Clin Proc. 1997 Oct;72(10):893-900 [9379690.001]
  • [Cites] J Clin Endocrinol Metab. 1985 Jul;61(1):98-103 [2860120.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jan;87(1):99-104 [11788630.001]
  • [Cites] Clin Endocrinol (Oxf). 2003 Jul;59(1):115-28 [12807513.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Feb;85(2):526-9 [10690849.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Apr;88(4):1913-4 [12679495.001]
  • [Cites] Growth Horm IGF Res. 2003 Aug;13 Suppl A:S144-51 [12914744.001]
  • [Cites] Eur J Endocrinol. 2001 Aug;145(2):137-45 [11454508.001]
  • [Cites] Eur J Endocrinol. 2000 Nov;143(5):577-84 [11078980.001]
  • [Cites] J Clin Pathol. 2006 Mar;59(3):274-9 [16505278.001]
  • [Cites] J Clin Endocrinol Metab. 1984 Dec;59(6):1148-51 [6092412.001]
  • [Cites] Clin Endocrinol (Oxf). 2008 Jun;68(6):970-5 [18031313.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Sep;87(9):4054-8 [12213843.001]
  • [Cites] Clin Endocrinol (Oxf). 2008 Mar;68(3):473-80 [17941902.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Apr;89(4):1577-85 [15070915.001]
  • [Cites] Ann Intern Med. 1992 Nov 1;117(9):711-8 [1416572.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Aug;93(8):2984-90 [18492760.001]
  • [Cites] Endocr Relat Cancer. 2006 Sep;13(3):955-62 [16954443.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jun;91(6):2112-8 [16537687.001]
  • [Cites] Science. 2000 Apr 7;288(5463):154-7 [10753124.001]
  • [Cites] Front Neuroendocrinol. 1999 Jul;20(3):157-98 [10433861.001]
  • [Cites] Metabolism. 1996 Aug;45(8 Suppl 1):27-30 [8769375.001]
  • [Cites] Growth Horm IGF Res. 2004 Oct;14(5):382-7 [15336231.001]
  • [Cites] Acta Endocrinol (Copenh). 1993 Jul;129 Suppl 1:18-20 [8372606.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Aug;87(8):3537-42 [12161471.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Apr;80(4):1386-92 [7714115.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Aug;87(8):3783-90 [12161511.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Sep;83(9):3034-40 [9745397.001]
  • [Cites] Clin Endocrinol (Oxf). 2004 Mar;60(3):375-81 [15009004.001]
  • [Cites] Clin Endocrinol (Oxf). 2004 Aug;61(2):224-31 [15272918.001]
  • [Cites] Clin Pharmacokinet. 1990 Oct;19(4):319-32 [2208899.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Oct;87(10):4554-63 [12364434.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Sep;88(9):4239-45 [12970293.001]
  • [Cites] Clin Endocrinol (Oxf). 2006 Mar;64(3):342-51 [16487447.001]
  • [Cites] Metabolism. 2002 Mar;51(3):387-93 [11887179.001]
  • [Cites] Life Sci. 1995;56(5):333-42 [7530798.001]
  • [Cites] Clin Endocrinol (Oxf). 2003 Oct;59(4):492-9 [14510913.001]
  • [Cites] Science. 1973 Jan 5;179(4068):77-9 [4682131.001]
  • [Cites] Clin Endocrinol (Oxf). 2001 Sep;55(3):411-5 [11589686.001]
  • [Cites] N Engl J Med. 2000 Apr 20;342(16):1171-7 [10770982.001]
  • [Cites] Eur J Endocrinol. 2004 Apr;150(4):489-95 [15080778.001]
  • [Cites] Clin Pharmacokinet. 2006;45(10 ):1003-11 [16984213.001]
  • [Cites] J Clin Invest. 1997 Feb 15;99(4):789-98 [9045884.001]
  • [Cites] Pituitary. 2006;9(3):221-9 [17036195.001]
  • [Cites] Endocrinology. 1997 Oct;138(10):4473-6 [9322965.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jul;88(7):3090-8 [12843148.001]
  • [Cites] Clin Endocrinol (Oxf). 2007 Jun;66(6):859-68 [17465997.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2558-73 [17167139.001]
  • [Cites] Clin Endocrinol (Oxf). 2007 Oct;67(4):512-9 [17555511.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Feb;89(2):638-45 [14764775.001]
  • (PMID = 19852525.001).
  • [ISSN] 1179-1950
  • [Journal-full-title] Drugs
  • [ISO-abbreviation] Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Peptides, Cyclic; 0 / Receptors, Somatostatin; 0G3DE8943Y / lanreotide; 12629-01-5 / Human Growth Hormone; 51110-01-1 / Somatostatin; RWM8CCW8GP / Octreotide
  • [Number-of-references] 130
  •  go-up   go-down


94. Tiemensma J, Kokshoorn NE, Biermasz NR, Keijser BJ, Wassenaar MJ, Middelkoop HA, Pereira AM, Romijn JA: Subtle cognitive impairments in patients with long-term cure of Cushing's disease. J Clin Endocrinol Metab; 2010 Jun;95(6):2699-714
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Furthermore, we included 54 patients previously treated for nonfunctioning pituitary macroadenomas (NFMA) and 54 controls matched for age, gender, and education.
  • [MeSH-major] Cognition Disorders / etiology. Cognition Disorders / psychology. Pituitary ACTH Hypersecretion / complications. Pituitary ACTH Hypersecretion / psychology
  • [MeSH-minor] ACTH-Secreting Pituitary Adenoma / complications. ACTH-Secreting Pituitary Adenoma / psychology. ACTH-Secreting Pituitary Adenoma / surgery. Adult. Aged. Anxiety / psychology. Depression / psychology. Female. Humans. Male. Memory / physiology. Memory, Short-Term / physiology. Middle Aged. Neuropsychological Tests. Pituitary Function Tests. Psychiatric Status Rating Scales. Survivors. Treatment Outcome. Wechsler Scales

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20371667.001).
  • [ISSN] 1945-7197
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. de Herder WW, Lamberts SW: Somatostatin analogs as radiodiagnostic tools. Rev Endocr Metab Disord; 2005 Jan;6(1):23-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenoma / diagnostic imaging. Pituitary Neoplasms / diagnostic imaging. Radiopharmaceuticals. Somatostatin / analogs & derivatives
  • [MeSH-minor] Humans. Indium Radioisotopes. Radionuclide Imaging. Receptors, Somatostatin / classification. Receptors, Somatostatin / drug effects

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nuklearmedizin. 2000;39(1):42-5 [10726258.001]
  • [Cites] J Nucl Med. 1998 Feb;39(2):238-40 [9476926.001]
  • [Cites] J Clin Endocrinol Metab. 1991 Oct;73(4):850-6 [1653785.001]
  • [Cites] Q J Nucl Med. 1995 Dec;39(4 Suppl 1):90-3 [9002759.001]
  • [Cites] Nuklearmedizin. 1999;38(2):66-7 [10100234.001]
  • [Cites] J Clin Endocrinol Metab. 2004 May;89(5):2214-21 [15126544.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Nov;79(5):1416-23 [7962337.001]
  • [Cites] Nuklearmedizin. 1997 Jun;36(4):117-24 [9289697.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jan;86(1):140-5 [11231991.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Sep;79(3):724-9 [7521350.001]
  • [Cites] N Engl J Med. 1996 Jan 25;334(4):246-54 [8532003.001]
  • [Cites] Nucl Med Commun. 1995 Sep;16(9):756-66 [7478408.001]
  • [Cites] J Clin Endocrinol Metab. 1989 Apr;68(4):844-50 [2537844.001]
  • [Cites] Acta Neurochir Suppl. 1996;65:102-4 [8738508.001]
  • [Cites] Neurosurg Rev. 1997;20(1):7-12 [9085281.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Feb;78(2):398-403 [8106629.001]
  • [Cites] Ann Oncol. 2001;12 Suppl 2:S31-6 [11762349.001]
  • [Cites] J Nucl Med. 1999 Aug;40(8):1252-6 [10450674.001]
  • [Cites] J Endocrinol Invest. 1999 Mar;22(3):176-83 [10219884.001]
  • [Cites] Int J Cancer. 1997 Mar 4;70(5):530-7 [9052751.001]
  • [Cites] Semin Nucl Med. 2002 Apr;32(2):110-22 [11965606.001]
  • [Cites] Horm Metab Res Suppl. 1993;27:59-62 [8330874.001]
  • [Cites] Metabolism. 1992 Sep;41(9 Suppl 2):59-61 [1325596.001]
  • [Cites] J Endocrinol Invest. 2001 Jun;24(6):430-7 [11434667.001]
  • [Cites] Clin Endocrinol (Oxf). 1992 Feb;36(2):147-50 [1348978.001]
  • [Cites] Semin Nucl Med. 2002 Apr;32(2):123-32 [11965607.001]
  • [Cites] Eur J Endocrinol. 2003 Mar;148(3):357-64 [12611618.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 Mar;30(3):417-22 [12634971.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Apr;84(4):1193-202 [10199752.001]
  • [Cites] J Neurosurg. 1989 Nov;71(5 Pt 1):687-90 [2809722.001]
  • [Cites] J Endocrinol Invest. 1997 Jul-Aug;20(7):424-8 [9309542.001]
  • [Cites] Postgrad Med J. 1999 Feb;75(880):65-6 [10448463.001]
  • [Cites] Clin Endocrinol (Oxf). 1997 Nov;47(5):589-98 [9425399.001]
  • [Cites] Eur J Nucl Med. 1997 Jul;24(7):728-31 [9211757.001]
  • [Cites] J Nucl Med. 1996 Sep;37(9):1449-51 [8790190.001]
  • [Cites] Eur J Nucl Med. 1998 Jul;25(7):675-86 [9662588.001]
  • [Cites] Eur J Endocrinol. 2003 Apr;148(4):433-42 [12656664.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Apr;80(4):1386-92 [7714115.001]
  • [Cites] Semin Nucl Med. 2002 Apr;32(2):148-55 [11965610.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Nov;75(5):1310-7 [1430093.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Jun;81(6):2356-62 [8964877.001]
  • [Cites] Biomed Pharmacother. 1999 Aug;53(7):319-22 [10472432.001]
  • [Cites] Life Sci. 1995;56(5):333-42 [7530798.001]
  • [Cites] Nucl Med Commun. 1998 Dec;19(12 ):1127-34 [9885802.001]
  • [Cites] Clin Endocrinol (Oxf). 2001 Apr;54(4):469-77 [11318782.001]
  • [Cites] Eur J Endocrinol. 1997 Apr;136(4):369-76 [9150695.001]
  • [Cites] Am J Med. 1994 Apr;96(4):305-12 [8166148.001]
  • (PMID = 15711911.001).
  • [ISSN] 1389-9155
  • [Journal-full-title] Reviews in endocrine & metabolic disorders
  • [ISO-abbreviation] Rev Endocr Metab Disord
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Indium Radioisotopes; 0 / Radiopharmaceuticals; 0 / Receptors, Somatostatin; 51110-01-1 / Somatostatin; G083B71P98 / pentetreotide
  • [Number-of-references] 50
  •  go-up   go-down


96. Levy MJ, Matharu MS, Meeran K, Powell M, Goadsby PJ: The clinical characteristics of headache in patients with pituitary tumours. Brain; 2005 Aug;128(Pt 8):1921-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The clinical characteristics of headache in patients with pituitary tumours.
  • The clinical characteristics of 84 patients with pituitary tumour who had troublesome headache were investigated.
  • It was not possible to classify the headache according to International Headache Society diagnostic criteria in six cases (7%).
  • Headache appears to be a significant problem in pituitary disease and is associated with a range of headache phenotypes.
  • A proposed modification of the current classification of pituitary-associated headache is given.
  • [MeSH-major] Adenoma / physiopathology. Headache / physiopathology. Pituitary Neoplasms / physiopathology. Somatostatin / analogs & derivatives

  • MedlinePlus Health Information. consumer health - Headache.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15888539.001).
  • [ISSN] 1460-2156
  • [Journal-full-title] Brain : a journal of neurology
  • [ISO-abbreviation] Brain
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents, Hormonal; 0 / Dopamine Agonists; 0 / Ergolines; 0 / Peptides, Cyclic; 118992-92-0 / lanreotide; 3A64E3G5ZO / Bromocriptine; 51110-01-1 / Somatostatin; 80Q9QWN15M / quinagolide; LL60K9J05T / cabergoline; RWM8CCW8GP / Octreotide
  •  go-up   go-down


97. Santhanam P, Saleem SF, Saleem TF: Diagnostic predicament of secondary adrenal insufficiency. Endocr Pract; 2010 Jul-Aug;16(4):686-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To propose an approach for the diagnosis of secondary adrenal insufficiency (AI) by presentation of 2 clinical cases and review of the literature.
  • METHODS: We describe 2 patients who were considered to have a normal hypothalamic-pituitary-adrenal axis on the basis of an appropriate response to the high-dose (250 microg) cosyntropin stimulation test (HST), with use of a cutoff value of 20 microg/dL.
  • Our first patient had undergone resection of a 4-cm pituitary tumor a few months previously, and the second patient had hyponatremia with empty sella syndrome.
  • We reviewed the literature to compare the utility of the different tests for the diagnosis of secondary AI.
  • [MeSH-major] Adrenal Insufficiency / diagnosis. Adrenal Insufficiency / etiology. Pituitary Diseases / physiopathology
  • [MeSH-minor] Adenoma / complications. Adenoma / surgery. Adult. Aged. Cosyntropin / administration & dosage. Empty Sella Syndrome / complications. Empty Sella Syndrome / physiopathology. Female. Humans. Hyponatremia / complications. Hypothalamo-Hypophyseal System / drug effects. Hypothalamo-Hypophyseal System / physiopathology. Insulin / adverse effects. Pituitary Neoplasms / complications. Pituitary Neoplasms / surgery. Pituitary-Adrenal System / drug effects. Pituitary-Adrenal System / physiopathology

  • MedlinePlus Health Information. consumer health - Pituitary Disorders.
  • Hazardous Substances Data Bank. Cosyntropin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20439244.001).
  • [ISSN] 1934-2403
  • [Journal-full-title] Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • [ISO-abbreviation] Endocr Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Insulin; 16960-16-0 / Cosyntropin
  •  go-up   go-down


98. Cristina C, Perez-Millan MI, Luque G, Dulce RA, Sevlever G, Berner SI, Becu-Villalobos D: VEGF and CD31 association in pituitary adenomas. Endocr Pathol; 2010 Sep;21(3):154-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] VEGF and CD31 association in pituitary adenomas.
  • Pituitary tumors are usually less vascularized than the normal pituitary, and the role of angiogenesis in these adenomas is contentious.
  • We determined the protein expression of VEGF and CD31, an endothelial marker, in a series of 56 surgically removed pituitary adenomas using Western blot assay.
  • Prolactinomas had higher VEGF protein expression compared to nonfunctioning or ACTH- and GH-secreting adenomas, while CD31 was similar in the different adenoma histotypes.
  • VEGF and CD31 were not affected by sex, age, years of adenoma evolution, or proliferation rate (Ki67 and PCNA) for all adenoma types.
  • Only in nonfunctioning adenomas CD31 concentration increased significantly with age.
  • There was a positive correlation between CD31 and VEGF expression when all adenoma histotypes were considered, or when prolactinomas and nonfunctioning adenomas were evaluated separately.
  • The positive association of VEGF and CD31 expression suggests the participation of angiogenesis in adenoma development, while epithelial cell proliferation in pituitary tumors is not directly related to VEGF or CD31 expression, and other factors, such as primary genetic alterations may be involved.
  • [MeSH-major] Adenoma / metabolism. Antigens, CD31 / biosynthesis. Biomarkers, Tumor / analysis. Pituitary Neoplasms / metabolism. Vascular Endothelial Growth Factor A / biosynthesis

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Neurochir (Wien). 2000;142(12):1345-51 [11214627.001]
  • [Cites] Br J Cancer. 2000 Apr;82(8):1441-5 [10780524.001]
  • [Cites] Endocr Pathol. 1997 Autumn;8(3):189-193 [12114722.001]
  • [Cites] Pituitary. 2005;8(2):163-8 [16379029.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Mar;85(3):1159-62 [10720055.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7481-6 [11404464.001]
  • [Cites] Endocrinology. 2005 Jul;146(7):2952-62 [15817666.001]
  • [Cites] Neuroendocrinology. 2001 Aug;74(2):95-105 [11474217.001]
  • [Cites] Arch Pathol Lab Med. 2000 Jul;124(7):1061-5 [10888784.001]
  • [Cites] Endocr Pathol. 1999 Jun;10(2):109-22 [27519215.001]
  • [Cites] Acta Neuropathol. 1998 Nov;96(5):453-62 [9829808.001]
  • [Cites] Am J Pathol. 1999 Feb;154(2):375-84 [10027396.001]
  • [Cites] Front Horm Res. 2006;35:50-63 [16809922.001]
  • [Cites] Am J Pathol. 1972 Apr;67(1):109-26 [5055626.001]
  • [Cites] Neurosurgery. 1996 Jan;38(1):99-106; discussion 106-7 [8747957.001]
  • [Cites] Endocr Pathol. 1999 Autumn;10(3):229-235 [12114703.001]
  • [Cites] Endocr Pathol. 2003 Fall;14(3):239-47 [14586069.001]
  • [Cites] Hum Pathol. 2005 Oct;36(10):1090-5 [16226108.001]
  • [Cites] Microsc Res Tech. 2003 Feb 1;60(2):231-5 [12539177.001]
  • [Cites] Virchows Arch. 2001 Jun;438(6):595-602 [11469692.001]
  • [Cites] Mol Cell Endocrinol. 2003 Sep 30;207(1-2):13-20 [12972179.001]
  • [Cites] J Biol Chem. 1992 Jun 5;267(16):10931-4 [1375931.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Sep;87(9):4238-44 [12213878.001]
  • [Cites] Endocr Pathol. 1997 Spring;8(1):65-74 [12114673.001]
  • [Cites] Endocr Pathol. 2009 Spring;20(1):41-5 [19089655.001]
  • [Cites] Cytobios. 2000;101(398):151-9 [10755214.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):361-81 [10666364.001]
  • [Cites] J Neurosurg. 1993 May;78(5):753-61 [8096873.001]
  • [Cites] J Endocrinol. 2000 May;165(2):475-81 [10810311.001]
  • [Cites] J Endocrinol Invest. 2003 Jan;26(1):23-8 [12602530.001]
  • [Cites] Hiroshima J Med Sci. 2004 Jun;53(2):23-7 [15453394.001]
  • [Cites] Endocr Pathol. 2004 Summer;15(2):131-9 [15299199.001]
  • [Cites] Endocr Pathol. 2009 Spring;20(1):35-40 [19172414.001]
  • [Cites] Endocr Rev. 2003 Oct;24(5):600-32 [14570746.001]
  • [Cites] Endocr Pathol. 1995 Summer;6(2):115-124 [12114647.001]
  • [Cites] Circulation. 1999 Jan 5-12;99(1):111-20 [9884387.001]
  • [Cites] Neuropathology. 2009 Feb;29(1):40-4 [18673444.001]
  • [Cites] Neurosurg Rev. 2008 Jul;31(3):271-81 [18327622.001]
  • [Cites] J Mol Histol. 2005 Oct;36(8-9):447-54 [16733790.001]
  • [Cites] Microsc Res Tech. 2003 Feb 1;60(2):244-50 [12539179.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2004 Nov;16(12):1401-6 [15618852.001]
  • (PMID = 20473646.001).
  • [ISSN] 1559-0097
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / Biomarkers, Tumor; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


99. Yoshida D, Teramoto A: Enhancement of pituitary adenoma cell invasion and adhesion is mediated by discoidin domain receptor-1. J Neurooncol; 2007 Mar;82(1):29-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhancement of pituitary adenoma cell invasion and adhesion is mediated by discoidin domain receptor-1.
  • However, no previous study has examined the expression and function of DDR1 in pituitary adenoma.
  • Tissue microarray analysis of DDR1 expression levels in 52 pituitary adenoma tissues revealed that DDR1 expression was significantly related to hormonal background (Kruskal-Wallis test; P < 0.0001).
  • To further elucidate the function of DDR1 in pituitary adenoma, we developed DDR1 over- and under-expressing cell lines using DDR1 clone transfection and short interfering ribonucleic acids (siRNA)-based DDR1 gene silencing, respectively, in a human pituitary adenoma cell line (HP-75).
  • Taken together, these results strongly suggest that DDR1 mediates cell invasion-related signaling between collagen type I and MMP-2 and -9 in pituitary adenoma cells.
  • [MeSH-major] Adenoma / pathology. Cell Adhesion / physiology. Collagen Type I / metabolism. Pituitary Neoplasms / pathology. Receptor Protein-Tyrosine Kinases / metabolism. Receptors, Mitogen / metabolism

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] EMBO Rep. 2001 May;2(5):446-52 [11375938.001]
  • [Cites] Neurol Med Chir (Tokyo). 2002 May;42(5):202-12; discussion 213 [12064154.001]
  • [Cites] Int J Dev Neurosci. 2005 Nov;23(7):657-62 [16095866.001]
  • [Cites] Arch Pharm Res. 2005 Nov;28(11):1257-62 [16350852.001]
  • [Cites] J Immunol. 2003 Oct 1;171(7):3520-32 [14500648.001]
  • [Cites] J Mol Biol. 2004 Dec 3;344(4):993-1003 [15544808.001]
  • [Cites] J Cell Physiol. 2005 Jul;204(1):146-54 [15672417.001]
  • [Cites] Clin Exp Metastasis. 2005;22(5):391-402 [16283482.001]
  • [Cites] J Neurooncol. 2006 Feb;76(3):239-48 [16234985.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Aug;85(8):2931-5 [10946906.001]
  • [Cites] Mol Cell Endocrinol. 2001 Apr 25;175(1-2):141-8 [11325524.001]
  • [Cites] Cerebellum. 2005;4(4):239-45 [16321879.001]
  • [Cites] Biol Proced Online. 2005;7:41-7 [16136223.001]
  • [Cites] J Clin Neurosci. 2005 Sep;12(7):791-4 [16198918.001]
  • [Cites] Am J Respir Cell Mol Biol. 2005 Dec;33(6):565-73 [16166739.001]
  • [Cites] J Biol Chem. 2006 Jan 6;281(1):213-20 [16204254.001]
  • [Cites] Bioessays. 2005 Nov;27(11):1181-91 [16237672.001]
  • [Cites] Clin Cancer Res. 2004 Jul 1;10 (13):4427-36 [15240533.001]
  • [Cites] Gene Expr Patterns. 2005 Apr;5(4):533-7 [15749083.001]
  • [Cites] J Biol Chem. 2006 Mar 3;281(9):5341-7 [16326713.001]
  • [Cites] Ann Biomed Eng. 2005 Nov;33(11):1469-90 [16341917.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11230-5 [16357123.001]
  • [Cites] FEBS Lett. 2006 Jan 9;580(1):15-22 [16337946.001]
  • [Cites] J Neurooncol. 2005 Aug;74(1):71-6 [16078111.001]
  • [Cites] Toxicol Appl Pharmacol. 2006 Jul 1;214(1):8-15 [16387334.001]
  • [Cites] Pathol Biol (Paris). 2005 Sep;53(7):369-71 [16085112.001]
  • [Cites] Neurosurgery. 2000 Dec;47(6):1400-9 [11126911.001]
  • [Cites] Acta Neurochir (Wien). 2005 Jun;147(6):641-8; discussion 649 [15812595.001]
  • [Cites] Mol Cell Biol. 2001 Apr;21(8):2906-17 [11283268.001]
  • [Cites] Z Gastroenterol. 2005 Dec;43(12):1329-36 [16315129.001]
  • [Cites] Matrix Biol. 2005 Dec;24(8):550-9 [16229994.001]
  • [Cites] Fertil Steril. 2005 Apr;83 Suppl 1:1206-15 [15831294.001]
  • [Cites] Mol Cell Endocrinol. 2003 Sep 30;207(1-2):13-20 [12972179.001]
  • [Cites] J Immunol. 2004 Feb 15;172(4):2332-40 [14764702.001]
  • [Cites] Circ Res. 2002 Jun 14;90(11):1147-9 [12065315.001]
  • [Cites] Comp Hepatol. 2005 Dec 07;4:7 [16336649.001]
  • [Cites] J Cell Biol. 2005 Aug 29;170(5):825-36 [16115956.001]
  • [Cites] J Cell Sci. 2001 Jun;114(Pt 11):2043-53 [11493640.001]
  • [Cites] Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):520-8 [15701836.001]
  • [Cites] Mol Cell. 1997 Dec;1(1):13-23 [9659899.001]
  • [Cites] Oncogene. 2006 Apr 13;25(16):2379-92 [16369494.001]
  • [Cites] J Biol Chem. 2000 Feb 25;275(8):5779-84 [10681566.001]
  • [Cites] World J Gastroenterol. 2005 Sep 21;11(35):5444-9 [16222734.001]
  • [Cites] Wound Repair Regen. 2004 May-Jun;12 (3):262-8 [15225204.001]
  • [Cites] Virchows Arch. 1998 Jul;433(1):29-34 [9692822.001]
  • [Cites] J Biol Chem. 2005 Dec 2;280(48):40187-94 [16186104.001]
  • [Cites] J Immunol. 2005 May 15;174(10 ):6490-8 [15879152.001]
  • [Cites] Eur Respir J. 2001 May;17(5):969-74 [11488334.001]
  • [Cites] J Clin Invest. 2001 Mar;107(6):727-35 [11254672.001]
  • [Cites] Circ Res. 2005 Nov 25;97(11):1093-107 [16306453.001]
  • [Cites] Chin Med Sci J. 2005 Jun;20(2):133-7 [16075756.001]
  • (PMID = 17001518.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Collagen Type I; 0 / RNA, Messenger; 0 / Receptors, Mitogen; EC 2.7.10.1 / Discoidin Domain Receptors; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


100. Shen MQ, Ye W, Zhang YY, Chen J: [Visual field defects in 169 cases of pituitary adenomas]. Zhonghua Yan Ke Za Zhi; 2009 Dec;45(12):1074-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Visual field defects in 169 cases of pituitary adenomas].
  • OBJECTIVE: To compare static visual field perimetry with Octopus 101 and Goldmann perimetry in patients with pituitary adenomas; To identify the factors of visual field defects and visual field prognosis.
  • Visual acuity, fundus, computed tomography (CT) or magnetic resonance imaging (MRI) and visual field were pre-operated assessed in 169 patients (338 eyes) diagnosed pituitary adenoma at the Department of Neurosurgery in Huashan Hospital between Feb.
  • CONCLUSIONS: Static visual field perimetry with Octopus 101 perimeter is more sensitive than Goldmann perimetry in the early diagnosis of pituitary adenomas.
  • [MeSH-major] Pituitary Neoplasms. Visual Fields

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20193428.001).
  • [ISSN] 0412-4081
  • [Journal-full-title] [Zhonghua yan ke za zhi] Chinese journal of ophthalmology
  • [ISO-abbreviation] Zhonghua Yan Ke Za Zhi
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down






Advertisement